

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number  
**WO 02/31134 A2**

(51) International Patent Classification<sup>7</sup>:

**C12N 9/64**

(21) International Application Number:

PCT/US01/31874

(22) International Filing Date: 12 October 2001 (12.10.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/240,117 12 October 2000 (12.10.2000) US

(71) Applicant (*for all designated States except US*): **FER-RING BV** [US/US]; Polaris Avenue 144, NL-2132 JX Hoofdorp (NL).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **QI, Steve** [GB/US]; 11034 West Ocean Air Drive, Apt. 24B, San Diego, CA 92130 (US). **AKINSANYA, Karen, O.** [GB/US]; 7675 Palmilla Drive, Apt. 642B, San Diego, CA 92122-5094 (US). **RIVIERE, Pierre, J.-M.** [FR/US]; 3993 Via Cangrejo, San Diego, CA 92130 (US). **JUNIEN, Jean-Louis** [FR/FR]; Ferring SAS, F-75507 Paris (FR).

(74) Agents: **SAMPLES, Kenneth, H.** et al.; Fitch, Even, Tabin & Flannery, 120 South LaSalle Street, Suite 1600, Chicago, IL 60603 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/31134 A2

(54) Title: NOVEL SERINE PROTEASE GENES RELATED TO DPPIV

(57) Abstract: Novel proteins or polypeptides having significant sequence homology to DPPIV, nucleic acids coding therefor, cells which have been modified with such nucleic acid so as to express these proteins, antibodies to these proteins, screening methods for the discovery of new therapeutic agents which are inhibitors of the activity of these proteins or of related proteins, and therapeutic agents discovered by such screening methods, as well as new therapeutic treatments, are all provided.

Best Available Copy

## Novel Serine Protease Genes Related to DPPIV

### Field of the Invention

The present invention relates to novel serine proteases related to dipeptidyl peptidase IV (DPPIV), and to isolated nucleic acids coding for these proteases, all of which are useful for the discovery of new therapeutic agents, for measuring protease 5 activity, and for determining the inhibitory activity of compounds against these proteases.

### Background of the Invention

Proteases and peptidases are enzymes that catalyse the hydrolysis of peptidic amide bonds. Proteases play an important role in the regulation of biological processes 10 in almost every life-form from bacteria to virus to mammals. They perform critical functions in, for example, digestion, blood clotting, apoptosis, activation of immune responses, zymogen activation, viral maturation, protein secretion and protein trafficking. They can be classified according to a number of criteria, such as site of action, substrate preference, and mechanism. So, for example, aminopeptidases act 15 preferentially at the N-terminal residues of a peptide, while carboxypeptidases act preferentially at the C-terminus and endopeptidases act at sites removed from the two termini. Among the carboxy- and aminopeptidases, peptidyl peptidases cleave a single amino acid residue from the substrate, dipeptidyl peptidases cleave a dipeptide unit (two amino acids) from the substrate, and tripeptidases cleave three amino acids from the 20 substrate. Substrate preference is frequently expressed in terms of the amino acid residue immediately N-terminal to the cleavage site. For example, trypsin-like peptidases will preferentially cleave a peptide next to a basic amino acid (arginine or lysine), i.e. where the bond hydrolysed is the Arg/Lys-Xaa bond. As another example, the chymotrypsin-like family of peptidases preferentially hydrolyse peptides adjacent to 25 an aromatic residue. Mechanistically, peptidases are classified as being serine-dependent, cysteine-dependent, aspartic acid-dependent or zinc-dependent.

Because peptidases and proteases are involved in the regulation of many physiological processes, they are attractive targets for the development of therapeutic agents. Protease and peptidase inhibitors are, for example, used in the treatment of 30 hypertension, coagulation disorders, and viral infection.

Proteolytic enzymes that exploit serine in their catalytic activity are ubiquitous, being found in viruses, bacteria and eukaryotes. Over 20 families (denoted S1 - S27) of serine protease have been identified; these are grouped into 6 clans (SA, SB, SC, SE, SF

and SG) on the basis of structural similarity and other functional evidence. Structures are known for four of the clans (SA, SB, SC and SE); these appear to be totally unrelated, suggesting at least four evolutionary origins of serine peptidases and possibly many more, Rawlings and Barrett, Meth. Enzymol. 244: 19-61 (1994).

- 5       The prolyl oligopeptidase family consists of a number of evolutionarily related peptidases whose catalytic activity seems to be provided by a charge relay system similar to that of the trypsin family of serine proteases, but which evolved by independent convergent evolution. A conserved serine residue has been shown experimentally (in *E. coli* protease II as well as in pig and bacterial PE) to be necessary for the catalytic
- 10      mechanism. This serine, which is part of the catalytic triad (Ser, His, Asp), is generally located about 150 residues away from the C-terminal extremity of these enzymes (which are all proteins that contain about 700 to 800 amino acids).

One of the most intensively studied prolyl oligopeptidases is dipeptidyl peptidase IV (DPPIV, EC 3.414.5), a type II glycoprotein, which is the only well characterised

15      dipeptidyl aminopeptidase known to be located on the outer side of plasma membranes. As indicated above, dipeptidyl aminopeptidases are characterised by their ability to cleave N-terminal dipeptides from a variety of small peptides. Dipeptidyl aminopeptidases show different substrate specificities and cellular localisation, suggesting different functions of each activity in peptide processing. DPPIV is characterised by its capacity to cleave N-

20      terminal dipeptides containing proline or alanine as the penultimate residue. The DPPIV gene spans approximately 70 kb and contains 26 exons, ranging in size from 45 bp to 1.4 kb. The nucleotide sequence (3,465 bp) of the cDNA contains an open reading frame encoding a polypeptide comprising 766 amino acids. The nucleotides that encode the active site sequence (G-W-S-Y-G) are split between 2 exons. This clearly distinguishes

25      the genomic organisation of the prolyl oligopeptidase family from that of the classic serine protease family.

DPPIV is widely distributed in mammalian tissues and is found in great abundance in the kidney, intestinal epithelium and placenta (Yaron, A. and Naider, F., Critical Reviews in Biochem. Mol. Biol. 1993 [1], 31). In the human immune system,

30      the enzyme is expressed almost exclusively by activated T-lymphocytes of the CD4<sup>+</sup> type where the enzyme has been shown to be synonymous with the cell-surface antigen CD26. Although the exact role of DP-IV in human physiology is still not completely understood, recent research has shown that the enzyme clearly has a major role in human physiology and pathophysiology.

On human T cells, DPPIV expression appears late in thymic differentiation and is preferentially restricted to the CD4<sup>+</sup> helper/memory population, and CD26 can deliver a potent co-stimulatory T-cell activation signal. DPPIV, also known as T-cell activation antigen CD26, therefore plays an important role in the immune response via association

5 with CD45 tyrosine phosphatase and, through its ability to bind adenosine deaminase (ADA) to the T-cell surface, protects the T-cell from adenosine-mediated inhibition of proliferation. Furthermore, the regulation of the function of chemokines by CD26/DPPIV appears to be essential for lymphocyte trafficking and infectivity of HIV strains. DPPIV has been associated with numerous functions including involvement in

10 T-cell activation, cell adhesion, digestion of proline containing peptides in the kidney and intestines, HIV infection and apoptosis, and regulation of tumorigenicity in certain melanoma cells, Pethiyagoda et al., *Clin. Exp. Metastasis* 2000;18(5):391-400. DPPIV is also implicated in the endocrine regulation and metabolic physiology. More particularly, DPPIV cleaves the amino-terminal His-Ala dipeptide of GLP-1, generating

15 a GLP-1 receptor antagonist, and thereby shortens the physiological response to GLP-1. Glucagon-like peptide-1 (GLP-1), an incretin that induces glucose-dependent insulin secretion, is rapidly degraded by DPPIV, and since the half-life for DPPIV cleavage is much shorter than the half-life for removal of GLP-1 from circulation, a significant increase in GLP-1 bioactivity (5- to 10- fold) is anticipated from DPP-IV inhibition.

20 Inhibitors of DPPIV are currently being studied in the clinic as potential therapeutic agents for type 2 diabetes and impaired glucose tolerance.

Various different inhibitors of DPPIV were known in 1993. One of these is a suicide inhibitor N-Ala-Pro-O-(nitrobenzoyl-) hydroxylamine. Another is a competitive inhibitor: e-(4-nitro) benzoxy carbonyl-Lys-Pro, and another is a polyclonal rabbit anti-porcine kidney DPPIV immunoglobulin. Others have since been developed and are described in detail in U.S. Patents Nos. 5,939,560, 6,110,949m 6,011,155 and 5,462,928.

In addition to, but independent of, its serine type catalytic activity, DPPIV binds closely to the soluble extracellular enzyme adenosine deaminase (ADA), acting as a receptor and is thought to mediate signal transduction. DPPIV structure is characterized

30 by two extracellular domains, an α/β fold hydrolase domain and a 7-blade beta-propeller domain consisting of repeated beta sheets of about 50 amino acids. Recently it has been shown that, besides selecting substrates by size, the beta-propeller domain, containing 10 of the 12 highly conserved cysteine residues, contributes to catalysis of the peptidase domain. In addition, the cysteine-rich domain is responsible for DPPIV-binding to

35 collagen I and to extracellular ADA. DPPIV is also reported to play a role in fibronectin-

mediated interactions of cells with extracellular matrix. Recent studies show that the protease activity of DPPIV is not required for its anti-invasive activity because mutants of DPPIV that lack the extracellular serine protease activity maintain such activity.

A number of proteins that share similarities with DPPIV have been reported in  
5 the literature. Several of these proteins have been cloned including DPP-I, DPP-II,  
DPP-III, DPP-X and fibroblast activation protein (FAP). These have been identified and  
characterised either by molecular cloning and functional studies of expressed proteins or  
as biochemical activities in tissue extracts. DPPIV-beta and other novel peptidases with  
functional similarities to DPPIV are not yet cloned. The identification, characterization  
10 and/or appropriate classification of further members of the family of prolyl  
oligopeptidases, the elucidation of their physiological (and particularly  
pathophysiological) role, and the application of that knowledge to the development of  
new therapeutic agents are significant challenges.

#### Summary of the Invention

15 The present invention provides proteins with prolyl oligopeptidase (post-proline  
cleaving) activities that constitute three novel members of a family of proteins related to  
DPPIV, including the full-length proteins, alternative splice forms, subunits, and  
mutants, as well as nucleotide sequences encoding the same. The present invention also  
provides methods of screening for substrates, interacting proteins, agonists, antagonists  
20 or inhibitors of the above proteins, and furthermore to pharmaceutical compositions  
comprising the proteins and/or mutants, derivatives and/or analogues thereof and/or  
ligands thereto.

These novel proteins having significant sequence homology to DPPIV are termed  
dipeptidyl peptidase IV-related protein-1, 2 & 3 (DPRP-1, DPRP-2 and DPRP-3). The  
25 amino acid sequences of DPRP-1, DPRP-2 and DPRP-3 are given in SEQ. ID NOS:1, 3  
and 5 respectively. Further disclosed are nucleic acid sequences coding for these  
proteins (SEQ. ID NOS:2, 4 and 6). Table 1 illustrates the homology (i.e. similarity)  
between the novel proteins DPRP-1, DPRP-2 and DPRP-3 and other known serine  
proteases.

**Table 1 – Comparison of the sequences of these three novel proteins with DPPIV and other Clan SC, Family S9 members and Subfamily B members**

Protease Family	Protease name	No. of a.a.	Homology with DPPIV	TM region	Ser-Asp-His Triad	Gene location	Optimal pH
Clan CA, Family C1	DPPI	463	N	N	N	11q14.1-q14.3	-
Clan SC, Family S28	DPPII	500	N	Y	N	-	4.5-6.0
	QPP	492	N	N	N	-	4.5-7.5
	PCP	496	N	N	N	-	-
Unassigned	DPPIII	737	N	N	N	-	-
Clan SC, Family S9, Subfamily B	DPPIV	766	100	Y	Y	2q24.3	7.5-8.0
	DPPVI	865	52	Y	Mutation	7	-
	FAP	760	70	Y	Y	2q23	7.5-8.0
	DPRP-1	882	41	N	Y	15q22.1-15q22.2	7.5-8.0
	DPRP-2	864	39	N	Y	19p13.3	7.5-8.0
	DPRP-3	796	54	Y	Mutation	2q12.3-2q14.1	-

The greatest homology between DPRP-1, DPRP-2 and DPPIV is seen in the C-terminal sequences. On the basis of sequence homology with DPPIV (see Figure 1), one might predict that these DPRP proteins would have functions that include, but are not limited to, roles as enzymes. Cloning, expression, biochemical and molecular characterization have confirmed this hypothesis.

The expression pattern of DPRPs and the localization to specialized epithelial cells and plasma cells (Leydig cells, prostate epithelial cells, lymphocytes, B cells) is consistent with a role in differentiation, proliferation and inflammation. The localization of the DPRP-1 gene in hormone sensitive cancers (breast, prostate, testicular), tissues regulated by testosterone and the abundant expression in poorly differentiated cancers, demonstrate that DPRP-activating or inhibiting molecules will have numerous therapeutic applications in the treatment of disorders characterized by disregulated growth, differentiation and steroid or polypeptide hormone synthesis and degradation. Data disclosed herein supports the hypothesis that DPRP-1 and DPRP-2 are involved in the regulation of proliferation of *in vitro* models of prostate and testis cancer well known to those skilled in the art.

DPRP-1 and DPRP-2 activities described herein and their expression patterns are compatible with their having functional roles as physiological regulators of the immune and neuroendocrine systems through the enzymatic modification of biochemical mediators like peptides and chemokines. The numerous functions previously described

for DPPIV based upon the use of inhibitors may be due in part to its action and that of similar proteins, like the DPRPs. Therefore, the discovery of selective and potent inhibitors of DPPIV, of the DPRPs and of other related proteases like FAP is considered central to achieving effective and safe pharmaceutical use of these and any newly identified serine protease inhibitors, as well as other active compounds that modify the function(s) of such proteins.

The invention thus provides novel proteins or polypeptides, the nucleic acids coding therefor, cells which have been modified with the nucleic acid so as to express these proteins, antibodies to these proteins, a screening method for the discovery of new therapeutic agents which are inhibitors of the activity of these proteins (or which are inhibitors of DPPIV and not of the proteins), and therapeutic agents discovered by such screening methods. The novel proteins and the nucleic acids coding therefor can be used to discover new therapeutic agents for the treatment of certain diseases, such as for example, reproductive, inflammatory and metabolic disorders and also in the preparation of antibodies with therapeutic or diagnostic value.

In accordance with one aspect of the present invention, there are provided novel, mature, biologically active proteins, principally of human origin. Such proteins may be isolated in small quantities from suitable animal (including human) tissue or biological fluids by standard techniques; however, larger quantities are more conveniently prepared in cultures of cells genetically modified so as to express the protein.

In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules encoding polypeptides of the present invention including mRNAs, DNAs, cDNAs, genomic DNAs thereof.

In accordance with a further aspect of the present invention, nucleic acid probes are also provided comprising nucleic acid molecules of sufficient length to specifically hybridize to a nucleic acid sequence of the present invention.

In accordance with a still further aspect of the present invention, processes utilizing recombinant techniques are provided for producing such polypeptides useful for *in vitro* scientific research, for example, synthesis of DNA and manufacture of DNA vectors. Processes for producing such polypeptides include culturing recombinant prokaryotic and/or eukaryotic host cells that have been transfected with DNA vectors containing a nucleic acid sequence encoding such a polypeptide and/or the mature protein under conditions promoting expression of such protein and subsequent recovery of such protein or a fragment of the expressed product.

In accordance with still another aspect, the invention provides methods for using DPRP polypeptides and polynucleotides, including the treatment of infections, such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2, pain, diabetes, precocious puberty, infertility, obesity, anorexia, bulimia,

5 Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, stroke, ulcers, asthma, allergies, benign prostatic hypertrophy, cancers including hormone-sensitive and androgen-independent cancers, migraines, vomiting, psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, dementia, and severe

10 mental retardation, and dyskinesias, hereinafter collectively referred to as "the Diseases".

In accordance with yet another aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotides encoding such polypeptides, for the discovery of compounds that inhibit the biological activity of the mature proteins thereof, e.g. by cleaving an N-terminal dipeptide, and such inhibitors are thus also

15 provided.

In accordance with a more specific aspect, the invention provides isolated nucleic acid which encodes (a) a polypeptide which includes the amino acid sequence of one of SEQ ID NOS:1, 3 and 5, or (b) a polypeptide having an amino acid sequence that is at least about 70% similar thereto and exhibits the same biological function, or which is an

20 alternative splice variant of one of SEQ ID NOS:2, 4 and 6, or which is a probe comprising at least 14 contiguous nucleotides from said nucleic acid encoding (a) or (b), or which is complementary to any one of the foregoing.

In accordance with another specific aspect, the invention provides a polypeptide which may be optionally glycosylated, and which (a) has the amino acid sequence of a

25 mature protein set forth in any one of SEQ ID NOS:1, 3 and 5; (b) has the amino acid sequence of a mature protein having at least about 70% similarity to one of the mature proteins of (a) and which exhibits the same biological function; (c) has the amino acid sequence of a mature protein having at least about 90% identity with a mature protein of any of SEQ ID NOS:1, 3 and 5; or (d) is an immunologically reactive fragment of (a).

30 In accordance with still another specific aspect, the invention provides a method for the screening for a compound capable of inhibiting the enzymatic activity of at least one mature protein of the invention, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more test compounds or salts thereof, measuring the enzymatic activity of said mature protein,

35 comparing said activity with comparable activity determined in the absence of a test

compound, and selecting the test compound or compounds that reduce the enzymatic activity, and it also provides a method for screening for a compound capable of inhibiting the enzymatic activity of DPPIV that does not inhibit the enzymatic activity of at least one mature protein and a suitable substrate in the presence of one or more 5 inhibitors of DPPIV or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the absence of the DPPIV inhibitor, and selecting a compound that does not reduce the enzymatic activity of said mature protein.

These and other aspects of the present invention should be apparent to those 10 skilled in the art from the detailed description which follows.

#### Brief Description of the Drawings

FIGS. 1A and 1B show the co-linear alignment of DPRP-1, DPRP-2, DPRP-3 and DPPIV, with shading being supplied to indicate the same (black) or similar (gray) amino acid residues at a particular location.

15 FIG. 2 is similar to FIG. 1 and shows co-linear alignment of human and mouse DPRP-2.

FIG. 3 is a graph which shows the effects of various tetrapeptide amide inhibitors on dipeptidyl peptidase enzyme activity.

20 FIGS. 4A-4C show the effects of three inhibitor compounds on the proliferation of PC3 prostate cancer cell lines at various doses.

#### Detailed Description of the Preferred Embodiments

In accordance with an aspect of the present invention, there are provided isolated nucleic acid sequences (polynucleotides), which encode the mature polypeptides having the deduced amino acid sequences of the three DPRP's (SEQ ID NOS:1, 3 and 5).

25 The polynucleotides of this invention were discovered using a human testis cDNA library (DPRP-1), a human colon library (DPRP-2) and a human hypothalamus cDNA library (DPRP-3). Isolated nucleic acid for DPRP-1 contains an open reading frame encoding a protein of approximately 882 amino acids in length which is structurally related to human DPPIV, showing 26% identity, and 41% similarity over the 30 entire human DPPIV protein sequence. Isolated nucleic acid for DPRP-2 contains an open reading frame encoding for a protein of approximately 864 amino acids, which is 39% similar to the entire DPPIV amino acid sequence. Analysis of DPRP-1 and DPRP-2 primary amino acid sequence using hydrophobicity plots predicts that these two proteins do not have a transmembrane domain. Despite this fact, it is possible that these 35 intracellular serine proteases are secreted upon cellular activation. Quiescent cell proline

dipeptidase (QPP) is a serine protease that is targeted to intracellular vesicles that are distinct from lysosomes (Chiravuri M, et al., J. Immunol. 2000 Nov 15;165(10):5695-702). This hypothesis expands the potential site(s) and scope of DPRP-1 and DPRP-2 involvement in mechanisms for post-translational regulation of chemokines, cytokines, 5 peptides and polypeptides. The full length DPRP-3 sequence contains 796 amino acids, a signal peptide from 1 to 48, and a transmembrane domain between 34 and 56. The mature protein is predicted to be a type II membrane protein and may be cleaved to produce a soluble form. The amino acid sequence is set forth in SEQ ID NO:5 , which was deduced from SEQ ID NO:6 and has 54% similarity with DPPIV.

10 Amino acid sequence alignments of these polypeptides with members of the prolyl oligopeptidase enzyme subfamily S9B show that all three DPRP proteins have overall sequence and structural homology to DPPIV and FAP. DPRPs are predicted to be members of the enzyme Clan SC (Serine nucleophile) with catalytic residues in the order Ser, Asp, His and the active site sequence (G-W-S-Y-G).

15 **Table 2.** Homology (i.e. similarity) between DPRP-1, DPRP-2, DPRP-3 and members of the prolyl oligopeptidase family S9B enzymes.

**DPPIV**

41	DPRP-1		DPRP-2		DPRP-3		FAP	DPPVI
39	74							
54		39	40					
70		41	39	52				
52		40	42	68	54			

20 DPRP-1, DPRP-2 and DPRP-3 do not exhibit sequence similarity with any members of the classical serine protease families, chymotrypsin and subtilisin. The order of the catalytic triad residues is different in the three main related SC clan families: His-Asp-Ser in chymotrypsin, Asp-His-Ser in subtilisin and Ser-Asp-His in the prolyl oligopeptidases.

As shown in Table 2, DPRP-3 has the highest homology with DPPVI (68% homology and 51% identity). Wada et al isolated cDNA clones for DPPVI, a DPPIV-related protein, from bovine, rat (Wada et al., Proc. Nat. Acad. Sci. 89: 197-201. (1992)) and human (Yokotani et al., Hum. Molec. Genet. 2:1037-1039 (1993)) brain libraries. They demonstrated that, unlike DPPIV, the catalytic triad in DPPVI does not have the first serine residue. In DPRP-3 two of the amino acids in the catalytic triad

characteristic of the serine protease family are conserved. However, the serine residue itself is replaced by glycine. While the absence of the serine residue is likely to prevent protease activity at this site, it is possible that multiple other functions mediated by other functional domains of the protein remain intact.

5 As briefly described above, DPPIV is a multifunctional molecule that exerts important functions depending on the expressed cells and tissues, in addition to its catalytic activity as a peptidase. DPRP-3 and DPPVI are also likely to maintain multiple functions despite the absence of an intact catalytic triad. For example, DPPVI has been implicated in the regulation of neuronal plasticity. DPPVI is highly expressed in the  
10 hippocampus, thalamus, hypothalamus and stiatum. In addition, developmental arrest and embryonic lethality of *rump white* *Rw/Rw* embryos is thought to be due to disruption of the DPPIV gene. *Rw* mutation is associated with a chromosomal inversion spanning 30 cM of the proximal portion of mouse chromosome 5. Genomic analysis of the DPPVI gene on the *Rw* chromosome places the inversion breakpoint in the coding region  
15 resulting in loss of a significant fraction of the C-terminal region, Hough R.B. et al., *Proc. Nat. Acad. Sci.*, 95; 13800-13805 (1998).

The human DPRP-1 gene, predicted to be 32668bp in length, has at least 22 exons and eight transcripts. It maps to chromosome 15 (NT\_010265) at position 15q21.1 – 15q22.1. The lengths of predicted alternative splice variant transcripts vary  
20 between 602bp and 4523bp (see SEQ ID NOS: 7-22). This is in agreement with the multiple transcripts observed by Northern blot analysis (See Example 2). ESTs representing the transcripts were found in numerous tissues including senescent fibroblasts, T-lymphocytes, germinal center B-cells, germ cell seminoma, testis, melanocytes, uterus, ovary breast, multiple sclerosis lesions, pancreas and placenta.

25 Human DPRP-2 belongs to a gene with at least 27 exons and nine splice variants (see SEQ ID NOS:23-40). One SNP was observed in the 3' UTR. (88% (37) C vs. 12% (5) T). The DPRP-2 gene maps to region 19p13.3 of chromosome 19. This location is host to a number of disease markers and is associated with various disorders including hypocalciuric hypercalcemia, type II cerebellar ataxia, muscular dystrophy, convulsions,  
30 susceptibility to atherosclerosis, psoriasis, ectodermal dysplasia, and acute myeloid leukemia. In agreement with the ubiquitous distribution of the mRNA observed by Northern blot analysis (see Example 2), DPRP-2 was expressed in a wide variety of tissues upon examination of EST's coverage (e.g. over 64 EST's expressed in liver, spleen, muscle, melanocytes, heart, lung, placenta, skin, pancreas, stomach, brain  
35 parathyroid gland).

Human DPRP-3 belongs to a gene with at least 23 exons and two splice variants (see SEQ ID NOS:41-44). The gene maps to chromosome 2 (NT\_005445) at position 2q12.3-2q14.1. Transcripts for DPRP-3 did not show as wide a distribution as DPRP-1 and DPRP-2. As shown by Northern blot in Example 2, DPRP-3 expression is restricted 5 to brain and pancreas. ESTs representing the DPRP-3 mRNA were abundant in tissue derived from multiple sclerosis lesions, hypothalamus, whole brain and nerves, with a few transcripts being found in uterus and colon.

- The relationships among human and rodent proteases in clan SC, including DPRP-1 DPRP-2 and DPRP-3, were analyzed using Neighbor Joining method (NJ), see 10 Saitou and Nei, *Mol. Biol. Evol.*, 4, 406-525 (1987). Phylogenetic analysis shows that among the S9 proteases, DPRP-1 and DPRP-2, both lacking a transmembrane domain, are distinguished from DPPIV and its closely related proteins like FAP. Similarity is shown however between DPPIV and FAP and between DPRP-3 and DPPVI, which are all type II membrane proteins.
- 15 A database search for additional DPRP-related genes revealed the presence of a murine sequence related to DPRP-1. Alignment of this mouse sequence with the novel human proteases shows that the mDPRP-1 displays considerable homology with its human counterpart (FIG. 2). One skilled in the art will readily recognize that the novel mouse protease gene can be isolated using the sequence information disclosed herein and 20 can be readily incorporated into one of the routinely used expression constructs which are well known in the art. Use of this disclosed sequence by those skilled in the art to generate a transgenic mouse model will employ development of gene-targeting vectors, for example, that result in homologous recombination in mouse embryonic stem cells. The use of knockout mice in further analysis of the function of DPRP genes is a valuable 25 tool.

The polynucleotides of the present invention may be in the form of RNA or in the form of DNA; DNA should be understood to include cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded and, if single-stranded, may be the coding strand or non-coding (antisense) strand. The coding 30 sequence which encodes the mature polypeptide may be identical to the coding sequence shown in SEQ ID NOS:2, 4 and 6 respectively, or it may be a different coding sequence encoding the same mature polypeptide, as a result of the redundancy or degeneracy of the genetic code or a single nucleotide polymorphism. For example, it may also be an RNA transcript which includes the entire length of any one of SEQ ID NOS:2, 4 and 6.

The polynucleotides which encode the mature proteins of SEQ ID NOS:1, 3, 5, respectively, may include but are not limited to the coding sequence for the mature protein alone; the coding sequence for the mature polypeptide plus additional coding sequence, such as a leader or secretory sequence or a proprotein sequence; and the 5 coding sequence for the mature protein (and optionally additional coding sequence) plus non-coding sequence, such as introns or a non-coding sequence 5' and/or 3' of the coding sequence for the mature protein.

Thus, the term "polynucleotide encoding a polypeptide" or the term "nucleic acid encoding a polypeptide" should be understood to encompass a polynucleotide or nucleic 10 acid which includes only coding sequence for the mature protein as well as one which includes additional coding and/or non-coding sequence. The terms polynucleotides and nucleic acid are used interchangeably.

The present invention also includes polynucleotides where the coding sequence for the mature protein may be fused in the same reading frame to a polynucleotide 15 sequence which aids in expression and secretion of a polypeptide from a host cell; for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell may be so fused. The polypeptide having such a leader sequence is termed a proprotein or a preproprotein and may have the leader sequence cleaved, by the host cell to form the mature form of the protein. These 20 polynucleotides may have a 5' extended region so that it encodes a proprotein, which is the mature protein plus additional amino acid residues at the N-terminus. The expression product having such a prosequence is termed a proprotein, which is an inactive form of the mature protein; however, once the prosequence is cleaved an active mature protein remains. Thus, for example, the polynucleotides of the present invention 25 may encode mature proteins, or proteins having a prosequence, or proteins having both a prosequence and a presequence (leader sequence).

The polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptides of the present invention. The marker sequence may be a polyhistidine tag, a hemagglutinin 30 (HA) tag, a c-myc tag or a V5 tag when a mammalian host, e.g. COS-1 cells, is used. The HA tag would correspond to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., *Cell*, 37:767 (1984)), and the c-myc tag may be an epitope from human Myc protein (Evans, G.I. et al., *Mol. Cell. Biol.* 5: 3610-3616 (1985)).

The term "gene" means the segment of DNA involved in producing a polypeptide 35 chain; it includes regions preceding and following the coding region (leader and trailer)

as well as intervening sequences (introns) between individual coding segments (exons). The term "significant sequence homology" is intended to denote that at least 25%, preferably at least 40%, of the amino acid residues are conserved, and that, of the non-conserved residues, at least 40% are conservative substitutions.

- 5       Fragments of the full-length genes of the present invention may be used as a hybridization probe for a cDNA library to isolate full-length cDNA as well as to isolate other cDNAs which have significant sequence homology to the gene and will encode proteins or polypeptides having similar biological activity or function. By similar biological activity or function, for purposes of this application, is meant the ability to
- 10      cleave an N-terminal dipeptide having Ala or Pro as the penultimate residue or other amino acids. Such a probe of this type has at least 14 bases (at least 14 contiguous nucleotides from one of SEQ ID NOS:2, 4 or 6), preferably at least 30 bases, and such may contain, for example, 50 or more bases. Such probe may also be used to identify a cDNA clone corresponding to a full-length transcript and/or a genomic clone or clones
- 15      that contains the complete gene, including regulatory and promoter regions, exons, and introns. Labelled oligonucleotides having a sequence complementary to that of the gene of the present invention are useful to screen a library of human cDNA, genomic DNA or mRNA to locate members of the library to which the probe hybridizes. As an example, a known DNA sequence may be used to synthesize an oligonucleotide probe which is then
- 20      used in screening a library to isolate the coding region of a gene of interest.

- The present invention is considered to further provide polynucleotides which hybridize to the hereinabove-described sequences wherein there is at least 70%, preferably at least 90%, and more preferably at least 95% identity or similarity between the sequences, and thus encode proteins having similar biological activity. Moreover, as
- 25      known in the art, there is "similarity" between two polypeptides when the amino acid sequences contain the same or conserved amino acid substitutes for each individual residue in the sequence. Identity and similarity may be measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue,
- 30      Madison, WI 53705). The present invention particularly provides such polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides. As herein used, the term "stringent conditions" means conditions which permit hybridization between polynucleotides sequences and the polynucleotide sequences of SEQ ID NOS:2, 4 and 6 where there is at least about 70% identity.
- 35      Suitably stringent conditions can be defined by, e.g., the concentrations of salt or

formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, by increasing the concentration of formamide, and/or by raising the hybridization temperature.

- 5       For example, hybridization under high stringency conditions may employ about 50% formamide at about 37°C to 42°C, whereas hybridization under reduced stringency conditions might employ about 35% to 25% formamide at about 30°C to 35°C. One particular set of conditions for hybridization under high stringency conditions employs 42°C, 50% formamide, 5x. SSPE, 0.3% SDS, and 200 µg/ml sheared and denatured
- 10      salmon sperm DNA. For hybridization under reduced stringency, similar conditions as described above may be used in 35% formamide at a reduced temperature of 35°C. The temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions
- 15      are well known in the art. Preferably, hybridization should occur only if there is at least 95%, and more preferably at least 97%, identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which exhibit substantially the same biological function or activity as the mature protein encoded by one of the cDNAs of
- 20      SEQ ID NOS:2, 4 and 6.

- As mentioned, a suitable polynucleotide probe may have at least 14 bases, preferably 30 bases, and more preferably at least 50 bases, and will hybridize to a polynucleotide of the present invention which has an identity thereto, as hereinabove described, and which may or may not retain activity. For example, such polynucleotides
- 25      may be employed as a probe for hybridizing to the polynucleotides of SEQ ID NOS:2, 4 and 6 respectively, for example, for recovery of such a polynucleotide, or as a diagnostic probe, or as a PCR primer. Thus, the present invention includes polynucleotides having at least a 70% identity, preferably at least a 90% identity, and more preferably at least a 95% identity to a polynucleotide which encodes the polypeptides of SEQ ID NOS:1, 3
- 30      and 5 respectively, as well as fragments thereof, which fragments preferably have at least 30 bases and more preferably at least 50 bases, and to polypeptides encoded by such polynucleotides.

- As is well known in the art, the genetic code is redundant in that certain amino acids are coded for by more than one nucleotide triplet (codon), and the invention
- 35      includes those polynucleotide sequences which encode the same amino acids using a

different codon from that specifically exemplified in the sequences herein. Such a polynucleotide sequence is referred to herein as an "equivalent" polynucleotide sequence. The present invention further includes variants of the hereinabove described polynucleotides which encode for fragments, such as part or all of the mature protein,

5     analogs and derivatives of one of the polypeptides having the deduced amino acid sequence of SEQ ID NOS:1, 3 and 5 respectively. The variant forms of the polynucleotides may be a naturally occurring allelic variant of the polynucleotides or a non-naturally occurring variant of the polynucleotides. For example, the variant in the nucleic acid may simply be a difference in codon sequence for the amino acid resulting

10    from the degeneracy of the genetic code, or there may be deletion variants, substitution variants and addition or insertion variants. As known in the art, an allelic variant is an alternative form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides that does not substantially alter the biological function of the encoded polypeptide.

15    The present invention further includes polypeptides which have the deduced amino acid sequence of SEQ ID NOS:1, 3 and 5, as well as fragments, analogs and derivatives of such polypeptides. The terms "fragment," "derivative" and "analog", when referring to the polypeptides of SEQ ID NOS:1, 3 and 5, means polypeptides that retain essentially the same biological function or activity as such polypeptides. An

20    analog might, for example, include a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature protein. The polypeptides of the present invention may be recombinant polypeptides, natural polypeptides or synthetic polypeptide; however, they are preferably recombinant polypeptides, glycosylated or unglycosylated.

25    The fragment, derivative or analog of a polypeptide of SEQ ID NOS:1, 3 and 5 respectively, may be (i) one in which one or more of the amino acid residues is substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid

30    residues includes a substituent group, or (iii) one in which additional amino acids are fused to the mature protein, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art to provide upon the basis of the teachings herein.

The polypeptides and polynucleotides of the present invention should be in an isolated form, and preferably they are purified to substantial homogeneity or purity. By substantial homogeneity is meant a purity of at least about 85%.

The term "isolated" is used to mean that the material has been removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not considered to be isolated, but the same polynucleotide or polypeptide, when separated from substantially all of the coexisting materials in the natural system, is considered isolated. For DNA, the term includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by polymerase chain reaction (PCR) or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence, e.g., a fusion protein. Further included is recombinant DNA which includes a portion of the nucleotides shown in one of SEQ ID NO:2,4 or 6 which encodes an alternative splice variant of the DPRP. Various alternative splice variants are exemplified in SEQ ID NOS:8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 and 46.

The polypeptides of the present invention include any one of the polypeptide of SEQ ID NOS:1, 3 and 5 (in particular the mature protein), as well as polypeptides which have at least 70% similarity (e.g. preferably at least 60% and more preferably at least 70% identity) to one of the polypeptides of SEQ ID NOS:1, 3 and 5, more preferably at least 90% similarity (e.g. preferably at least 90% identity) to one of the polypeptides of SEQ ID NOS:1, 3 and 5, and most preferably at least 95% similarity (e.g. preferably at least 95% identity) to one of the polypeptides of SEQ ID NOS:1, 3 and 5. Moreover, they should preferably include exact portions of such polypeptides containing a sequence of at least 30 amino acids, and more preferably at least 50 amino acids.

Fragments or portions of the polypeptides of the present invention may be employed as intermediates for producing the corresponding full-length polypeptides by peptide synthesis. Fragments or portions of the polynucleotides of the present invention may also be used to synthesize full-length polynucleotides of the present invention.

The present invention also includes vectors which include such polynucleotides, host cells which are genetically engineered with such vectors and the production of polypeptides by recombinant techniques using the foregoing. Host cells are genetically

engineered (transduced or transformed or transfected) with such vectors which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, 5 selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those commonly used with the host cell selected for expression, as well known to the ordinarily skilled artisan.

The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotides may be 10 included in any one of a variety of expression vectors for expressing polypeptides. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may 15 be used as long as it is replicable and viable in the host.

The appropriate DNA sequence may be inserted into the vector by any of a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures well known in the art, which procedures are deemed to be within the scope of those skilled in this art.

20 The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the *E. coli*. lac or trp, the phage lambda P.sub.L promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. 25 The expression vector should also contain a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase or neomycin-resistance for 30 eukaryotic cell culture, or such as tetracycline- or ampicillin-resistance in *E. coli*.

The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as *E. coli*, 35 *Streptomyces*, *Salmonella typhimurium*; fungal cells, such as yeast; insect cells, such as

Drosophila S2 and Spodoptera Sf9; animal cells, such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

Synthetic production of nucleic acid sequences is well known in the art as is apparent from CLONTECH 95/96 Catalogue, pages 215-216, CLONTECH, 1020 East Meadow Circle, Palo Alto, Calif. 94303. Thus, the present invention also includes expression vectors useful for the production of the proteins of the present invention

The present invention further includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs may comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example: Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pKK233-3, pDR540 and pRIT5 (Pharmacia); and Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia). However, any other suitable plasmid or vector may be used as long as it is replicable and viable in the host.

Promoter regions can be selected from any desired gene using CAT (chloramphenicol acetyl transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P.sub.R, P.sub.L and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

Components of the expression vector may generally include: 1) a neomycin phosphotransferase (G418), or hygromycin B phosphotransferase (hyg) gene as a selection marker, 2) an E. coli origin of replication, 3) a T7 and SP6 phage promoter sequence, 4) lac operator sequences, 5) the lactose operon repressor gene (lacIq) and 6) a multiple cloning site linker region. Such an origin of replication (oriC) may be derived from pUC19 (LTI, Gaithersburg, Md.).

A nucleotide sequence encoding one of the polypeptides SEQ ID NOS:2,4 and 6 having the appropriate restriction sites is generated, for example, according to the PCR

protocol described in Example 1 hereinafter, using PCR primers having restriction sites for KpnI (as the 5' primer) and NotI or SacI (as the 3' primer) for DPRP-1, or sites for HindIII (as the 5' primer) and NotI or BamHI (as the 3' primer) for DPRP-2. The PCR inserts are gel-purified and digested with compatible restriction enzymes. The insert and vector are ligated according to standard protocols.

In a further embodiment, the present invention provides host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell 10 can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofection or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

Such constructs in host cells are preferably used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the 15 polypeptides of the invention can be synthetically produced by conventional peptide synthesizers or by chemical ligation of suitable fragments thus prepared.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of 20 the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989).

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. 25 Enhancers include cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

Generally, recombinant expression vectors will include origins of replication and 30 selectable markers permitting transformation of the host cell, e.g., the ampicillin-resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. Such 35 promoters can be derived from operons encoding glycolytic enzymes, such as 3-phosphoglycerate kinase (PGK), alpha-factor, acid phosphatase, or heat shock proteins,

- among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion
- 5 protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter.

10 The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desired, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice.

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example,

20 pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, Wis., U.S.A.). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g.,

25 temperature shift or chemical induction), and cells are cultured for an additional period. Cells are typically harvested by centrifugation and then disrupted by physical or chemical means, with the resulting crude extract being retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption and use of

30 cell-lysing agents; such methods are well known to those skilled in the art.

Various mammalian cell culture systems can also be employed to express a recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, *Cell*, 23:175 (1981). Other cell lines capable of expressing a compatible vector include, for example, the C127, 3T3,

35 CHO, HeLa and BHK cell lines. Mammalian expression vectors will generally comprise

an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to 5 provide required nontranscribed genetic elements.

The polypeptides can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography 10 and lectin chromatography. Recovery can be facilitated if the polypeptide is expressed at the surface of the cells, but such is not a prerequisite. Recovery may also be desirable of cleavage products that are cleaved following expression of a longer form of the polypeptide. Protein refolding steps as known in this art can be used, as necessary, to complete configuration of the mature protein. High performance liquid chromatography 15 (HPLC) can be employed for final purification steps.

The polypeptides of the present invention may be purified natural products, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect or mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the 20 present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.

In a preferred embodiment, the proteins of the invention are isolated and purified so as to be substantially free of contamination from other proteins. For example, the proteins of the invention should constitute at least 80% by weight of the total protein 25 present in a sample, more preferably at least 90%, even more preferably at least 95%, and most preferably at least 98% by weight of the total protein.

These proteins may be in the form of a solution in water, another suitable solvent, such as dimethyl sulphoxide (DMSO) or ethanol, or a mixture of suitable solvents. Examples of mixtures of solvents include 10% (by weight) ethanol in water and 2% (by 30 weight) DMSO in water. A solution may further comprise salts, buffering agents, chaotropic agents, detergents, preservatives and the like. Alternatively, the proteins may be in the form of a solid, such as a lyophilised powder or a crystalline solid, which may also comprise a residual solvent, a salt or the like.

As used herein, the term "antibodies" includes polyclonal antibodies, 35 affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding

fragments, such as F(ab')<sub>2</sub>, and Fab' proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veeneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans should be reduced.

Alternative techniques for generating or selecting antibodies useful herein include in vitro exposure of lymphocytes to human prohormone DPRP protein or a peptide therefrom, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled human DPRP protein or peptide). Genes encoding polypeptides having potential human DPRP polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding such polypeptides can be obtained in a number of ways well known in this art.

As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals, such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice and rats, with a human DPRP polypeptide or a fragment thereof. The immunogenicity of a human prohormone DPRP polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant, or surface active substances, such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH or dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and *Corynebacterium parvum* are especially preferable. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of DPRP or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like", such portion may be advantageously joined or linked to a macromolecular carrier, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid, for immunization. Antibodies to DPRP may also be generated using methods that are well known in the art. Such antibodies may

include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which block or modify interactions at the active sites) are especially preferred for therapeutic use.

- 5 For the production of antibodies, binding proteins, or peptides which bind specifically to DPRP, libraries of single chain antibodies, Fab fragments, other antibody fragments, non-antibody protein domains, or peptides may be screened. The libraries could be generated using phage display, other recombinant DNA methods, or peptide synthesis (Vaughan, T. J. et al. Nature Biotechnology 14: 309-314 (1996)). Such  
10 libraries would commonly be screened using methods which are well known in the art to identify sequences which demonstrate specific binding to DPRP.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to DPRP have an amino acid sequence consisting of at least about 5 amino acids and, more preferably, of at least about 10 amino acids. It is also preferable that  
15 these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of DPRP amino acids may also be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to DPRP may be prepared using any well known  
20 technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique, although monoclonal antibodies produced by hybridoma cells may be preferred.

In addition, techniques developed for the production of "chimeric antibodies",  
25 such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used, see Neuberger, M.S. et al. Nature 312: 604-608 (1984). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce DPRP-specific single chain antibodies. Antibodies with related  
30 specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (Burton D. R. Proc. Natl. Acad. Sci. 88: 11120-11123 (1991)).

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly

specific binding reagents as disclosed in the literature. (Orlandi, R. et al. Proc. Natl. Acad. Sci. 86: 3833-3837 (1989)).

Antibody fragments which contain specific binding sites for DPRP may also be generated. For example, such fragments include, but are not limited to, F(ab')<sub>2</sub>,

5 fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (Huse, W. D. et al. Science 254: 1275-1281 (1989)).

10 Various immunoassays may be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between DPRP and its specific antibody. A two-site, monoclonal-based  
15 immunoassay utilizing monoclonal antibodies reactive to two non-interfering DPRP epitopes is preferred, but a competitive binding assay may also be employed.

As earlier mentioned, the DPRPs can be used in treatment of the Diseases. Pharmaceutical compositions suitable for use in this aspect of the invention include compositions wherein the active ingredients are contained in an effective amount to  
20 achieve the intended purpose relating to one of the Diseases. The determination of a therapeutically effective dose is well within the capability of those skilled in the art and can be estimated initially either in cell culture assays, e.g. of neoplastic cells, or in animal models, usually mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration, which  
25 information is then commonly used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, e.g. a DPRP or fragment thereof, antibodies of DPRP, or an agonist, antagonist or inhibitor of DPRP, which ameliorates particular symptoms or conditions of the Disease. For  
30 example, the amount to be administered may be effective to cleave a desired target substrate upon contact therewith. Therapeutic efficacy and toxicity may likewise be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED50 (the dose therapeutically effective in 50% of the population) or LD50 (the dose lethal to 50% of the population) statistics. The dose  
35 ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the

LD<sub>50</sub>/ED<sub>50</sub> ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

- 5 An exact dosage will normally be determined by the medical practitioner in light of factors related to the subject requiring treatment, with dosage and administration being adjusted to provide a sufficient level of the active moiety or to maintain a desired effect.
- 10 Factors to be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or even once every two weeks, depending
- 15 on the half-life and clearance rate of the particular formulation.

Yet another aspect of the invention provides polynucleotide molecules having sequences that are antisense to mRNA transcripts of DPRP1, DPRP2 and DPRP-3 polynucleotides. Administration of an antisense polynucleotide molecule can block the production of the protein encoded by DPRP-1, DPRP2 or DPRP-3. The techniques for 20 preparing antisense polynucleotide molecules and administering such molecules are known in the art. For example, antisense polynucleotide molecules can be encapsulated into liposomes for fusion with cells.

In particular, the expression of DPRP-1, DPRP-2 and DPRP-3 in specialized epithelial cells, immune cells (lymphocytes and B cells), astrocytic tumors, and in 25 various hormone sensitive cancers provides evidence of a potential role in the pathophysiology of cancer, metaplasia and metastasis. Therefore in a further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate DPRP activity or expression levels. Antibodies that specifically bind DPRP may be used for the diagnosis of disorders characterized by expression of DPRP, or in assays to 30 monitor patients being treated with DPRP or with agonists or antagonists (inhibitors) of DPRP. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for DPRP include methods that utilize the antibody and a label to detect DPRP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and they 35 may be labeled by covalent or non-covalent joining with a reporter molecule. A wide

variety of reporter molecules are known in the art. Recombinant DPRP proteins that have been modified so as to be catalytically inactive can also be used as dominant negative inhibitors. Such modifications include, for example, mutation of the active site.

A variety of protocols for measuring DPRP, including ELISAs, RIAs and FACS, 5 are known in the art and provide a basis for diagnosing altered or abnormal levels of DPRP expression. Normal or standard values for DPRP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to DPRP under conditions suitable for complex formation. The method for detecting DPRP in a biological sample would comprise the 10 steps of: a) providing a biological sample; b) combining the biological sample and an anti-DPRP antibody under conditions which are suitable for complex formation to occur between DPRP and the antibody; and c) detecting complex formation between DPRP and the antibody, thereby establishing the presence of DPRP in the biological sample. The amount of complex formation then may be quantified by various methods, 15 preferably by photometric means. Quantities of DPRP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding DPRP are used for diagnostic purposes, which polynucleotides may include oligonucleotide 20 sequences, complementary RNA and DNA molecules, and PNAs. These polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of DPRP may be correlated with one of the Diseases. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of DPRP and to monitor regulation of DPRP levels during therapeutic 25 intervention. Moreover, pharmacogenomic, single nucleotide polymorphisms (SNP) analysis of the DPRP genes can be used as a method to screen for mutations that indicate predisposition to disease or modified response to drugs.

DPRP polynucleotide and polypeptide sequences, fragments thereof, antibodies 30 of DPRPs, and agonists, antagonists or inhibitors of DPRPs can be used to as discovery tools to identify molecular recognition events and therefore proteins, polypeptides and peptides that interact with DPRP proteins. A specific example is phage display peptide libraries where greater than 108 peptide sequences can be screened in a single round of panning. Such methods as well as others are known within the art and can be utilized to identify compounds that inhibit or enhance DPRP-1, DPRP-2 or DPRP-3 activity. 35 Coupled links represent functional interactions such as complexes or pathways, and

proteins that interact with DPRPs can be identified by a yeast two-hybrid system, proteomics (differential 2D gel analysis and mass spectrometry) and genomics (differential gene expression by microarray or serial analysis of gene expression SAGE). Proteins identified as functionally linked to DPRPs and the process of interaction form

5 the basis of methods of screening for inhibitors, agonists and antagonists and modulators of these DPRP-protein interactions.

- The term "antagonist," as it is used herein, refers to an inhibitor molecule which, when bound to DPRP, decreases the amount or the duration of the effect of the biological or immunological activity of DPRP, e.g. decreasing the enzymatic activity of
- 10 the peptidase to cleave the N-terminal dipeptide. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of DPRP; for example, they may include small molecules and organic compounds that bind to and inactivate DPRPs by a competitive or non-competitive type mechanism. Specific examples of DPRP tetrapeptide peptidic enzyme activity inhibitors are
- 15 described in Example 6 and 7. Inhibitors can be, for example, inhibitors of the DPRP protease activity, or alternatively inhibitors of the binding activity of the DPRP to proteins with which they interact. Specific examples of such inhibitors can include, for example, anti-DPRP antibodies, peptides, protein fragments, or small peptidyl protease inhibitors, or small non-peptide, organic molecule inhibitors which are formulated in a
- 20 medium that allows introduction into the desired cell type. Alternatively, such inhibitors can be attached to targeting ligands for introduction by cell-mediated endocytosis and other receptor mediated events. Such methods are described further below and can be practiced by those skilled in the art given the DPRP nucleotide and amino acid sequences described herein.
- 25 A further use for DPRPs is for the screening of potential antagonists for use as therapeutic agents, for example, for inhibiting binding to DPRP, as well as for screening for agonists. DPRP, its immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds which are prospective agonists or antagonists in any of a variety of drug screening techniques. The fragment employed in such screening
- 30 may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between DPRP and the agent being tested is then measured. Other assays to discover antagonists that will inhibit DPRP are apparent from the disclosures of U.S. Patents Nos. 6,011,155, 6,107,317, 6,110,949, 6,124,305 and 6,166,063, which describe inhibitors of DPPIV. Another worthwhile use

of these DPRPs is the screening of inhibitors of DPPIV to show that they will not have undesired side effects by also inhibiting one or more of the DPRPs.

A method provided for screening a library of small molecules to identify a molecule which binds DPRP generally comprises: a) providing a library of small molecules; b) combining the library of small molecules with the polypeptide of either SEQ ID NOS:1, 3 or 5, or with a fragment thereof, under conditions which are suitable for complex formation; and c) detecting complex formation, wherein the presence of such a complex identifies a small molecule which binds DPRP.

One method for identifying an antagonist comprises delivering a small molecule which binds DPRP into extracts from cells transformed with a vector expressing DPRP along with a chromogenic substrate (e.g. Ala-Pro-AFC or Ala-Pro-AMC) under conditions where cleavage would normally occur, and then assaying for inhibition of cleavage by the enzyme by monitoring changes in fluorescence, or UV light absorption, by spectrophotometry to identify molecules that inhibit cleavage. A reduced rate of reaction or total amount of fluorescence or UV light absorption, in the presence of the molecule, establishes that the small molecule is an antagonist which reduces DPRP catalytic/enzymatic activity. Once such molecules are identified, they may be administered to reduce or inhibit cleaving by a DPRP.

The term "agonist," as used herein, refers to a molecule which, when bound to DPRP, increases or prolongs the duration of the effect of DPRP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules that bind to and modulate the effect of DPRP. Although it is less likely that small molecules will prove to be effective DPRP agonists, a method for identifying such a small molecule, which binds DPRP as an agonist, comprises delivering a chromogenic form of a small molecule that binds DPRP into cells transformed with a vector expressing DPRP and assaying for fluorescence or UV light absorption changes by spectrophotometry. An increased amount of UV absorption or fluorescence would establish that the small molecule is an agonist that increases DPRP activity.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with DPRP, or with fragments thereof, and then washed. Bound DPRP is then detected by methods well known in the art. Purified DPRP can also be coated directly onto plates for use in the

aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

- In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding DPRP specifically compete with a test compound for binding DPRP. In this manner, antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants with DPRP.
- 5

As indicated above, by investigating the binding sites, ligands may be designed that, for example, have more interactions with DPRP than do its natural ligands. Such antagonist ligands will bind to DPRP with higher affinity and so function as competitive 10 ligands. Alternatively, synthetic or recombinant proteins homologous or analogous to the ligand binding site of native DPRP may be designed, as may other molecules having high affinity for DPRP. Such molecules should also be capable of displacing DPRP and provide a protective effect.

As indicated above, the knowledge of the structures of DPRP enables synthetic 15 binding site homologues and analogues to be designed. Such molecules will facilitate greatly the use of the binding properties to target potential therapeutic agents, and they may also be used to screen potential therapeutic agents. Furthermore, they may be used as immunogens in the production of monoclonal antibodies, which antibodies may themselves be used in diagnosis and/or therapy as described hereinbefore.

Given the ubiquitous expression of several members of the prolyl oligopeptidase 20 S9B family, cell lines in which targeted gene disruption of DPPIV, DPRP-1, DPRP-2, DPRP-3, FAP and DPPVI to establish the null phenotype will be of great value to assist screening for selective and potent compounds. Accordingly, the invention provides such cell lines engineered with Lox-Neo IRES tk cassette and GFP-IRES-Neo Knock-in/out 25 cassette DNA element for constructing somatic gene targeting vectors.

#### Example 1

##### Cloning and Expression of DPRP genes Using the Mammalian Expression System

DNA fragments encoding the full-length polypeptide DPRP-1 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene, 30 i.e. SEQ ID NO:45 and NO:46. In addition, DNA fragments encoding the full length polypeptide DPRP-2 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of that gene, i.e. SEQ ID NO:50 and NO:51. Furthermore, DNA fragments encoding the full length polypeptide DPRP-3 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of that gene, i.e. SEQ 35 ID NO:55 and NO:56.

The three amplified sequences were respectively isolated from a 0.7% agarose gel using commercially available kit (GFX PCR DNA and Gel Band Purification Kit, Amersham Pharmacia Biotech Inc., Piscataway NJ, USA). The fragments were then ligated into cloning vector, pGEM-7Zf(-) (Promega Corporation, Madison WI, USA) 5 and sequenced. The corresponding cloning constructs were respectively designated pGEM7-DPRP1, pGEM7-DPRP2 and pGEM7-DPRP3. The DNA sequences encoding the truncated DPRP-1 or DPRP-2 or DPRP-3 were amplified using pGEM7-DPRP1 or pGEM7-DPRP2 or pGEM7-DPRP3 as a template and PCR oligonucleotide primers. SEQ ID NO:45 and NO:47 were used for DPRP-1; SEQ ID NO:50 and NO:52 were used 10 for DPRP-2; and SEQ ID NO:57 and NO:58 for DPRP-3. The amplified sequences were again isolated from a 0.7% agarose gel using the same purification kits and sub-cloned into pGEM-7Zf(-). The resulting constructs were designated pGEM7-DPRP1f, pGEM7-DPRP2f and pGEM7-DPRP3f.

To make the DPRP-1 mammalian expression construct, pGEM7-DPRP1 was 15 digested with the restriction enzymes KpnI and NotI to release the full length DPRP-1 gene. The DNA fragment carrying the DPRP-1 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-1 expression construct, which was designated pcDNA-DPRP1. pGEM7-DPRP1f was digested with the restriction enzymes XbaI and HindIII 20 to release the truncated DPRP-1f gene. The DNA fragment carrying the DPRP-1f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His A (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-1 expression construct pcDNA-MycHis-DPRP1.

To make the DPRP-2 mammalian expression construct, pGEM7-DPRP2 was 25 digested with the restriction enzymes HindIII and BamHI to release the full length DPRP-2 gene. The DNA fragment carrying the DPRP-2 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-2 expression construct, which was designated pcDNA-DPRP2. pGEM7-DPRP2f was digested with the restriction enzymes 30 EcoRI and BamHI to release the truncated DPRP-2f gene. The DNA fragment carrying the DPRP-2f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His B (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-2 expression construct designated pcDNA-MycHis-DPRP2.

To make the DPRP-3 mammalian expression construct, pGEM7-DPRP3 was 35 digested with the restriction enzymes EcoRI and XhoI to release the full length DPRP-3

gene. The DNA fragment carrying the DPRP-3 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-3 expression construct designated pcDNA-DPRP3. pGEM7-DPRP3f was digested with the restriction enzymes NheI and ApaI to release the 5 truncated DPRP-3f gene. The DNA fragment carrying the DPRP-3f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His B (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-3 expression construct pcDNA-MycHis-DPRP3.

#### Example 2

##### 10 Expression Pattern of DPRP genes in human tissues

Quantitative PCR analysis was carried out to examine the levels of expression of the mRNAs for the polypeptides of the present invention in human tissues. RT PCR was also carried out on a number of human cell lines including but not limited to prostate cancer cells (LNCaP, PC3, DU145), the MLTC-1 line (mouse testis), and MDA-MB231 15 cells (breast cancer). Bands of the expected sizes for DPRP-1, DPRP-2 and DPPIV were all expressed in the various cancer cells lines, with FAP also being expressed at very low levels.

##### Northern Blot Analysis

20 Northern blot analysis was performed with 2 $\mu$ g poly(A)<sup>+</sup> RNA isolated from eight different tissues using DPRP probes. Specifically, a human Multiple Tissue Northern (MTN) blot (Clontech, Palo Alto, Calif.) was probed with a 1 kb N-terminal fragment that had been radioactively labeled by random priming in the presence of a <sup>32</sup>PdCTP (A. P. Feinberg et al., *Anal. Biochem.*, 132, 6 (1983)). Hybridization was performed at 68°C overnight in ExpressHyb™ hybridization solution (Clontech, Palo 25 Alto, Calif.). The blots were first washed at room temperature in 2 times SSC and 0.05% SDS, and then washed at 60°C (DPRP-1 & DPRP-2) and 50°C (DPRP-3) in 0.1 times SSC and 0.1% SDS.

30 Northern analysis showed expression of DPRP-1 in several tissues with the most abundant signal being in testis, prostate, muscle and brain. Testis showed 3 transcripts approximately 7.5, 4.5 and 2.5 kb in length. The shorter mRNA species was very abundant in testis but negligible in the other tissues tested. DPRP-2 was ubiquitously expressed in every tissue with highest levels in liver and muscle and a predominant transcript at 5kb. DPRP-3 expression was limited to brain and pancreas. Further analysis was conducted for the three proteases in specific brain regions (cerebellum, 35 cortex, medulla, spinal cord, occipital lobe, frontal lobe temporal lobe and putamen).

DPRP-1 was expressed in all regions with low levels present in the spinal cord, while DPRP-2 was expressed in all brain regions tested.

Oligonucleotide primers SEQ ID NO:48 and NO:49 were used for DPRP-1 quantitative PCR, whereas oligonucleotide primers SEQ ID NO:53 and NO:54 were 5 used for DPRP-2 quantitative PCR. Human Multiple Tissue cDNA (MTC<sup>TM</sup>) Panel I and Panel II (Clontech, Palo Alto CA, USA) were used as normalized cDNA templates. 0.5 ng of each cDNA were used in a 25 µl PCR reaction, with each primer at a final concentration of 300 nM. The PCR reaction was performed using a SYBR Green PCR Core Reagents Kit (Applied Biosystems, Foster City CA, USA) and detected with an 10 Applied Biosystems GeneAmp 5700 sequence detection system. Manufacturer's recommended thermal cycling parameter, e.g. 50°C for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min was used. Data obtained shows relatively high rates of expression for both DPRP-1 and DPRP-2 in the pancreas, ovary and testis, and a particularly high rate for DPRP-2 in the liver.

15 **Example 3 – Production of DPRP Polyclonal Antibodies and Western Blotting**

The amino acid sequence deduced from the cDNA encoding DPRP-1 was analyzed using DNASTAR software (DNASTAR, Inc.) to determine regions of high immunogenicity, and a corresponding oligopeptide was synthesized and used to raise anti-DPRP-1 antibodies. The procedure was repeated for DPRP-2 and DPRP-3. The 20 selection of appropriate peptide sequences and the techniques for antibody production are methods well known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is well known in this art.

Typically, oligopeptides that are about 15 to 20 residues in length, e.g. SEQ ID NO:59 for DPRP-1, SEQ ID NO:60 for DPRP-2 and SEQ ID NO:61 for DPRP-3, were 25 synthesized using an Applied Biosystems Peptide Synthesizer Model 431 A. Fmoc-chemistry was used and the 19- or 15-residue peptides were respectively coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, Mo.) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS). Rabbits were immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting 30 antisera were tested for antipeptide activity, e.g., by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

Western blotting was performed using normal human protein samples (Protein Medley) obtained from Clontech (about 36 µg of total proteins). Proteins were 35 fractionated through 10% SDS-polyacrylamide gels, and transferred to 0.45 mm

nitrocellulose membranes. Membranes were blocked in Tris-buffered saline (TBS) with 0.05% Tween 20 and 1% BSA. Anti DPRP-1 or DPRP-2 specific antibodies were used as primary antibodies and were diluted 1:5,000 in Tris-buffered saline with 0.05% Tween 20 (TBST) and the Alkaline Phosphatase (AP) conjugated goat anti-Rabbit IgG (Promega) was diluted 1: 5,000 in the same buffer before use. The positive reaction was visualized by incubating the membrane in Western Blue Stabilized Substrate (Promega) for AP until the bands of interest have reached the desired intensity. DPRP-1 and DPRP-2 proteins were detected in brain, muscles, kidney, prostate, testis and ovary tissues. DPRP-1 and DPRP-2 were synthesized as approximately 101kDa and 100kDa forms, respectively, which are in good agreement with the molecular masses estimated from their primary structure as shown in Table 3.

**Table 3.** Predicted Molecular Weight, Number of potential N-linked glycosylation sites (Asn residues) and predicted pI values of DPRP-1, DPRP-2 and DPRP-3, based on sequence analysis using the method developed by Hopp and Woods, Proc. Nat. Acad. Sci. 78:3824-3828 (1981).

	M.W. (Da.)	No. of Asn	pI
DPRP1	101422	26	5.39
DPRP2	98263	27	6.01
DPRP3	90914	33	6.11

Several additional bands of similar molecular weight were observed. These are thought to be due to the presence of post-translational glycosylation of the proteins. Table 3 also shows the number of potential N-glycosylation sites for the DPRP proteins. The presence of glycosylated and unglycosylated forms of the proteins was evaluated using tunicamycin, an inhibitor of the oligosaccharide synthesis. It is evident that the smaller forms were unglycosylated forms. The correlation between mRNA (Northern analysis) and protein quantity (Western analysis) for DPRP-1 is shown in Table 4.

**Table 4.** Correlation of mRNA and protein expression of DPRP-1 in human tissues

	Heart	Brain	Placenta	Muscles	Kidney	Prostate	Testis	Ovary
<b>Northern</b>	++	+++	+	+++	++	+++	++++	+
<b>Western</b>	-	++++	-	+	++	+	+++	+++

Example 4Immunohistochemical localization of DPRP proteins in human tissues

Four-micron sections were prepared from a number of different formalin-fixed, paraffin-embedded human tissues. Tissue sections were deparaffined through 4 immersions in xylenes for 5 minutes, followed by a graded alcohol series to distilled water. Steam heat induced epitope recovery (SHIER) was used with several different SHIER solutions with and without enzyme digestion tissue in two different concentrations (Ladner et al, Cancer Res.; 60, p 3493-3503, 2000). The treatments and antibody dilutions employed are outlined below.

- 10        1. Blocking Reagent for 15 minutes (Normal Goat Serum)  
            2. Primary Antibody for 25, 60 min or overnight incubation  
            3. Secondary Antibody for 25 minutes (Biotinylated Goat-anti-rabbit IgG)  
            4. Endogenous Peroxidase Blocking for 3 x 1.5 minutes  
            5. ABC (avidin-biotin complex) / Horse Radish Peroxidase for 25 minutes  
15        6. DAB Chromogen for 3 x 5 minutes (Brown reaction product)  
            7. Light Hematoxylin Counter Stain 1 minute

Positive controls were run to assure the detection chemistries and antigen pretreatments were working appropriately. Rabbit IgG was run as a negative control. An avidin-biotin based tissue staining system was used for the detection of the DPRP-1 antibody. Horseradish peroxide was used as a reporter enzyme with DAB as chromogen. After staining, slides were dehydrated through an alcohol series to absolute ethanol followed by xylene rinses. Slides were permanently coverslipped with glass coverslips and permount. Digital images of representative staining, where positive staining was indicated by a dark brown chromogen (DAB-HRP reaction product), were captured using a video camera from Olympus. Hematoxylin counterstain provides a blue nuclear stain to assess cell and tissue morphology.

DPRP-1 rabbit polyclonal antibody labels formalin-fixed, paraffin-embedded human tissues, including normal testis, prostate glands, endometrial glands, tonsils and pancreas. It was also present in endothelial cells of normal ovary, bladder and kidney. Staining was localized in the cytoplasm in epithelial and some stromal cells such as fibroblasts, endothelial cells and lymphocytes. Interestingly in normal testis tested with DPRP-1 antibodies, there was distinctive expression in Leydig cells and multinucleated macrophages found in interstitial tissue, which is the space surrounding the seminiferous tubules. Tonsil B cells were stained with DPRP-1 antibody.

**Example 5****Mammalian and Insect Cell Expression of DPRP Proteins and Purification**

Plasmid DNA of pcDNA-DPRP1, pcDNA-MycHis-DPRP1, pcDNA-DPRP-2 or pcDNA-MycHis-DPRP2 was transfected into PEAK (EdgeBioSystems, Gaithersburg MD, USA) or COS-1 (ATCC CRL-1650) using LipofectAmine (Life Technologies, Gaithersburg MD, USA) method recommended by the manufacturer. Transfected cells were maintained in DMEM with 5% FBS at 37°C with 5% CO<sub>2</sub> for 48 hours. Cells were then collected and used for recombinant protein extraction. Cells were harvested 48 hours after transfection, homogenized and then spun at 18,000 x g for 40 min. The supernata were collected as cytosolic fractions. This fraction was loaded on TALON spin column (Clontech), and His-tagged proteins were eluted with 50mM PBS, 150mM imidazole, pH 7. Recombinant proteins were then detected by western blotting with anti-myc antibody and visualized using a ProtoBlot II AP system (Promega). Recombinant affinity purified fusions of the DPRP-1 and DPRP-2 were detected by western blot, and DPRP-1 and DPRP-2 were synthesized as 112kDa and 109kDa forms as predicted.

Naturally occurring or recombinant DPRP proteins were substantially purified by immunoaffinity chromatography using antibodies specific for DPRP-1, DPRP-2 or DPRP-3. An immunoaffinity column was constructed by covalently coupling DPRP antibodies to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin was blocked and washed according to the manufacturer's instructions.

Media or cell extracts containing DPRP proteins were passed over the immunoaffinity column, and the column was washed under conditions that allow the preferential absorbance of DPRPs (e.g., high ionic strength buffers in the presence of detergent). The column was eluted under conditions that disrupt antibody/DPRP binding (e.g., a buffer of pH 2-3 or a high concentration of a chaotropic, such as urea or thiocyanate ion), and purified DPRP was collected.

**Example 6****Enzymatic Activity of DPRP proteins and Methods of Screening for Inhibitors**

The kinetic properties of recombinant DPRP-1 and DPRP-2 were determined in a continuous fluorimetric assay. Buffer, pH and temperature dependence optimization led to the following assay conditions: Enzyme assays were performed in 50mM PBS, pH7.4 50 µl (50 µg/ml) of purified enzymes were mixed with 1 µl of different concentration of Ala-Pro-AMC (Enzyme Systems). Plates were then incubated at 37°C for 30 min, and

fluorescence was detected using a Wallac 1420 Fluorimeter with  $\lambda_{ex}40355$  and  $\lambda_{em}535$ . The  $K_m$  values of DPRP-1 and DPRP-2 were similar (208 and 161  $\mu\text{M}$  respectively).

- Further biochemical characterization reveals that DPRP-1 and DPRP-2 have similar profiles to DPPIV. The two purified proteases and DPPIV were preincubated
- 5 with inhibitors at room temperature for 30 min. Substrate, Ala-Pro-AMC (100  $\mu\text{M}$ ), was then added, and the fluorescence intensity was recorded as 60 readings during a 60 min period. The irreversible serine protease inhibitor AEBSF was the only inhibitor tested that showed strong inhibition of all three enzymes (Table 5). This confirms the structural and domain analysis prediction that these proteins belong to the serine protease
- 10 superfamily.

**Table 5.** Inhibition of DPRP-1 and DPRP-2 by Protease Inhibitors

Inhibitor	Inhibitor Property	Concentration	Residual activity (% of control)		
			DPRP-1	DPRP-2	DPPIV
AEBSF	serine, irreversible	5mM	29.6	23.9	21.1
Aprotinin	serine, reversible	5 $\mu\text{g}/\text{ml}$	77.5	63.2	80.2
Pepstatin	aspartic, reversible	2 $\mu\text{g}/\text{ml}$	97.3	95.0	93.5
DTT	cysteine	2mM	100.1	94.8	98.3
B-Mercaptoethonal	cysteine	100mM	93.2	84.0	98.0
EDTA	metallo, reversible	2mM	91.5	86.0	93.5
Leupeptin	serine, reversible	50 $\mu\text{g}/\text{ml}$	91.1	90.4	90.7

- 20 In addition to Ala-Pro-AMC, additional substrates tested also confirmed that DPRP-1 and DPRP-2 are dipeptidyl peptidases. The data were derived by determining the fluorescence change following a 30-minute incubation of the substrates (125  $\mu\text{M}$ ) with enzymes as a percentage of the fluorescence measured at Ala-Pro-AMC and Gly-Pro-AMC were the only good substrates among those tested.

- 25 **Table 6.** DPRP-1 and DPRP-2 are dipeptidyl peptidases.

Substrate	% Change in Fluorescence at 30 minutes		
	DPRP-1	DPRP-2	DPPIV
Ala-Pro-AMC	239.0	127.5	379.0
Gly-Pro-AMC	341.5	205.0	444.0
Ala-Pro-pNA	45.5	44.0	29.5
Pro-pNA	-1	-2.5	0.0
Gly-Arg-pNA	-4.5	-0.5	0.0
Lys-Ala-pNA	2.5	0.5	0.5
Ala-Phe-Pro-pNA	-4	-0.5	2.0

Additional natural and non-natural amino acid di-, tri- and tetra-peptides were tested in order to find an optimal substrate for testing each of the DPRP proteins that will also show reduced activity when incubated DPPIV.

The enzyme assay method described here is one of a number of methods that can  
5 be utilized to screen for peptide and non-peptide inhibitors of the DPRP enzymes.  
Libraries of tetrapeptide inhibitors were tested to discover inhibitors of enzyme activity.  
Candidate inhibitors were prepared as 10-20 mM stock solutions in DMSO and stored at  
-20°C. Dilutions were made in assay buffer. Inhibition was determined by comparing  
the changes in fluorescence of the inhibited enzyme to the change in fluorescence of the  
10 control (vehicle) enzyme. 100-(f1 units of sample/f1 units of control x 100) gives  
percent inhibition value. The percent inhibition and the inhibitor concentration at which  
the enzyme was 50% inhibited ( $IC_{50}$ ) was ascertained by plotting percent inhibition vs.  
inhibitor concentration on the log scale. As shown in Figure 3, several tetrapeptides  
amides inhibited enzyme activity, wherein data are expressed as the % of activity in the  
15 presence of vehicle (0.02% DMSO) alone. Compounds were added at 1 mM. Most  
interesting was the apparent differential activity of some tetrapeptides for DPRP-1 and  
DPRP-2, compared to DPPIV. While all three enzymes were inhibited by Peptide-1,  
only DPRP-1 and DPRP-2 were significantly inhibited by Peptide-4 and Peptide-5. This  
demonstrates that selective inhibition of the purified enzymes is achievable.

20 The assay described in this example can also be used to screen additional  
synthetic or naturally occurring compound libraries, including macromolecules, for  
agents that either inhibit or enhance DPRP activity. The DPRP-1 and DPRP-2  
polypeptides to be used in the assay can be obtained by, for example, *in vitro* translation,  
recombinant expression (see Example 5) or biochemical procedures. Methods other than  
25 those described here can also be used to screen and identify compounds that inhibit  
DPRP-1, DPRP-2 or DPRP-3, which methods can include, for example, binding assays  
such as ELISAs and RIAs.

#### Example 7

##### Effect of DPRP Inhibitors on the Proliferation of Human Cancer Cells In Vitro

30 In an attempt to assess the effect that several inhibitors of DPRP-1 and DPRP-2  
activity may have on the proliferation of human cancer cells, LNCap, PC3 and Du145,  
mouse testis line MLTC-1 and MDA-MB231 breast cancer cells were plated ( $10^4$  per  
well) in 96-well tissue culture plates and allowed to grow and attach for 24 hours at 37°C  
in a CO<sub>2</sub> incubator. Compounds at various dilutions (final dilutions: 0.1 nM – 10 µM)  
35 were then added to the wells for various incubation periods from 24 hours to 96 hours,

with fresh compound being replaced each day. Addition of the diluent DMSO alone served as the control. Following incubation with these compounds in triplicate, proliferation of the cells was determined using an XTT cell proliferation assay (Roche 1-465-015). The plates were read at 490 and 650nm 5 hours after the XTT mix was added.

- 5 An increase in cell proliferation was observed with three of the inhibitors at concentrations equal to 0.1, 1, 10 and 100 x IC<sub>50</sub>, and the results are shown in FIGS. 4A, 4B and 4C for PC3 cells.

Overall, the DPRPs are expressed in a wide variety of tissues as has been demonstrated by mRNA amplification, western blotting and immunohistochemistry.

- 10 DPRP-1 was most abundant in the testis by Northern blot and western blot. The large number of expressed sequence tags (ESTs) from testis cDNA sources that are homologous to DPRP-1 also confirms abundant expression of DPRP-1 in testis. Example 4 describes the immunohistochemical localization of DPRP-1 protein in human testis using a specific DPRP-1 antibody. DPRP-1 is strongly expressed in epitheloid Leydig cells, and Leydig cells are the primary source of testicular androgens (male steroid hormones) in the mammalian male. In the interstitium of the testis, Leydig cells and macrophages are in close association with "digitation" of Leydig cell process extending onto macrophage surface. Multinucleated cells in close proximity to the Leydig cells were also stained with DPRP-1 antibody suggesting that the protease was also expressed in macrophages, and macrophages in the testis play an important role in the paracrine regulation of Leydig cells. Cytokines secreted by the testicular macrophages are mitogenic to Leydig cells and play an important role in the differentiation of mesenchymal progenitor cell into mature Leydig cells. A clearer understanding of the proteins and pathways involved in the maturation of the testis is important for the discovery of new treatments for precocious puberty. In addition, Leydig cells cause tumors such as sex cord-stromal tumors via sexual steroid production (predominantly testosterone). Testosterone is associated with several neoplasia and diseases such as breast carcinoma and uterine cancers, ovarian carcinoma and androgenic alopecia (hair loss). Further examination of the localization of DPRP proteins in other glands in the body (e.g. adrenal glands) that produce testosterone and other androgenic hormones are currently under investigation. The possible association of DPRP-1 with steroid and polypeptide hormone biosynthetic pathways functions is being investigated, and Example 7 is relevant to understanding the role of DPRP proteins in prostate, testis and breast in vitro cell models.

Immunochemical analysis also localized DPRP-1 to endometrial glands in the uterus (see Example 4), pancreatic acini, glomeruli of the kidney, plasma cells in the bladder, a subset of B-cells in the tonsils, columnar epithelial cells of the prostate and poorly differentiated prostate squamous metaplasia, Gleason grade 4 prostatic carcinoma, and hyperplastic glands in benign prostatic hyperplasia. Positive staining in breast carcinoma, as well as in seminoma and prostate squamous metaplasia, suggests a general association of DPRP-1 with hormone-sensitive tissues, particularly in cells that become poorly differentiated. The presence of the DPRP-1 in specialized epithelial cells and in inflammatory plasma cells (lymphocytes) is also of interest. Inflammatory breast carcinoma has an abundance of infiltrating lymphocytes and an overall bad prognosis. DPRP-1 and other DPRP proteins appear in medullary carcinomas that typically have a constant infiltrating lymphoplasmacytic component at the periphery of the tumor, which is thought to represent a reaction of the host tissues to the neoplasm. Most of the lymphocytes are T Cells, and most of the plasma cells are of the IgG-producing type.

Several antigens are abundant on B cells, a subgroup of breast-cancer cells, and other epithelial cancer cells, and these antigens are targets for a new class of therapeutic monoclonal antibodies with some notable success having been achieved with a humanized monoclonal antibody against the B-cell-specific antigen CD20. Accordingly, monoclonal antibodies to DPRP proteins are felt to be useful to diagnose and treat diseases in which they are involved, including cancer.

The expression of DPRP-1 in specialized epithelial cells of a number of tissues suggests that DPRP-1 and other DPRP proteins may be involved in growth and differentiation thereof. Testing using inhibitors described in Example 6 in *in vitro* models of prostate and testis cancer (Example 7) showed that DPRP-1/DPRP-2 inhibitors caused a 50-60% increase in proliferation of PC3 cells at nM concentrations as shown in FIGS. 4A-4C.

Although the invention has been described in accordance with its preferred embodiments, which constitute the best mode presently known to the inventors, it should be understood that changes and modifications as would be obvious to those skilled in this art may be made without departing from its scope which is set forth in the claims appended hereto. For example, although the disclosure focuses on DPRP-1 and DPRP-2 in certain instances, DPRP-3 and its fragments are considered to be similarly useful, as are nucleic acids encoding same. Particular features of the invention are emphasized in the claims that follow.

## CLAIMS:

1. Isolated nucleic acid which encodes (a) a polypeptide, which includes the amino acid sequence of one of SEQ ID NOS:1, 3 and 5, or (b) a polypeptide having an amino acid sequence that is at least about 70% similar thereto and exhibits the same biological function; or which is an alternative splice variant of one of SEQ ID NOS:2, 4 and 6; or which is a probe comprising at least 14 contiguous nucleotides from said nucleic acid encoding (a) or (b); or which is complementary to any one of the foregoing.
2. The isolated nucleic acid of claim 1 which is DNA or RNA.
3. The isolated nucleic acid of claim 1 which is a DNA transcript that includes the entire length of any one of SEQ ID NOS:2, 4 and 6 or which is complementary to the entire coding region of one of SEQ ID NOS:2, 4 and 6.
4. An antisense oligonucleotide directed against the DNA of claim 3.
5. The isolated nucleic acid of claim 1 which is an RNA transcript which includes the entire length of any one of SEQ ID NOS:2, 4 and 6.
6. The isolated nucleic acid of claim 1 which is an alternative splice variant of one of SEQ ID NOS:2, 4 and 6.
7. A polypeptide encoded by the nucleic acid of claim 6.
8. The isolated nucleic acid of claim 1 which encodes a polypeptide having an amino acid that is at least about 90% similar to one of SEQ ID NOS:1, 3 and 5.
9. The isolated nucleic acid of claim 1 which encodes a polypeptide having an amino acid that is at least about 95% similar to one of SEQ ID NOS:1, 3 and 5.
10. The isolated nucleic acid of claim 1 which encodes a polypeptide that has at least about 90% identity with one of SEQ ID NOS:1, 3 and 5.
11. A nucleic acid probe according to claim 1 comprising at least 14 contiguous nucleotides from one of SEQ ID NOS:2, 4 and 6.
12. An isolated recombinant polynucleotide molecule comprising nucleic acid according to claim 1 plus expression-controlling elements linked operably with said nucleic acid to drive expression thereof.
13. An expression vector comprising the nucleic acid of claim 1 encoding a polypeptide having the entire amino acid sequence set forth in any one of SEQ ID NOS:1, 3 and 5 operably linked to a promoter, said expression vector being present in a compatible host cell.

14. A mammalian, insect or bacterial host cell that has been genetically engineered by the insertion of nucleic acid according to claim 1 which codes for at least the mature protein portion of the amino acid sequence of SEQ ID NO:1, 3 or 5.

15. A process for producing a polypeptide which includes the mature protein portion of one of SEQ ID NOS:1, 3 and 5, which process comprises culturing the host cell of claim 11 under conditions sufficient for the production of said polypeptide.

16. The process of claim 15 wherein said polypeptide is expressed at the surface of said cell and further includes the step of recovering the polypeptide or a fragment thereof from the culture.

17. A polypeptide

which may be optionally glycosylated, and

which (a) has the amino acid sequence of a mature protein set forth in any one of SEQ ID NOS:1, 3 and 5; (b) has the amino acid sequence of a mature protein having at least about 70% similarity to one of the mature proteins of (a) and which exhibits the same biological function; (c) has the amino acid sequence of a mature protein having at least about 90% identity with a mature protein of any of SEQ ID NOS:1, 3 and 5; or (d) is an immunologically reactive fragment of (a).

18. The polypeptide according to claim 14 which is a mature protein having at least about 95% similarity to a mature protein of (a).

19. The polypeptide according to claim 14 which is a mature protein having at least about 95% similarity to a mature protein of (a).

20. The polypeptide according to claim 14 having the amino acid sequence of the mature protein of one of SEQ ID NOS:1, 3 and 5, or is a fragment thereof which exhibits the same biological function as the respective mature protein.

21. A DPRP antagonist which inhibits the biological function of one of said mature proteins of claim 17, 18 and 19.

22. An antibody that recognizes a polypeptide or a fragment according to claim 17.

23. The antibody of claim 22 which recognizes a polypeptide having an amino acid sequence of SEQ ID NO:1 or 3 or 5.

24. A method for the screening for a compound capable of inhibiting the enzymatic activity of at least one mature protein of claim 17, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more test compounds or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the

absence of a test compound, and selecting the test compound or compounds that reduce the enzymatic activity.

25. A method for the screening for a compound capable of inhibiting the enzymatic activity of DPPIV that does not inhibit the enzymatic activity of at least one of the mature proteins of claim 20, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more inhibitors of DPPIV or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the absence of the DPPIV inhibitor, and selecting a compound that does not reduce the enzymatic activity of said mature protein.

DPP4	1	.....MFTPNVLLCGLC.....AAEFLT
DPRP1	1	MAAAMETEQLGVFETADCENIESQDRPKPEFYVEYSWSLKKKLEDTRKYHGYMM
DPRP2	1	.....ATTGTPADRGDAAATDDPAARFQVKHSWDGLESEHGRKYSGLV
DPRP3	1	.....NOTAEVSHIKCOPSKTEKELGSNSPPQESWKGLIAIALLVILVCS
DPP4	20	ITVPVVLLNKGTLCATADSRTYTLTD...MLKN..TYRLKLYRWISDHEYLKQEN
DPRP1	61	AKAPHDFIFVKRNPDGPHSDRYYLAMSGENRENELFYSEIPKINRAAVIMLSUKPLL
DPRP2	50	NKAPHDEOFVORTDESGPHSHRYYLAMPYGSRENELLYSETPKKURKEALLLLSJKOML
DPRP3	48	ITMSVILLSP..DELTNSSETRLSED..LFRKE..EVLHD.PEARWINDTDVVIKSEN
DPP4	75	.LVLVNAEYGNSS....FLENSTFDEFCHSINDYSASPDGQFNLLEYNYVKQMRHSYT
DPRP1	121	.DFQATIYGMSREEELLRERKRIGTVGIASYDYHQG.SGTFLFOAGSGGTHVBDGGP
DPRP2	110	.DHFOATPHHGMSREEELLRERKRLGVFGTISYDHESE.SGLFLFOASMSLHC RDGGK
DPRP3	101	GHIKLMETNAT....LLENTTEVTI..KHSRHSASPDLKMLLAYDVVKOIEHSYI
DPP4	130	ASNDIYDINK...RCLITEERIPNNTOQWVWSPVGHKLAQNNNDIVVKIEPNLPSYR
DPRP1	179	QGETQQPIEP...NIETSCPNI. MDPKICPADPDWIAIHSNDIVSNIVTREERRLT
DPRP2	168	NGAMISPEZP...LEIKTQCSGPR. MDPKICPADPAEFLINNSDEVANIEGEERRLT
DPRP3	155	ASQVYINNTREVWELNPPEVEDSVIQAAGVQGQOLIIEENAIYQOPDIKSSSLRLT
DPP4	187	AG....KEIDITYNCITDWVYEEEVFSAYSALWWSPNCTELAY....A..QENLNEVP
DPRP1	235	VHMEIANMEEDARSAGVATEVLFQEEFDRSYWWCPKAETTPS.GGKILRILYEENDES
DPRP2	224	ECHOGLSNVLEDPKSAGVATFVIQEEFDRSYWWCPTAQEESEGLKTLRILYEEDES
DPRP3	215	SSG....KEPIIFNQIADWLYEEELLHSIHWWSPDGERLAF.....LQINPSLVP
DPP4	235	LAEYSFYADESLQYPKTVRVPYPKAGAVNP..TKEFVVNTDSLSSNTNATSIDTAPAS
DPRP1	294	EVEIIHVTSPLLETRRADSRYPKTGEANPKVTEKSEEMIDAEGRNIFDVIDKELQPFE
DPRP2	284	EVEVIHVPSPALEERKTDSYFYPETGSKNPKEAEKLAEFOTDSOGKIVSTQEKELOPFS
DPRP3	263	TEVIPRFTGAQYP...KGKOYYPKAGQVNP..TAKLEVNLVLYG....PTHTLELPEDS
DPP4	293	ELIG.DHYCDVTWAHQ.ERISQWLRRION.....
DPRP1	354	LFEGVEYIARAGWTPEGKYAWAFLDRSOTRLQVLSPELFIPVEEDVMERQRRIESV
DPRP2	344	SLFPKVEYIARAGWTRDGKYAWAFLDRPOQWLOVLPALFIPSTNEEQRLASARAV
DPRP3	314	FKSR.EYYITMVKWVN.TKTVWRWLNRPQN.....
DPP4	322	.YSVYDQCDYDGGGRWNCLVARQHEMSHTGWVGRFRPSEEHFTLDGNSFYKIISNE..
DPRP1	414	PDSVTPLIIYEEITDWINIHDIFFPQS.HEEEEFIFASECKTGFRHLYKITSZLKE
DPRP2	404	PRNVQPYVVYEEVTNQWINHDIFYPFQSEGDEDPCFIRANECKTGFOHLYKETAVLKS
DPRP3	343	.ISIETCETTTG.....ACSKYEMTSPTWLSQNE.EPVFSRDGSFIMTVPVKQG

FIG. 1A

DPP4	379	E.....GRRHICYFQIDK.....ECEATKGTWEVREG....IEAITSSELYYYISNEYK
DPRP1	473	SAYKRSSGGLPAPSFKCPIK....EEIAITSGEWEVEGRHGSNIQVDEVRALVYFEGTK
DPRP2	464	QGYDWSEPFSEGEDFKCPIK....EEIAITSGEWEVEGRHGSKIWVNEETLVYEGTK
DPRP3	394	GR.....GEFHIIAMFLIQSKSEQITVRHITSGNWEVIK....IAYDETTQKTYFLSTE
DPP4	424	GMPGGRNLYKEQLSDYTKVTCLSCELNPERCQYYSVSFSKEEKYYGLRGSGPGLEPYTLH
DPRP1	529	DSPLEPHLYVVSYVNPGEVTRLADRCYSHSCCISQHCDFLSKYSNONP.HCVSLEYKLS
DPRP2	520	DIPLEPHLYVVSYEAGEAVRLTPGNSHSCMSQNFDMFSSYSSYSTP.PCVHLYKLS
DPRP3	445	SSPRGEOLYSASTEQLLNRCQCNFMKEOCHYFDASFSPMNQHFLLFOEGPRVPVSIH
DPP4	484	SSVNDKGLEYEDNSALDKMLQNVOMPSKKLDLLENFTREMYQMLPPHFDKSKKYP
DPRP1	588	SPEDDPPTCKTKEFWAEEAGPLPDYTPPEIFSFESTFGTLYGMLYKPHDLOPGKKYP
DPRP2	579	GPDPPDPLHKOPREWAKMEASCPPDYVPPEIFFHHERSDUVRILYGMELYKPHALQPGKKHP
DPRP3	505	STDNPACYFILFSNSMLKEAILKKKIGKP..ETPTEHHDDYELPLQLSLPRDFMDRNOYA
DPP4	542	LFLDVYANGPCSQKAETVFE..LNWATYLAENIIVASFDGRGSGQGDKIMHAINRREG
DPRP1	648	TWLFYGGPQVQLVNNFKGKYGRNLTIASLGYVVVIDNRGSCHRGLKFEGAEKYNG
DPRP2	639	TWLFVYGGPQVQLVNNFSKGEKYLRNLTASLGYAVVVIDGRGSCQRGLKFEGAEKNQMG
DPRP3	563	LFLINDEEPGGQLVTEKF..IDWDHSVLEDMDNV1VARFDGRGSGEOGLKILQEIRRLIG
DPP4	600	TEEVEDQEEARQES.KMGFVDNKRNIAIWGSYGGYMSMVLGSGSGVFKCGIAVAPVER
DPRP1	708	QIEEDQEEALQFLASRYDFIDLDRVGIHCWSYGGYLSLMALFQSDIEBVIAJAGAPVT
DPRP2	699	QVEVEDQEEALQFLAEKYGFIDLRSVATHGWSYGGNLSLMGLHPOVFKVIAJAGAPVT
DPRP3	621	SVEVKDQITAWKFL.KLPWIDSKRCSIEGKGYGGYMSMILKSDEKEFNCSSVVAPETD
DPP4	659	WEEYDSVYTERYMGEPTPEDNLHDTRNSTVMSRAENFKQVEYLEHGTAENVHFOQSAQ
DPRP1	768	WEEYDGYTERYMGHPDQNEEGYYLGSVALQAEKEESEPNRLIHGFLDENVHEAHISI
DPRP2	759	WMAYDGYTERYMDPENNQHGYEAGSVAEHVEKLPNEPNRLIHGFLDENVHFHNINF
DPRP3	680	LKLYASVTERYMGPSKEES..TYQAAVHNVHGLKEENLICHGTAADTKVHFQHSAE
DPP4	719	ISKALDVGVDTQAMWYTDEDHGIASSTEHCHIYTHSHFEEKCFSLP.....
DPRP1	828	LESFLWRAGKPYDLQIYPQERHSIRVPESEGEHYELHLLLHLOENLGSRIAAALKVI.....
DPRP2	819	LWSQLIRAGKPYQLQIYPNERHSIRCPESGEHYEVTLHFLQEYL.....
DPRP3	738	LEKHLIAGVNNTMOKYPDEGHNYSK.SKYHLYSTELAFFSCLKEEISVLPQEPEDDE

FIG. 1B

hDPRP1	1	MAAAMETEQLGVEIFETADCEEN.
mDPRP1	1	MAAAMETEQLGVEIFETADCEEGNGESQDRPKLEPFYVERYSWSQLKKLLADTRKYHGYM
hDPRP1	60	MAKAPHDFMFVKRNDPDGPHSDRYYLAMSGENRENTLFYSEIPKTINRAAVLMLSWKPL
mDPRP1	61	MAKAPHDFMFVKRNDPDGPHSDRYYLAMSGENRENTLFYSEIPKTINRAAVLMLSWKPL
hDPRP1	120	LDLFQATLDYGMYSREEELLRERKRIGTVGIA SYDYHOGSGTFLFQAGSGIYH KDGGPQ
mDPRP1	121	LDLFQATLDYGMYSREEELLRERKRIGTVGIA AYDYHOGSGTFLFQAGSGIYH KDGGPQ
hDPRP1	180	GFTQQPLRPNLVETSCPNT RMDPKLC PADPDWIAFIHSNDI WISN VTREERR TYVHNE
mDPRP1	181	GFTQQPLKP NLVETSCPNT RMDPKLC PADPDWIAFIHSNDI WISN VTREERR TYVHNE
hDPRP1	240	LANMEEDARSAGVATFVLQEEFD RYSGYWWCPKAETPSGGKILRILYEENDESEVEIIH
mDPRP1	241	LANMEEDPRSAGVATFVLQEEFD RYSGYWWCPQAERTPSGGKILRILYEENDESEVEIIH
hDPRP1	300	VTSPMLETRRADSF RY PKTGTANPKVTFKMSEI DAEGRIIDVIDKEL QPFEILFEGV
mDPRP1	301	VTSPMLETRRADSF RY PKTGTANPKVTFKMSEI DAAGGIIDVIDKEL QPFEILFEGV
hDPRP1	360	EYIARAGWTPEGKIAWSII LDRSQTE LQIVLISPELFIPV EDDAM RQLIESVPDSVTP
mDPRP1	361	EYIARAGWTPEGKIAWSII LDRSQTE LQIVLISPELFIPV EDDAM RQLIESVPDSVTP
hDPRP1	420	LIIYEETTDIWINIHDIFHVFPQHE EIEFIFASECKTGFRHLYKITSILKESKYKRSS
mDPRP1	421	LIIYEETTDIWINIHDIFHVFPQHE EIEFIFASECKTGFRHLYKITSILKESKYKRSS
hDPRP1	480	GGLPAPSDFKCPIKEEIAITSGEWEVLGRHGSNIQVDEVRLVYFEGTKDSPLEHHLYVV
mDPRP1	481	GGLPAPSDFKCPIKEEITITSGEWEVLGRHGSNIWVDEARL VYFEGTKDSPLEHHLYVV
hDPRP1	540	SYVNPGEVTRLTDRGYSHSCC SOHCDF FISKYSNQKNPHCVSLYKLSSPEDDP TCKTKE
mDPRP1	541	SYANPGEVVR LTD RGYSHSCC SRHCDF FISKYSNQKNPHCVSLYKLSSPEDDP VHKTKE
hDPRP1	600	FWATILD SAGPLPDYTPPEIFS FESTTGFTLYGMLYKPHDLQPGKKYPTVLFYGGPQVQ
mDPRP1	601	FWATILD SAGPLPDYTPPEIFS FESTTGFTLYGMLYKPHDLQPGKKYPTVLFYGGPQVQ
hDPRP1	660	LVNNRFKGKVYFRLNTLASLG YVVV VIDNRGSCHRGLKFEGAFKYKMGQIEIDDQVEGLQ
mDPRP1	661	LVNNRFKGKVYFRLNTLASLG YVVV VIDNRGSCHRGLKFEGAFKYKMGQIEIDDQVEGLQ
hDPRP1	720	YLASRYDFT DLD RVG I H GWS YGGYLSI M ALM QRS D I FRVAIAGAPVTLW IFYDTGYTERY
mDPRP1	721	YLASQYDFT DLD RVG I H GWS YGGYLSI M ALM QRS D I FRVAIAGAPVTLW IFYDTGYTERY
hDPRP1	780	MGH PDQNEQGYYLGSVAMQAEKFPSEPNRLLLHGFLDENVFAHTSILLSFLVRAGKPY
mDPRP1	781	MGH PDQNEQGYYLGSVAMQAEKFPSEPNRLLLHGFLDENVFAHTSILLSFLVRAGKPY
hDPRP1	840	DLQIYPQERHSIRVPESGEHYELHILH YLQENLGSRIAALKVI
mDPRP1	841	DLQIYPQERHSIRVPESGEHYELHLLH YLQENLGSRIAALKVI

FIG. 2




FIG. 3




FIG. 4A




FIG. 4B




FIG. 4C

Sequence Listing Summary

## SEQ ID.

1. DPRP1 a.a. sequence
2. DPRP1 DNA sequence
- 5      3. DPRP2 a.a. sequence
4. DPRP2 DNA sequence
5. DPRP-3 a.a. sequence
6. DPRP-3 DNA sequence
7. DPRP-1 transcript 0 a.a. sequence
- 10     8. DPRP-1 transcript 0 DNA sequence
9. DPRP-1 transcript 1 a.a. sequence
10. DPRP-1 transcript 1 DNA sequence
11. DPRP-1 transcript 2 a.a. sequence
12. DPRP-1 transcript 2 DNA sequence
- 15     13. DPRP-1 transcript 3 a.a. sequence
14. DPRP-1 transcript 3 DNA sequence
15. DPRP-1 transcript 4 a.a. sequence
16. DPRP-1 transcript 4 DNA sequence
17. DPRP-1 transcript 5 a.a. sequence
- 20     18. DPRP-1 transcript 5 DNA sequence
19. DPRP-1 transcript 6 a.a. sequence
20. DPRP-1 transcript 6 DNA sequence
21. DPRP-1 transcript 7 a.a. sequence
22. DPRP-1 transcript 7 DNA sequence
- 25     23. DPRP-2 transcript 0 a.a. sequence
24. DPRP-2 transcript 0 DNA sequence
25. DPRP-2 transcript 1 a.a. sequence
26. DPRP-2 transcript 1 DNA sequence
27. DPRP-2 transcript 2 a.a. sequence
- 30     28. DPRP-2 transcript 2 DNA sequence
29. DPRP-2 transcript 3 a.a. sequence
30. DPRP-2 transcript 3 DNA sequence
31. DPRP-2 transcript 4 a.a. sequence
32. DPRP-2 transcript 4 DNA sequence
- 35     33. DPRP-2 transcript 5 a.a. sequence

- 34. DPRP-2 transcript 5 DNA sequence
- 35. DPRP-2 transcript 6 a.a. sequence
- 36. DPRP-2 transcript 6 DNA sequence
- 37. DPRP-2 transcript 7 a.a. sequence
- 5 38. DPRP-2 transcript 7 DNA sequence
- 39. DPRP-2 transcript 8 a.a. sequence
- 40. DPRP-2 transcript 8 DNA sequence
- 41. DPRP-3 transcript 0 a.a. sequence
- 42. DPRP-3 transcript 0 DNA. Sequence
- 10 43. DPRP-3 transcript 1 a.a. sequence
- 44. DPRP-3 transcript 1 DNA sequence
- 45. DPRP1 forward primer used for cloning
- 46. DPRP1 reverse primer used for cloning full length gene
- 47. DPRP1 reverse primer used for cloning fusion gene
- 15 48. DPRP1 forward primer used for expression profiling
- 49. DPRP1 reverse primer used for expression profiling
- 50. DPRP2 forward primer used for cloning
- 51. DPRP2 reverse primer used for cloning full length gene
- 52. DPRP2 reverse primer used for cloning fusion gene
- 20 53. DPRP2 forward primer used for expression profiling
- 54. DPRP2 reverse primer used for expression profiling
- 55. DPRP3 forward primer used for cloning
- 56. DPRP3 reverse primer used for cloning full length gene
- 57. DPRP3 forward primer used for cloning fusion gene
- 25 58. DPRP3 reverse primer used for cloning fusion gene
- 59. DPRP1 peptide antigen sequences
- 60. DPRP2 peptide antigen sequences
- 61. DPRP3 peptide antigen sequences

## SEQUENCE LISTING

<110> Qi, Steve  
Akinsanya, Karen  
Riviere, Pierre  
Junien, Jean-Louis

<120> NOVEL SERINE PROTEASE GENES RELATED TO DPPIV

<130> 70669

<150> US 60/240,117

<151> 2000-10-12

<160> 61

<170> Patent In version 3.1

<210> 1  
<211> 882  
<212> PRT  
<213> Homo sapiens  
<400> 1

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu  
1 5 10 15  
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu  
20 25 30  
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu  
35 40 45  
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro  
50 55 60  
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser  
65 70 75 80  
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr  
85 90 95  
Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu  
100 105 110  
Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp  
115 120 125  
Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg  
130 135 140  
Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly  
145 150 155 160  
Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly  
165 170 175  
Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu  
180 185 190  
Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp  
195 200 205  
Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn  
210 215 220  
Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu  
225 230 235 240  
Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val  
245 250 255

Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys  
                  260                 265                 270  
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu  
                  275                 280                 285  
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met  
                  290                 295                 300  
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr  
                  305                 310                 315                 320  
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala  
                  325                 330                 335  
 Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe  
                  340                 345                 350  
 Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr  
                  355                 360                 365  
 Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr  
                  370                 375                 380  
 Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu  
                  385                 390                 395                 400  
 Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser  
                  405                 410                 415  
 Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn  
                  420                 425                 430  
 Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile  
                  435                 440                 445  
 Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr  
                  450                 455                 460  
 Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly  
                  465                 470                 475                 480  
 Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile  
                  485                 490                 495  
 Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn  
                  500                 505                 510  
 Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys  
                  515                 520                 525  
 Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro  
                  530                 535                 540  
 Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys  
                  545                 550                 555                 560  
 Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys  
                  565                 570                 575  
 Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp  
                  580                 585                 590  
 Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala  
                  595                 600                 605  
 Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser  
                  610                 615                 620  
 Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu  
                  625                 630                 635                 640  
 Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Pro  
                  645                 650                 655  
 Gln Val Gln Leu Val Asn Asn Arg Phe Lys Gly Val Lys Tyr Phe Arg  
                  660                 665                 670  
 Leu Asn Thr Leu Ala Ser Leu Gly Tyr Val Val Val Ile Asp Asn  
                  675                 680                 685  
 Arg Gly Ser Cys His Arg Gly Leu Lys Phe Glu Gly Ala Phe Lys Tyr  
                  690                 695                 700  
 Lys Met Gly Gln Ile Glu Ile Asp Asp Gln Val Glu Gly Leu Gln Tyr  
                  705                 710                 715                 720

Leu Ala Ser Arg Tyr Asp Phe Ile Asp Leu Asp Arg Val Gly Ile His  
 725 730 735  
 Gly Trp Ser Tyr Gly Gly Tyr Leu Ser Leu Met Ala Leu Met Gln Arg  
 740 745 750  
 Ser Asp Ile Phe Arg Val Ala Ile Ala Gly Ala Pro Val Thr Leu Trp  
 755 760 765  
 Ile Phe Tyr Asp Thr Gly Tyr Thr Glu Arg Tyr Met Gly His Pro Asp  
 770 775 780  
 Gln Asn Glu Gln Gly Tyr Tyr Leu Gly Ser Val Ala Met Gln Ala Glu  
 785 790 795 800  
 Lys Phe Pro Ser Glu Pro Asn Arg Leu Leu Leu His Gly Phe Leu  
 805 810 815  
 Asp Glu Asn Val His Phe Ala His Thr Ser Ile Leu Leu Ser Phe Leu  
 820 825 830  
 Val Arg Ala Gly Lys Pro Tyr Asp Leu Gln Ile Tyr Pro Gln Glu Arg  
 835 840 845  
 His Ser Ile Arg Val Pro Glu Ser Gly Glu His Tyr Glu Leu His Leu  
 850 855 860  
 Leu His Tyr Leu Gln Glu Asn Leu Gly Ser Arg Ile Ala Ala Leu Lys  
 865 870 875 880  
 Val Ile

<210> 2  
 <211> 2671  
 <212> DNA  
 <213> Homo sapiens  
 <400> 2

cggttaccatg	gcagcagcaa	tggaaacaga	acagctgggt	gtttagatat	ttgaaactgc	60
ggactgtgag-	gagaatattt-	aatcacagga	tcggcctaaa	ttggagcctt	tttatgttga	120
gcggatttcc-	tggagtgcgc-	ttaaaaaagct	gcttgcgcgt	accagaaaaat	atcatggcta	180
catgatggct	aaggcaccac	atgatttcat	gttgtgaag	aggaatgatc	cagatggacc	240
tcattcagac-	agaatetatt-	accttgccat	gtctggtag	aacagagaaa	atacactgtt	300
ttattctgaa	atccccaaaa	ctatcaatag	agcagcagtc	ttaatgctct	cttggaaagcc	360
tcttttggat	cttttcagg	caacactgga	ctatggatg	tattctcgag	aagaagaact	420
attaagagaa	agaaaacgca	ttggaacagt	cggaattgct	tcttacgatt	atcaccaagg	480
aagtggaca	tttctgtttc	aagccggtag	tggatttat	cacgtaaaag	atggagggcc	540
acaaggattt	acgcaacaac	ctttaaggcc	caatctagtg	gaaacttagtt	gtcccaacat	600
acggatggat	ccaaaattat	gcctgctga	tccagactgg	attgctttt	tacatagcaa	660
cgtatattgg	atatctaaca	tcgttaaccag	agaagaaaagg	agactcaatt	atgtgcacaa	720
tgagctagcc	aacatggaaag	aagatgccag	atcagctgga	gtcgctacct	ttgttctcca	780
agaagaattt	gatagatatt	ctggctattt	gtgggtgtcca	aaagctgaaa	caactcccag	840
tgggtgtaaa	attcttagaa	ttcttatatga	agaaaatgt	aatctgagg	tggaaatttat	900
tcatgttaca	tcccctatgt	tggaaacaag	gagggcagat	tcattccgtt	atcctaaaac	960
aggtacagca	aatcctaaag	tcacttttaa	gatgtcagaa	ataatgattt	atgctgaagg	1020
aaggatcata	gatgtcatag	ataaggaact	aattcaaccc	ttttagattt	tatttgaagg	1080
agttgaatat	attgccagag	ctggatggac	tcctgaggga	aatatgttt	ggtccatcct	1140
actagatcgc	tcccagactc	gcctgcagat	agtgttgatc	tcacctgaat	tatttattccc	1200
agtagaaat	gatgttatgg	aaaggcagag	actcatttgag	tcagtgctt	attctgtgac	1260
gccactaatt	atctatgaag	aaacaacaga	catctggata	aatatccatg	acatcttca	1320
tgttttccc	caaagtacg	aagagggaaat	tgagtttatt	tttgcctctg	aatgaaaaac	1380
aggtttccgt	catttataca	aaattacatc	tattttaaag	gaaagcaaat	ataaacgatc	1440
cagtgggtgg	ctgcctgctc	caagtgtattt	caagtgcct	atcaaagagg	agatagcaat	1500
taccagtgtt	gaatgggaag	ttcttggccg	gcatggatct	aatatccaag	ttgtatgttgt	1560
cagaaggctg	gtatattttg	aaggcaccaa	agactcccct	tttagagcatc	acctgtacgt	1620
agtcaagttac	gtaaatccctg	gagaggtgac	aaggctgact	gaccgtggct	actcacattc	1680
ttgctgcattc	agtcagact	gtgacttctt	tataagtaag	tatagtaacc	agaagaatcc	1740
acactgtgtg	tcccttaca	agctatcaag	tcctgaagat	gacccaacct	gaaaaacaaa	1800
ggaattttgg	gccaccattt	tgattcagc	aggtccctt	cctgactata	ctcccccaga	1860
aattttctct	tttgaagta	ctactggatt	tacattgtat	gggatgtctt	acaagcctca	1920

tgatctacag	cctggaaaaga	aatatcctac	tgtgctgttc	atatatggtg	gtcctcaggt	1980
gcagttggtg	aataatcgat	ttaaaggagt	caagtatttc	cgcttgaata	ccctagcctc	2040
tctaggttat	gtgggttag	tgatagacaa	cagggatcc	tgtcaccgag	ggcttaaatt	2100
tgaaggcgcc	tttaaatata	aatgggtca	aatagaatt	gacgatcagg	tggaaggact	2160
ccaatatcta	gcttctcgat	atgatttcat	tgacttagat	cgtgtggca	tccacggctg	2220
gtcctatgga	ggataacctct	ccctgatggc	attaatgcag	aggtcagata	tcttcagggt	2280
tgctattgct	ggggccccag	tcactctgtg	gatcttctat	gatacaggat	acacggaacg	2340
ttatatgggt	caccctgacc	agaatgaaca	gggctattac	ttaggatctg	tggccatgca	2400
agcagaaaag	ttcccctctg	aaccaaattcg	tttactgctc	ttacatgggt	tcctggatga	2460
gaatgtccat	tttgcacata	ccagtatatt	actgagttt	ttagtgaggg	ctggaaaagcc	2520
atatgattta	cagatctatc	ctcaggagag	acacagcata	agagttcctg	aatcgggaga	2580
acattatgaa	ctgcacatctt	tgcaactacct	tcaagaaaac	cttggatcac	gtattgctgc	2640
tctaaaagtg	atatgagcgg	ccgcgagctc	c			2671

<210> 3  
<211> 863  
<212> PRT  
<213> Homo sapiens  
<400> 3

Met Ala Thr Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala			
1	5	10	15
Thr Asp Asp Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp			
20	25	30	
Gly Leu Arg Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile			
35	40	45	
Val Asn Lys Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu			
50	55	60	
Ser Gly Pro His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly			
65	70	75	80
Ser Arg Glu Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg			
85	90	95	
Lys Glu Ala Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe			
100	105	110	
Gln Ala Thr Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu			
115	120	125	
Arg Glu Arg Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe			
130	135	140	
His Ser Glu Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe			
145	150	155	160
His Cys Arg Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys			
165	170	175	
Pro Leu Glu Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys			
180	185	190	
Ile Cys Pro Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp			
195	200	205	
Leu Trp Val Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe			
210	215	220	
Cys His Gln Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly			
225	230	235	240
Val Ala Thr Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr			
245	250	255	
Trp Trp Cys Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr			
260	265	270	
Leu Arg Ile Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile			
275	280	285	
His Val Pro Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg			
290	295	300	
Tyr Pro Arg Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala			
305	310	315	320

Glu Phe Gln Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys  
                  325                 330                 335  
 Glu Leu Val Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile  
                  340                 345                 350  
 Ala Arg Ala Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe  
                  355                 360                 365  
 Leu Asp Arg Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala  
                  370                 375                 380  
 Leu Phe Ile Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala  
                  385                 390                 395                 400  
 Arg Ala Val Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val  
                  405                 410                 415  
 Thr Asn Val Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln  
                  420                 425                 430  
 Ser Glu Gly Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys  
                  435                 440                 445  
 Thr Gly Phe Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln  
                  450                 455                 460  
 Gly Tyr Asp Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys  
                  465                 470                 475                 480  
 Cys Pro Ile Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val  
                  485                 490                 495  
 Leu Ala Arg His Gly Ser Lys Ile Trp Val Asn Glu Glu Thr Lys Leu  
                  500                 505                 510  
 Val Tyr Phe Gln Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr  
                  515                 520                 525  
 Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro  
                  530                 535                 540  
 Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val  
                  545                 550                 555                 560  
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys  
                  565                 570                 575  
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp  
                  580                 585                 590  
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro  
                  595                 600                 605  
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met  
                  610                 615                 620  
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val  
                  625                 630                 635                 640  
 Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe  
                  645                 650                 655  
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr  
                  660                 665                 670  
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg  
                  675                 680                 685  
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp  
                  690                 695                 700  
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp  
                  705                 710                 715                 720  
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser  
                  725                 730                 735  
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala  
                  740                 745                 750  
 Gly Ala Pro Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu  
                  755                 760                 765

Arg	Tyr	Met	Asp	Val	Pro	Glu	Asn	Asn	Gln	His	Gly	Tyr	Glu	Ala	Gly
770					775					780					
Ser	Val	Ala	Leu	His	Val	Glu	Lys	Leu	Pro	Asn	Glu	Pro	Asn	Arg	Leu
785					790				795					800	
Leu	Ile	Leu	His	Gly	Phe	Leu	Asp	Glu	Asn	Val	His	Phe	His	Thr	
					805				810				815		
Asn	Phe	Leu	Val	Ser	Gln	Leu	Ile	Arg	Ala	Gly	Lys	Pro	Tyr	Gln	Leu
					820			825			830				
Gln	Ile	Tyr	Pro	Asn	Glu	Arg	His	Ser	Ile	Arg	Cys	Pro	Glu	Ser	Gly
					835			840			845				
Glu	His	Tyr	Glu	Val	Thr	Leu	Leu	His	Phe	Leu	Gln	Glu	Tyr	Leu	
					850			855			860				

<210> 4  
<211> 2617  
<212> DNA  
<213> Homo sapiens  
<400> 4

caagcttacc	atggccacca	ccgggacccc	aacggccgac	cgaggcgacg	cagccgccac	60
agatgacccg	gccgcccgt	tccaggtgc	gaagcactcg	tggacgggc	tccggagcat	120
catccacggc	agccgcaga	actcgggc	cattgtcaac	aaggcgcccc	acgacttcca	180
gttgtgcag	aagacggatg	agtctggcc	ccactccac	cgcctctact	acctggaaat	240
gccatatggc	agccgagaga	actccctcct	ctactctgag	attcccaaga	aggtccggaa	300
agaggctctg	ctgctcctgt	cctggaagca	gatgctggat	catttccagg	ccacgccccca	360
ccatggggtc	tactctcggg	aggaggagct	gctgagggag	cggaaaacgccc	tgggggtctt	420
cggcatcacc	tcctacgact	tccacagcga	gagtggcctc	ttccttctcc	aggccagcaa	480
cagcctcttc	cactgtcg	acggcggca	gaacggcttc	atgggttccc	ctatgaaacc	540
gctggaaatc	aagaccagt	gctcagggcc	ccggatggac	cccaaaatct	gccctgcccga	600
ccctgccttc	ttctccttca	tcaataacag	cgacctgtgg	gtggccaaca	tgcagacagg	660
cgaggagcgg	cggctgaccc	tctgcccacca	aggtttatcc	aatgttctgg	atgaccccaa	720
gtctgcgggt	gtggccaccc	tctgtatata	ggaagagttc	gaccgcttca	ctgggtactg	780
gtggtgcucc	acagcctcct	gggaagggttc	agagggcctc	aagacgctgc	gaatcctgta	840
tgaggaagtc	gatgatccg	agggtggaggt	cattcacgtc	ccctctctgg	cgctagaaga	900
aaggaagacg	gactcgatc	ggtaccccg	gacaggcage	aagaatccca	agattgcctt	960
gaaactggct	gagttccaga	ctgacagcca	gggcaagatc	gtctcgaccc	aggagaagga	1020
gctggtgcag	cccttcagct	cgtgttccc	gaaggtggag	tacatgcaca	gggcccgggtg	1080
gaccggggat	ggcaaatacg	cctggccat	gttcctggac	cggcccccagc	agtggctcca	1140
gctcgtcctc	ctcccccccg	ccctgttcat	cccgagcaca	gagaatgagg	agcagcggct	1200
agcctctgcc	agagctgtcc	ccaggaatgt	ccagccgtat	gtgggttacg	aggaggtcac	1260
caacgtctgg	atcaatgttc	atgacatctt	ctatcccttc	ccccaaatcag	agggagagaga	1320
cgagctctgc	tttctcccg	ccaatgaatg	caagaccggc	ttctgccatt	tgtacaaatg	1380
caccgcgtt	ttaaaatccc	agggtacga	ttggagttag	cccttcagcc	ccggggaaaga	1440
tgaatttaag	tgccccatta	aggaagagat	tgctctgacc	agcgggtgaat	gggaggtttt	1500
ggcgaggcac	ggctccaaga	tctgggtcaa	tgaggagacc	aagctgtgt	acttccagg	1560
caccaaggac	acgcccgtgg	agcaccaccc	ctacgtggc	agctatgagg	cggccggcga	1620
gatcgta	ctcaccacgc	ccggcttctc	ccatagctgc	tccatgagcc	agaacttcga	1680
catgttcgtc	agccactaca	gcagcgttag	cacgcccccc	tgcgtgcacg	tctacaagct	1740
gagggcccc	gacgacgacc	ccctgcacaa	gcagcccccc	ttctgggtct	gcatgatgga	1800
ggcagccagc	tgcccccccg	attatgtcc	tccagagatc	ttccatttcc	acacgcgctc	1860
ggatgtgcgg	ctctacggca	tgtatctacaa	gccccacgccc	ttgcagccag	ggaagaagca	1920
cccaccgtc	ctctttgtat	atggaggccc	ccaggtgcag	ctgggtgaata	actcctcaa	1980
aggcatcaag	tacttgcggc	tcaacacact	ggcctccctg	ggctacgcgg	tgggtgtat	2040
tgacggcagg	ggctcctgtc	agcgagggtc	tgggttgc	ggggccctga	aaaaccaat	2100
ggggccagggt	gagatcgagg	accaggtgga	gggcctgcag	ttcgtggcc	agaagtatgg	2160
cttcatcgac	ctgagccgag	ttgccatcca	tggctggtcc	tacgggggtct	tcctctcgct	2220
catggggcta	atccacaaggc	cccagggttt	caagggtggcc	atcgccgggt	ccccgggtcac	2280
cgtctggatg	gcctacgaca	cagggtacac	tgagcgctac	atggacgtcc	ctgagaacaa	2340
ccagcacggc	tatgaggcgg	gttccgtggc	cctgcacgtg	gagaagctgc	ccaatgagcc	2400
caaccgcttgc	cttacatcctcc	acggcttcc	ggacgaaaac	gtgcacttt	tccacacaaa	2460

cttcctcgta tcccaactga tccgaggcagg gaaacccatc cagctccaga tctaccccaa 2520  
 cgagagacac agtattcgct gcccccgcgtc gggcgagcac tatgaagtca cgttgctgca 2580  
 ctttctacag gaataccctct gagcggccgc ggatccg 2617

<210> 5

<211> 796

<212> PRT

<213> Homo sapiens

<400> 5

Met	Asn	Gln	Thr	Ala	Ser	Val	Ser	His	His	Ile	Lys	Cys	Gln	Pro	Ser
1															
															15
Lys	Thr	Ile	Lys	Glu	Leu	Gly	Ser	Asn	Ser	Pro	Pro	Gln	Arg	Asn	Trp
															30
Lys	Gly	Ile	Ala	Ile	Ala	Leu	Leu	Val	Ile	Leu	Val	Val	Cys	Ser	Leu
															45
Ile	Thr	Met	Ser	Val	Ile	Leu	Leu	Ser	Pro	Asp	Glu	Leu	Thr	Asn	Ser
															60
Ser	Glu	Thr	Arg	Leu	Ser	Leu	Glu	Asp	Leu	Phe	Arg	Lys	Asp	Phe	Val
															80
Leu	His	Asp	Pro	Glu	Ala	Arg	Trp	Ile	Asn	Asp	Thr	Asp	Val	Val	Tyr
															95
Lys	Ser	Glu	Asn	Gly	His	Val	Ile	Lys	Leu	Asn	Ile	Glu	Thr	Asn	Ala
															110
Thr	Thr	Leu	Leu	Leu	Glu	Asn	Thr	Thr	Phe	Val	Thr	Phe	Lys	Ala	Ser
															125
Arg	His	Ser	Val	Ser	Pro	Asp	Leu	Lys	Tyr	Val	Leu	Leu	Ala	Tyr	Asp
															140
Val	Lys	Gln	Ile	Phe	His	Tyr	Ser	Tyr	Thr	Ala	Ser	Tyr	Val	Ile	Tyr
															160
Asn	Ile	His	Thr	Arg	Glu	Val	Trp	Glu	Leu	Asn	Pro	Pro	Glu	Val	Glu
															175
Asp	Ser	Val	Leu	Gln	Tyr	Ala	Ala	Trp	Gly	Val	Gln	Gly	Gln	Leu	
180															190
Ile	Tyr	Ile	Phe	Glu	Asn	Asn	Ile	Tyr	Tyr	Gln	Pro	Asp	Ile	Lys	Ser
															205
Ser	Ser	Leu	Arg	Leu	Thr	Ser	Ser	Gly	Lys	Glu	Glu	Ile	Ile	Phe	Asn
															220
Gly	Ile	Ala	Asp	Trp	Leu	Tyr	Glu	Glu	Glu	Leu	Leu	His	Ser	His	Ile
															240
225															
Ala	His	Trp	Trp	Ser	Pro	Asp	Gly	Glu	Arg	Leu	Ala	Phe	Leu	Met	Ile
															255
245															
Asn	Asp	Ser	Leu	Val	Pro	Thr	Met	Val	Ile	Pro	Arg	Phe	Thr	Gly	Ala
															270
260															
Leu	Tyr	Pro	Lys	Gly	Lys	Gln	Tyr	Pro	Tyr	Pro	Lys	Ala	Gly	Gln	Val
															285
275															
Asn	Pro	Thr	Ile	Lys	Leu	Tyr	Val	Val	Asn	Leu	Tyr	Gly	Pro	Thr	His
															300
290															
Thr	Leu	Glu	Leu	Met	Pro	Pro	Asp	Ser	Phe	Lys	Ser	Arg	Glu	Tyr	Tyr
															320
305															
Ile	Thr	Met	Val	Lys	Trp	Val	Ser	Asn	Thr	Lys	Thr	Val	Val	Arg	Trp
															335
325															
Leu	Asn	Arg	Pro	Gln	Asn	Ile	Ser	Ile	Leu	Thr	Val	Cys	Glu	Thr	Thr
															350
340															
Thr	Gly	Ala	Cys	Ser	Lys	Lys	Tyr	Glu	Met	Thr	Ser	Asp	Thr	Trp	Leu
															365
355															
Ser	Gln	Gln	Asn	Glu	Glu	Pro	Val	Phe	Ser	Arg	Asp	Gly	Ser	Lys	Phe
															380
370															
Phe	Met	Thr	Val	Pro	Val	Lys	Gln	Gly	Gly	Arg	Gly	Glu	Phe	His	His
															400
385															
390															
395															

Ile Ala Met Phe Leu Ile Gln Ser Lys Ser Glu Gln Ile Thr Val Arg  
                  405                 410                 415  
 His Leu Thr Ser Gly Asn Trp Glu Val Ile Lys Ile Leu Ala Tyr Asp  
                  420                 425                 430  
 Glu Thr Thr Gln Lys Ile Tyr Phe Leu Ser Thr Glu Ser Ser Pro Arg  
                  435                 440                 445  
 Gly Arg Gln Leu Tyr Ser Ala Ser Thr Glu Gly Leu Leu Asn Arg Gln  
                  450                 455                 460  
 Cys Ile Ser Cys Asn Phe Met Lys Glu Gln Cys Thr Tyr Phe Asp Ala  
                  465                 470                 475                 480  
 Ser Phe Ser Pro Met Asn Gln His Phe Leu Leu Phe Cys Glu Gly Pro  
                  485                 490                 495  
 Arg Val Pro Val Val Ser Leu His Ser Thr Asp Asn Pro Ala Lys Tyr  
                  500                 505                 510  
 Phe Ile Leu Glu Ser Asn Ser Met Leu Lys Glu Ala Ile Leu Lys Lys  
                  515                 520                 525  
 Lys Ile Gly Lys Pro Glu Ile Lys Ile Leu His Ile Asp Asp Tyr Glu  
                  530                 535                 540  
 Leu Pro Leu Gln Leu Ser Leu Pro Lys Asp Phe Met Asp Arg Asn Gln  
                  545                 550                 555                 560  
 Tyr Ala Leu Leu Leu Ile Met Asp Glu Glu Pro Gly Gly Gln Leu Val  
                  565                 570                 575  
 Thr Asp Lys Phe His Ile Asp Trp Asp Ser Val Leu Ile Asp Met Asp  
                  580                 585                 590  
 Asn Val Ile Val Ala Arg Phe Asp Gly Arg Gly Ser Gly Phe Gln Gly  
                  595                 600                 605  
 Leu Lys Ile Leu Gln Glu Ile His Arg Arg Leu Gly Ser Val Glu Val  
                  610                 615                 620  
 Lys Asp Gln Ile Thr Ala Val Lys Phe Leu Leu Lys Leu Pro Tyr Ile  
                  625                 630                 635                 640  
 Asp Ser Lys Arg Leu Ser Ile Phe Gly Lys Gly Tyr Gly Tyr Ile  
                  645                 650                 655  
 Ala Ser Met Ile Leu Lys Ser Asp Glu Lys Leu Phe Lys Cys Gly Ser  
                  660                 665                 670  
 Val Val Ala Pro Ile Thr Asp Leu Lys Leu Tyr Ala Ser Ala Phe Ser  
                  675                 680                 685  
 Glu Arg Tyr Leu Gly Met Pro Ser Lys Glu Glu Ser Thr Tyr Gln Ala  
                  690                 695                 700  
 Ala Ser Val Leu His Asn Val His Gly Leu Lys Glu Glu Asn Ile Leu  
                  705                 710                 715                 720  
 Ile Ile His Gly Thr Ala Asp Thr Lys Val His Phe Gln His Ser Ala  
                  725                 730                 735  
 Glu Leu Ile Lys His Leu Ile Lys Ala Gly Val Asn Tyr Thr Met Gln  
                  740                 745                 750  
 Val Tyr Pro Asp Glu Gly His Asn Val Ser Glu Lys Ser Lys Tyr His  
                  755                 760                 765  
 Leu Tyr Ser Thr Ile Leu Lys Phe Phe Ser Asp Cys Leu Lys Glu Glu  
                  770                 775                 780  
 Ile Ser Val Leu Pro Gln Glu Pro Glu Glu Asp Glu  
                  785                 790                 795

<210> 6  
<211> 2583  
<212> DNA  
<213> Homo sapiens  
<400> 6

gcctggatt gtgactgtc cagggcctg aaacatgaac caaaactgcc a c g t g t c c c a      60  
tcacatcaag tgtcaaccct caaaaacaat caaggaactg gaaagtaca g c c t c c a c a      120  
gagaaaactgg aaggaaattt ctattgctt gctggatt ttatgtat gtcactcat      180

cactatgtca	gtcatccctc	taagcccaga	tgaactcaca	aattcgtcag	aaaccaggatt	240
gtctttggaa	gacctctta	ggaaaagactt	tgtgcttcac	gatccagagg	ctcggtggat	300
caatgataca	gatgtggtgt	ataaaagcga	gaatggacat	gtcattaaac	tgaatataga	360
aacaaatgt	accacattat	tattggaaaa	cacaactttt	gtaaccttca	aagcatcaag	420
acattcagtt	tcaccagatt	taaaaatatgt	ccttctggca	tatgatgtca	aacagatttt	480
tcattattcg	tatactgctt	catactgtat	ttacaacata	cacactaggg	aagtttggga	540
gttaaatcct	ccagaagtag	aggactccgt	cttgcagtac	gcggcctggg	gtgtccaagg	600
gcagcagctg	atttatattt	ttgaaaataa	tatctactat	caacctgata	taaagagcag	660
ttcattgcga	ctgacatctt	ctggaaaaga	agaaataatt	ttaatggga	ttgctgactg	720
gttatatgaa	gaggaactcc	tgcatctca	catgc(cc)ac	tgggtggcac	cagatggaga	780
aagacttgcc	ttcctgtatga	taaatgactc	tttggtaccc	accatggta	tccctcggtt	840
tactggagcg	ttgtatcccc	aaggaaagca	gtatccgtat	cctaaggcag	gtcaagtcaa	900
cccaacaata	aaattatatg	ttgtaaacct	gtatggacca	actcacactt	tggagctcat	960
gccacctgac	agctttaat	caagagaata	ctatatcact	atggtaaat	gggtaagcaa	1020
taccaagact	gtggtaagat	ggttaaaccg	acctcagaac	atctccatcc	tcacagtctg	1080
tgagaccact	acaggtgctt	gtataaaaaa	atatgagatg	acatcagata	cgtggctctc	1140
tcagcagaat	gaggagcccg	tgtttctag	agacggcagc	aaattctta	tgacagtgcc	1200
tgttaagcaa	gggggacgtg	gagaatttca	ccacatagct	atgttcctca	tccagagtaa	1260
aagttagcaa	attaccgtgc	ggcatctgac	atcagggaaac	tgggaagtga	taaagatctt	1320
ggcatacgat	gaaactactc	aaaaaaattt	cttctgagc	actgaatctt	ctcccagagg	1380
aaggcagctg	tacagtgctt	ctactgaagg	attattgaat	cgccaatgca	tttcatgtaa	1440
tttcatgaaa	gaacaatgta	catatttga	tgccagttt	agtcccattga	atcaacattt	1500
cttattattc	tgtgaaggc	caagggtccc	agtggtcagc	ctacatagta	cggacaaccc	1560
agcaaaaat	tttatattgg	aaagcaattc	tatgctgaag	gaagctatcc	tgaagaagaa	1620
gataggaaag	ccagaaatta	aaatcctca	tattgacgac	tatgaacttc	ctttacagtt	1680
gtcccttccc	aaagatttt	tggaccggaa	ccagttatct	cttctgttaa	taatggatga	1740
agaaccagga	ggccagctgg	ttacagataa	gttccatatt	gactgggatt	ccgtactcat	1800
tgacatggat	aatgtcattt	tagcaagatt	tgatggcaga	ggaagtggat	tccagggtct	1860
gaaaattttg	caggagattc	atcgaagatt	aggttcagta	gaagtaaagg	accaaataac	1920
agctgtgaaa	tttttgcgt	aactgcctt	cattgactcc	aaaagattaa	gcattttgg	1980
aaagggttat	ggtggtata	ttgcatcaat	gatctaaaa	ttagatgaaa	agctttttaa	2040
atgtggatcc	gtgggtgcac	ctatcacaga	cttgcattt	tatgcctcag	ctttctctga	2100
aaagataacctt	gggatgcccatt	ctaaggaaga	aagcacttac	caggcagcca	gtgtgttaca	2160
taatgttcat	ggcttggaaag	aagaaaat	attaataatt	catggactg	ctgacacaaa	2220
agttcatttc	caacactcag	cagaattt	caagcaccta	ataaaagctg	gagtgaatta	2280
tactatgcag	gtctaccat	atgaaggtca	taacgtatct	gagaagagca	agtatcatct	2340
ctacagcaca	atcctcaaatt	tcttcagtga	ttgtttgaag	gaagaaat	ctgtgttacc	2400
acaggaacca	gaagaagatg	aataatggac	cgtattata	cagaactgaa	gggaatattt	2460
aggctcaatg	aaacctgaca	aagagactgt	aatattgtt	ttgctccaga	atgtcaaggg	2520
cagcttacgg	agatgtcact	ggagcagcac	gctcagagac	agtgaactg	catttgaata	2580
cac						2583

<210> 7  
 <211> 690  
 <212> PRT  
 <213> Homo sapiens  
 <400> 7

Met	Ala	Ala	Ala	Met	Glu	Thr	Glu	Gln	Leu	Gly	Val	Glu	Ile	Phe	Glu
1				5				10					15		
Thr	Ala	Asp	Cys	Glu	Glu	Asn	Ile	Glu	Ser	Gln	Asp	Arg	Pro	Lys	Leu
							20			25			30		
Glu	Pro	Phe	Tyr	Val	Glu	Arg	Tyr	Ser	Trp	Ser	Gln	Leu	Lys	Lys	Leu
							35			40			45		
Leu	Ala	Asp	Thr	Arg	Lys	Tyr	His	Gly	Tyr	Met	Met	Ala	Lys	Ala	Pro
							50			55			60		
His	Asp	Phe	Met	Phe	Val	Lys	Arg	Asn	Asp	Pro	Asp	Gly	Pro	His	Ser
							65			70			75		80
Asp	Arg	Ile	Tyr	Tyr	Leu	Ala	Met	Ser	Gly	Glu	Asn	Arg	Glu	Asn	Thr
							85			90			95		

Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu  
 100 105 110  
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp  
 115 120 125  
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg  
 130 135 140  
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly  
 145 150 155 160  
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly  
 165 170 175  
 Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu  
 180 185 190  
 Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp  
 195 200 205  
 Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn  
 210 215 220  
 Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu  
 225 230 235 240  
 Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val  
 245 250 255  
 Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys  
 260 265 270  
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu  
 275 280 285  
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met  
 290 295 300  
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr  
 305 310 315 320  
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala  
 325 330 335  
 Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe  
 340 345 350  
 Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr  
 355 360 365  
 Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr  
 370 375 380  
 Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu  
 385 390 395 400  
 Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser  
 405 410 415  
 Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn  
 420 425 430  
 Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile  
 435 440 445  
 Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr  
 450 455 460  
 Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly  
 465 470 475 480  
 Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile  
 485 490 495  
 Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn  
 500 505 510  
 Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys  
 515 520 525  
 Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro  
 530 535 540  
 Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys  
 545 550 555 560  
 Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys  
 565 570 575

Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp .  
 580 585 590  
 Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala  
 595 600 605  
 Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser  
 610 615 620  
 Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu  
 625 630 635 640  
 Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Arg  
 645 650 655  
 Leu Leu Leu Gly Pro Gln Ser Leu Cys Gly Ser Ser Met Ile Gln  
 660 665 670  
 Asp Thr Arg Asn Val Ile Trp Val Thr Leu Thr Arg Met Asn Arg Ala  
 675 680 685  
 Ile Thr  
 690

<210> 8  
 <211> 4523  
 <212> DNA  
 <213> Homo sapiens  
 <400> 8

aagtgctaaa gcctccgagg ccaaggccgc tgctactgcc gccgctgctt ctttagtgccg 60  
 cgttcgccgc ctgggttgtc accggcgccg ccggccgagga agccactgca accaggaccc 120  
 gagtggaggc ggccgcagcat gaagccggcgc aggcccgc catagcgcac gtcgggacgg 180  
 tccggggcggg gccggggggg aggaaaatgc aacatggcag cagcaatgga aacagaacag 240  
 ctgggtgttgc agatatttga aactgcggac tgtgaggaga atattgaatc acaggatcgg 300  
 cctaaatttgg agcctttta tggatggcgg tattcctgga gtcagcttaa aaagctgctt 360  
 gccgatacca gaaaatatca tggctacatg atggcttaagg caccacatga ttcatgttt 420  
 gtgaagagga atgatccaga tggacctcat tcagacagaa tctattacat tgccatgtct 480  
 ggtgagaaca gagaaaatac actgttttat tctgaaattc caaaactat caatagagca 540  
 gcagtcttaa tgctcttgc gaagccctt ttggatctt ttccaggcaac actggactat 600  
 ggaatgtatt ctgcgagaaga agaactatta agagaaagaa aacgcattgg aacagtcgga 660  
 attgcttctt acgattatca ccaaggaagt ggaacatttc tggatggatc tgccatgtct 720  
 atttacacg taaaagatgg agggccacaa ggatttacgc aacaacctt aaggcccaat 780  
 ctatgtggaaa ctatgttgc caacatacgg atggatccaa attatgccc tgctgatcca 840  
 gactggatttgc ttatataca tagcaacgt atttggatcat ctaacatcg aaccagagaa 900  
 gaaaggagac tcacttatgt gcacaatgag ctggcaaca tggatggatc tgccatgtca 960  
 gctggagtgc ctaccttgc tctccaagaa gaatttgata gatattctgg ctattggatgg 1020  
 tggatccaaaat ctgaaacaac tcccaatgg ggtaaaatttcaatggatctt atatggatgg 1080  
 aatggatcat ctgaggttgc aatttattcat gttacatccc ctatgttgc aacaaggagg 1140  
 gcagattcat tccgttatcc taaaacaggc acagcaaattc ctaaagtccat tttaagatgc 1200  
 tcagaaataa tgattgtatgc tgaaggaagg atcatagatg tcatagataa ggaactaatt 1260  
 caaccttttgc agattcttgc tgaaggatgtt gaatatatttgc ccaaggactgg atggactcct 1320  
 gagggaaaat atgcttggtc catcctacta gatcgctccc agactcgctt acagatagtgc 1380  
 ttgatctcac ctgaattttat tatcccagta gaagatgtatg ttatggaaaat gcagagactc 1440  
 attggatgtatgc tggctgttgc tggatggatc ctaattatctt atggatggatc aacagacatc 1500  
 tggataaataa tccatgacat ctttcatgtt tttcccaatggatggatc gaaatttgatgc 1560  
 ttatggatggatc cctctgaatgc caaaacaggc ttccgttgc tatacaatgc tacatctt 1620  
 ttaaaggaaa gcaaatataa acatccatgc ggtggctgc ctgctccaatg tgatttgc 1680  
 tggatgtatgc aagaggatgttgc agtggatggatc gggatggatc tggccggcat 1740  
 ggtatctaata tccaaatggatgc tgaagtcaga aggctggatc attttgcaggc caccaaaagac 1800  
 tcccttttagt acatccatgc tggatggatc agtggatggatc tggccggcat 1860  
 ctgactgacc tggatgtatgc acatccatgc tggatggatc agtggatggatc tggccggcat 1920  
 agttaatgtatgc tggatggatc gaaatggatgc tggatggatc tggccggcat 1980  
 gaagatgtatgc caacttgcataa aacaaaggaa ttttggccat ccatggatgc tggatggatc 2040  
 cctcttcctgc actataactcc tccagaaatttgc tggatggatc tggccggcat 2100  
 ttgtatggatgc tggatggatc gaaatggatgc tggatggatc tggccggcat 2160

ctgttcata	atgggttgtcg	gttgctattg	ctggggcccc	agtcactctg	tggatcttct	2220
atgatacagg	atacacggaa	cgttatatgg	gtcacccctga	ccagaatgaa	cagggctatt	2280
acttaggatc	tgtggccatg	caagcagaaa	agttccccte	tgaaccaa	at cgtttactgc	2340
tcttacatgg	tttcctggat	gagaatgtcc	atttgcaca	taccagtata	ttactgagtt	2400
ttttagttag	ggctggaaag	ccatatgatt	tacagatcta	tcctcaggag	agacacagca	2460
taagagttcc	tgaatcggga	gaacattatg	aactgcac	tttgcactac	cttcaagaaa	2520
accttggatc	acgtattgtc	gctctaaaag	tgatataatt	ttgacctgtg	tagaactctc	2580
tggtatacac	tggctattta	accaa	at gag	gagg	tttaat caacagaaaa	2640
atcatcacat	tttgatacct	gccatgtaac	atctactcct	gaaaataa	at gtgggccat	2700
gcaggggtct	acggttgtg	gtagtaatct	aataccttaa	ccccacatgc	tcaaaatcaa	2760
atgatacata	ttcctgagag	acccagcaat	accataagaa	ttactaaaaa	aaaaaaa	2820
aaaaagacat	tagcaccatg	tattcataact	accctat	ttt cactttaat	agtattataa	2880
acttcatgaa	cttaattatg	gtat	ttt tac	agtat	ttt tgat	2940
gatattatgt	attgggttgg	ttcagttcca	gaatcttga	ctagttacag	at ttgat	3000
acttaaatgt	aattgaatag	ttatgc	ttt ctttgc	attgcttgg	catatccagc	3060
ctaataacta	ttaaactga	cttaaccagt	cattcattaa	taat	ttt tca aggataactt	3120
agtggcctcc	taaagacact	tgtttggca	ctgaccagtt	tttagccat	ttaatctgt	3180
tctagtataa	ataattctca	tttttcttgc	atgatattaa	cagagtggc	ttttcc	3240
gcataaaaggc	tagtaactgt	at atgttagca	tggat	tttaat	ttt tagtcatgat	3300
acaggcagaa	aatttttaat	caa	at agt	gat	ttt gataatt	3360
ttttcc	tttta	agaaaaggaa	aa	at g	ttt gac	3420
tgccagttc	catttggat	ttc	ttt tta	aa	at tttc	3480
ggaatcacag	tgggttgggg	agac	cttgggt	ttt gg	ttt gat	3540
ggccctgatt	aaaaactaag	caga	actt	ttt gat	aaatgtt	3600
aaactgaaat	ttaaacaact	gt	at	ttt gat	aaatgtt	3660
ccagcacagc	tacagat	ttt gat	ttt gat	ttt gat	ttt gat	3720
taattcttt	ttttttct	ttt gat	ttt gat	ttt gat	ttt gat	3780
taaaattatt	tga	ttt gat	ttt gat	ttt gat	ttt gat	3840
cctcttacc	at	ttt gat	ttt gat	ttt gat	ttt gat	3900
aagcctgtaa	ac	ttt gat	ttt gat	ttt gat	ttt gat	3960
agctatgaag	ag	ttt gat	ttt gat	ttt gat	ttt gat	4020
tgggtgtca	gat	ttt gat	ttt gat	ttt gat	ttt gat	4080
cttttatca	cac	ttt gat	ttt gat	ttt gat	ttt gat	4140
aagaaaattt	gctatattt	ttt ct	ttt c	ttt c	ttt c	4200
gcacagc	catt	ttt c	ttt c	ttt c	ttt c	4260
<210>	9					4320
<211>	241					4380
<212>	PRT					4440
<213>	Homo sapiens					4500
<400>	9					4523

<210> 9  
 <211> 241  
 <212> PRT  
 <213> Homo sapiens  
 <400> 9

Met	Ala	Ala	Ala	Met	Glu	Thr	Glu	Gln	Leu	Gly	Val	Glu	Ile	Phe	Glu
1				5				10				15			
Thr	Ala	Asp	Cys	Glu	Glu	Asn	Ile	Glu	Ser	Gln	Asp	Arg	Pro	Lys	Leu
							20			25			30		
Glu	Pro	Phe	Tyr	Val	Glu	Arg	Tyr	Ser	Trp	Ser	Gln	Leu	Lys	Lys	Leu
							35		40		45				
Leu	Ala	Asp	Thr	Arg	Lys	Tyr	His	Gly	Tyr	Met	Met	Ala	Lys	Ala	Pro
							50		55		60				
His	Asp	Phe	Met	Phe	Val	Lys	Arg	Asn	Asp	Pro	Asp	Gly	Pro	His	Ser
							65		70		75		80		
Asp	Arg	Ile	Tyr	Tyr	Leu	Ala	Met	Ser	Gly	Glu	Asn	Arg	Glu	Asn	Thr
							85		90		95				
Leu	Phe	Tyr	Ser	Glu	Ile	Pro	Lys	Thr	Ile	Asn	Arg	Ala	Ala	Val	Leu

	100		105		110										
Met	Leu	Ser	Trp	Lys	Pro	Leu	Leu	Asp	Leu	Phe	Gln	Ala	Thr	Leu	Asp
			115				120				125				
Tyr	Gly	Met	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg	Lys	Arg
			130				135				140				
Ile	Gly	Thr	Val	Gly	Ile	Ala	Ser	Tyr	Asp	Tyr	His	Gln	Gly	Ser	Gly
						145	150			155					160
Thr	Phe	Leu	Phe	Gln	Ala	Gly	Ser	Gly	Ile	Tyr	His	Val	Lys	Asp	Gly
						165			170					175	
Gly	Pro	Gln	Gly	Phe	Thr	Gln	Gln	Pro	Leu	Arg	Pro	Asn	Leu	Val	Glu
						180			185					190	
Thr	Ser	Cys	Pro	Asn	Ile	Arg	Met	Asp	Pro	Lys	Leu	Cys	Pro	Ala	Asp
						195			200					205	
Pro	Asp	Trp	Ile	Ala	Phe	Ile	His	Ser	Asn	Asp	Ile	Trp	Ile	Ser	Asn
			210				215					220			
Ile	Val	Thr	Arg	Glu	Glu	Arg	Arg	Leu	Thr	Tyr	Val	His	Asn	Gly	Lys
						225			230			235			240
Ala															

&lt;210&gt; 10

&lt;211&gt; 1356

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

aagtgc	aaa	gcctccgagg	ccaaggccgc	tgctactgcc	ggcgctgctt	cttagtgccg	60	
cg	tgc	ccgc	ctgggttg	tc accggc	ccgccc	aggcactgca	accaggac	120
gag	tgg	gggc	gcgc	at gat	ggc	catagcgcac	gtcgggac	180
tcc	ggg	ccgg	ggc	aaatgc	ggc	cagatgg	aacagaac	240
ctgg	gttgc	ggat	attttga	aaatgc	ggc	actggc	atattgaa	300
cct	aaatttgg	act	tgccggac	tgtgaggaga	tgt	tttgc	acaggatc	360
ggc	gttgc	tttta	tttgc	tttgc	tttgc	tttgc	tttgc	420
ccgata	at	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	480
gttgc	at	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	540
ggatgtt	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	600
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	660
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	720
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	780
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	840
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	900
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	960
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	1020
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	1080
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	1140
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	1200
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	1260
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	1320
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	1356

&lt;210&gt; 11

&lt;211&gt; 661

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

Met	Ala	Ala	Ala	Met	Glu	Thr	Glu	Gln	Leu	Gly	Val	Glu	Ile	Phe	Glu
1				5				10					15		
Thr	Ala	Asp	Cys	Glu	Glu	Asn	Ile	Glu	Ser	Gln	Asp	Arg	Pro	Lys	Leu
							20				25			30	
Glu	Pro	Phe	Tyr	Val	Glu	Arg	Tyr	Ser	Trp	Ser	Gln	Leu	Lys	Lys	Leu

35	40	45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro		
50	55	60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser		
65	70	75
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr		80
85	90	95
Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu		
100	105	110
Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp		
115	120	125
Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg		
130	135	140
Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly		
145	150	155
Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly		160
165	170	175
Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu		
180	185	190
Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp		
195	200	205
Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn		
210	215	220
Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu		
225	230	235
Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val		240
245	250	255
Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys		
260	265	270
Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu		
275	280	285
Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met		
290	295	300
Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr		
305	310	315
Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala		320
325	330	335
Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe		
340	345	350
Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr		
355	360	365
Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr		
370	375	380
Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu		
385	390	395
Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser		400
405	410	415
Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn		
420	425	430
Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile		
435	440	445
Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr		
450	455	460
Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly		
465	470	475
Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile		480
485	490	495
Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn		
500	505	510
Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys		

515	520	525
Asp Ser Pro Leu Glu His His	Leu Tyr Val Val	Ser Tyr Val Asn Pro
530	535	540
Gly Glu Val Thr Arg Leu Thr Asp Arg Gly	Tyr Ser His Ser Cys Cys	560
545	550	555
Ile Ser Gln His Cys Asp Phe Phe	Ile Ser Lys Tyr Ser Asn Gln Lys	575
565	570	575
Asn Pro His Cys Val Ser Leu Tyr Lys	Leu Ser Ser Pro Glu Asp Asp	590
580	585	
Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile	Leu Asp Ser Ala	
595	600	605
Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile	Phe Ser Phe Glu Ser	
610	615	620
Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr	Lys Pro His Asp Leu	
625	630	635
Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe	Ile Tyr Gly Gly Leu	640
645	650	655
Leu Arg Cys Ser Trp		
660		

<210> 12  
<211> 4829  
<212> DNA  
<213> Homo sapiens  
<400> 12

aagtgcataaa	gcctccgagg	ccaaggccgc	tgctactgcc	ggcgctgctt	cttagtgccg	60
cgttcgccgc	ctgggttgtc	accggcgccg	ccgcccagga	agccactgca	accaggacccg	120
gagtggaggc	ggcgcagcat	gaagcggcgc	aggccccctc	catagcgcac	gtcgggacgg	180
tccggggcggg	gcccgggggg	aggaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agcctttta	tgtgagcgg	tattcttgg	gtcagcttaa	aaagctgctt	360
gcgcataccca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattac	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctcttgc	gaagcctctt	ttggatctt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgttcaagc	cggtagtgg	720
atttatcacg	aaaaagatgg	aggccacaa	ggatttacgc	aacaacctt	aaggcccaat	780
ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattg	cttttataca	tagcaacgtat	atttggatat	ctaacatcgt	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggagaaga	tgccagatca	960
gctggagtgc	ctaccttgc	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtgg	ggtaaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgagggtgg	aattattcat	gttacatccc	ctatgttgg	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaattc	ctaaagtccac	ttttaagatg	1200
tcagaaataa	tgattgtatgc	tgaaggaagg	atcatagatg	tcatagataa	ggaactaatt	1260
caaccttttgc	agattctatt	tgaaggagtt	gaatatattg	ccagagctgg	atggactcct	1320
gaggaaaaat	atgcttggtc	cattctacta	gatcgctccc	agactcgct	acagatagtg	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgcctgattc	tgtgacgcca	ctaattatct	atgaagaaac	aacagacatc	1500
tggataaata	tccatgacat	ctttcatgtt	tttccccaaa	gtcacgaaga	ggaatttgag	1560
tttatttttg	cctctgaatg	caaaacaggt	ttccgtcatt	tataaaaaat	tacatctatt	1620
ttaaaggaaa	gcaaataataa	acgatccagt	ggtgggctgc	ctgctccaag	tgatttcaag	1680
tgccttatca	aagaggagat	agcaattacc	agtggtgaat	ggaaagtct	tggccggcat	1740
gcatctaata	tccaagggtga	tgaagtccaga	aggctgtat	attttgaagg	caccaaagac	1800
tccccttttag	agcatcacct	gtacgtagtc	agttacgtaa	atcctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattcttgc	tgcacatcg	agcactgtga	cttcttata	1920
agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	tttacaagct	atcaagtcc	1980
gaagatgacc	caacttgcaa	aacaaaggaa	ttttggcca	ccattttgg	ttcagcaggt	2040

cctcttcctg	actatactcc	tccagaaaatt	ttctcttttgc	aaagtactac	tggatttaca	2100
ttgtatggga	tgctctacaa	gcctcatgt	ctacagcctg	gaaagaaaata	tcctactgtg	2160
ctgttcataat	atgggtgtct	cctcagggtgc	agttggtgaa	taatcggttt	aaaggagtca	2220
agtatttccg	cttgaatacc	ctagcctctc	taggttatgt	ggttgttagt	atagacaaca	2280
ggggatcctg	tcaccgaggg	cttaaattttg	aaggccctt	taaatataaa	atgggtcaaa	2340
tagaaattga	cgatcagggtg	gaaggactcc	aatatctagc	ttctcgatata	gatttcatttgc	2400
acttagatcg	tgtggcattc	cacggctgg	cctatggagg	atacctctcc	ctgatggcat	2460
taatgcagag	gtcagatatac	ttcagggttg	ctattgctgg	ggccccagtc	actctgtgga	2520
tcttctatga	tacaggatac	acggaacgtt	atatggtca	ccctgaccag	aatgaacagg	2580
gctattactt	aggatctgtg	gccatgcag	cagaaaagtt	ccctctgaa	ccaaatcggtt	2640
tactgctctt	acatggtttgc	ctggatgaga	atgtccattt	tgcacataacc	agtatattac	2700
tgagtttttgc	ggaaagccat	atgatttaca	gatctatcct	caggagagac	2760	
acacgcataag	agttctgaa	tcgggagaac	attatgaact	gcatcttttgc	2820	
aagaaaacct	tggatcacgt	attgctgctc	taaaagtgtat	ataattttgaa	cctgtgtaga	2880
actctctgg	atacactggc	tatthaacca	aatgaggagg	ttaatcaac	agaaaacaca	2940
gaattgatca	tcacattttgc	atacctgcca	tgtaacatct	actcctgaaa	ataaatgtgg	3000
tgcctatgcag	gggtctacgg	tttgggttag	taatctaata	ccttaacc	acatgctcaa	3060
aatcaaatttgc	tacatattcc	tgagagaccc	agcaatacc	taagaattac	taaaaaaaaaa	3120
aaaaaaaaaaaa	agacatttgc	acatgtatttgc	catactaccc	tattttcaact	ttaatagta	3180
ttataaactt	catgaacttac	attatgttat	ttttacagta	tactttttag	tttggtaaaa	3240
tatgatgata	ttatgtatttgc	gttccagaat	ctttgacttag	ttacagattt	3300	
gatagcactt	aaatgtatttgc	gaatagcttac	tgcttcatttgc	cttgggcata	tccagcatgt	3360
tatgaacttac	taacttattaa	acttgcatttgc	accagtcatttgc	cattaataat	ttttcaagga	3420
taacttagtgc	gcctccat	gacacttgc	ttggcacttgc	ccagtttttgc	ccaaatttgc	3480
tctgtatctt	gtataaataa	tttcatttttgc	tcttttgcatttgc	tatthaacaga	gtgggcttttgc	3540
ccttttgcatttgc	aaaggctgtt	aactgtatata	gtagcatggc	ttaattttgc	catgatatttgc	3600
ataatttacag	gcagaaaatttgc	ttaatcaaa	tgattagagc	ttaatattttgc	gcaggcaagt	3660
tttttttttttgc	cctttaagaa	aaggaaaaaa	tacacatttgc	ctagaatttgc	tcagaaaatttgc	3720
tagtgggtcc	agtttccatttgc	ttgtatttttgc	ttatthaat	attctagaat	ttaaggaga	3780
ttgaaggggaa	tcacagtggg	tttggggagac	ctgggttttgc	ggaatgacag	agagaagagg	3840
ttgtgaggggc	ctgatttttttgc	actaaggcaga	agtagtttgc	acaaaaatata	tcatgaaaat	3900
gtttggaaac	tgaatttttgc	acaactgttac	tatthaaggaa	accagaatata	ataaatcact	3960
gtcttgcac	cacagtttgc	gagtaacatgc	attcaggggc	ggaaaagtttgc	cttagagtttgc	4020
cttttataat	tcttttttttgc	tttgcatttgc	tttttttttttgc	tcttacaaat	ttaatcttgc	4080
tccttttataat	attatgttgc	cataatttttgc	atattgttgc	ctttaatata	aaatgttttgc	4140
agataaacctt	tttaccatata	actaatcccttgc	ggcaagccat	ggctctcttgc	tttttttttttgc	4200
tgtttaaaggc	ctgttttttgc	tttttgcatttgc	tgatcatgttgc	cttttcttgc	tttagcacttgc	4260
ggatttttttttgc	atgaagagag	ctcataggttgc	ttcagggttgc	atttttttttgc	tgccctgttgc	4320
gagtcttggg	gtgcttagatttgc	ggtcacatttgc	acaccagggttgc	cagggaaaggc	atctatgttttgc	4380
tttatgttttttgc	ttatcacatata	cttcagggttgc	tagaaaggta	ttaccaataat	tttttttttttgc	4440
cactccaatata	aaatttgcatttgc	tatthaatttttgc	tcatcaatata	agagagatgttgc	gatttttttttgc	4500
tagagagcac	agcctccatttgc	agtaagggttgc	tttggggagac	tttttttttttgc	tttttttttttgc	4560
acaccaaggc	ggaggttaggg	aaagcccaga	aatggcaggta	tgatatgggttgc	tttggggagac	4620
tggggaaaggc	atttttttttttgc	gttcttgcatttgc	tttataactgttgc	ataatagata	ccacgttttgc	4680
tcttatttttttgc	tgttatatgttgc	tttgcatttgc	tttttgcatttgc	tttttttttttgc	caagatttttgc	4740
tttatatatata	tttcaatgttgc	aaatttttttttgc	tttttgcatttgc	tttttttttttgc	ccaaagaaaggc	4800
attttttttttttgc	ttaagtataat	atctgacttgc	tttttttttttgc	tttttttttttgc	tttttttttttgc	4829

<210> 13  
<211> 358  
<212> PRT  
<213> Homo sapiens  
<400> 13

Met	Ala	Ala	Ala	Met	Glu	Thr	Glu	Gln	Ieu	Gly	Val	Glu	Ile	Phe	Glu
1				5				10					15		
Thr	Ala	Asp	Cys	Glu	Glu	Asn	Ile	Glu	Ser	Gln	Asp	Arg	Pro	Lys	Ieu
							20		25			30			
Glu	Pro	Phe	Tyr	Val	Glu	Arg	Tyr	Ser	Trp	Ser	Gln	Ieu	Lys	Lys	Ieu
							35		40			45			

Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro  
       50                     55                     60  
 His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser  
       65                     70                     75                     80  
 Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr  
       85                     90                     95  
 Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu  
       100                    105                    110  
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp  
       115                    120                    125  
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg  
       130                    135                    140  
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly  
       145                    150                    155                    160  
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly  
       165                    170                    175  
 Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu  
       180                    185                    190  
 Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp  
       195                    200                    205  
 Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn  
       210                    215                    220  
 Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu  
       225                    230                    235                    240  
 Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val  
       245                    250                    255  
 Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys  
       260                    265                    270  
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu  
       275                    280                    285  
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met  
       290                    295                    300  
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr  
       305                    310                    315                    320  
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala  
       325                    330                    335  
 Glu Gly Arg Ser Lys Leu Met Lys Ser Glu Gly Trp Tyr Ile Leu Lys  
       340                    345                    350  
 Ala Pro Lys Thr Pro Leu  
       355

&lt;210&gt; 14

&lt;211&gt; 4309

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

aagtgtaaa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgcctt	cttagtgccg	60
cgttcggcgc	ctgggttgtc	accggcgccg	ccgcccagga	agccactgca	accaggacgg	120
gagtgaggc	ggcgcagcat	gaagcggcgc	aggccgcctc	catagcgcac	gtcgggacgg	180
tccgggcggg	gccgggggga	agaaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgtt	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acagatcg	300
cctaaattgg	agcctttta	tgttgagcgg	tattcctgga	gtcagcttaa	aaagctgttt	360
gccgatacca	aaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tgcacatcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctttg	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggttagtgg	720
atttatcacg	taaaagatgg	agggccacaa	ggatttacgc	aacaacctt	aaggcccaat	780

ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgcc	tgctgatcca	840
gactggattg	cttttataca	tagcaacgt	atttggatat	ctaacatcg	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctaccttgt	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtgg	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacatccc	ctatgttgg	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacagg	acagcaaata	ctaaagtca	tttaagatg	1200
tcagaaataa	tgattgtatgc	tgaaggaaga	tccaagttga	tgaagtca	aggctggat	1260
attttgaagg	caccaaagac	tcccctttag	agcatcacct	gtacgtatgc	agttacgtaa	1320
atcctggaga	ggtgacaagg	ctgactgacc	gtggctactc	acattcttc	tgcatcagtc	1380
agcaactgtga	cttcttata	agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	1440
tttacaagct	atcaagtcc	gaagatgacc	caacttgc	aacaaggaa	ttttgggcca	1500
ccatttttgg	ttcagcaggt	cctcttcctg	actataactcc	tccagaaatt	ttctcttttgc	1560
aaagtactac	tggatttaca	ttgtatggg	tgctctacaa	gcctcatgat	ctacagcctg	1620
gaaagaaata	tcctactgtg	ctgttcatat	atgggtgtct	cctcagggtc	agttgggtgaa	1680
taatcggttt	aaaggagtca	agatattccg	cttgaatacc	ctagcctctc	tagttatgt	1740
ggttgtatgt	atagacaaca	ggggatcctg	tcaccgaggg	cttaaattttg	aaggccctt	1800
taaatataaa	atgggtcaaa	tagaaattga	cgatcagg	gaaggactcc	aatatctagc	1860
ttctcgatat	gatttcattt	acttagatcg	tgtggcattc	cacggctgg	cctatggagg	1920
atacctctcc	ctgatgcat	taatgcagag	gtcagatata	ttcagggtt	ctattgtgg	1980
ggccccagtc	actctgttgg	tcttctatga	tacaggatac	acggaacgtt	atatgggtca	2040
ccctgaccag	aatgaacagg	gcttattactt	aggatctgt	gccatgcaag	cagaaaagtt	2100
ccccctgtt	ccaaatcg	tactgtctt	acatggttt	ctggatgaga	atgtccattt	2160
tgcacatacc	agtatattac	ttagttttt	agtggggct	ggaaagccat	atgatttaca	2220
gatctatct	caggagagac	acagcataag	agttcctgaa	tcgggagaac	attatgaact	2280
gcatcttttgc	ca	cttaccc	aagaaaac	tggatcacgt	attgtctc	2340
ataattttga	cctgtgtaga	actctctgg	atacactgg	tatthaacca	aatgaggagg	2400
tttaatcaac	agaaaaacaca	gaattgatca	tcacat	tttgc	tgtaacatct	2460
actcctgaaa	ataaaatgtgg	tgccatgcag	gggtctacgg	tttgggttag	taatctaata	2520
ccttaacccc	acatgctcaa	aatcaa	atga	tacatattcc	tgagagaccc	2580
taagaattac	taaaaaaaaaa	aaaaaaa	agacattagc	accatgtatt	catactaccc	2640
tattttca	ttaatagta	ttataaactt	catgaactt	attagtgtat	ttttacagta	2700
tac	tttggtag	tttggtaaaa	tatgatgata	tttagtattt	gttgggttca	2760
ctttgactag	ttacagattt	gatagcattt	aaatgtatt	gaatagctt	tgcttcattt	2820
cttggcata	tccagcatgt	tatgactaa	taactattaa	acttgactt	accagtcatt	2880
cattaataat	ttttcaagga	taacttagt	gcctcc	tttgc	ttggcactga	2940
ccagtttttgc	gccaatttta	tctgtatcta	gtataaataa	ttctcattt	tcttgatga	3000
tattaacaga	gtgggctttt	cctttgc	aaaggctgt	aactgtat	gtatgttgc	3060
tttaatttgc	catgatatttgc	ataatttacag	gcagaaattt	tttaatcaaa	tgattagagc	3120
ttaaatatttgc	gcaggcaagt	ttttttttt	cctttaagaa	aaggaaaaag	tacacattca	3180
ctagaatttgc	tcagaaaattt	tagtggtgc	agtttccattt	tgttatttcc	ttattaaat	3240
attctagaat	tttaaggaga	ttgaagggaa	tcacagtgg	gtggggagac	ctgggtttgg	3300
ggaatgacag	agagaagagg	tggtagggc	ctgat	aaaa	actaagcaga	3360
acaaaaatac	tcatgaaaat	gttggaaac	tgaaattttaa	acaactgtaa	tattaaggaa	3420
accagaatca	ataaaatact	gtcttgc	cacagctaca	gagtaacatg	attcagggg	3480
ggaaaagttc	cttagagtt	ctttataat	tctttttt	tttccttta	gttttagaaa	3540
tcttacaaat	ttaaacttta	tcctttttaa	attatttgc	cataatttgc	atatttgc	3600
cttaaaatac	aaatgtttat	agataaccc	tttaccataa	actaattcc	ggcaagccat	3660
ggctctctt	tttttttgg	tgtttaaagc	ctgttac	tttttctgaa	tgatcatgaa	3720
cttttcttgc	tttagacta	ggat	tttgc	acttgc	ttcagggt	3780
aatttgc	tgccttgc	tttgc	tttgc	tttgc	tttgc	3840
cagggaaaggc	atctatgt	tttgc	tttgc	tttgc	tttgc	3900
ttaccaatac	ttttaaaca	cactcca	aaatttgc	tatttctt	tcatcactac	3960
agagagagta	gatttcccc	tagagagc	agcctcc	actaagg	tgactatttgc	4020
gtaagaggtg	gacttcat	acacca	ggaggt	aaagccc	aatggcagga	4080
tgtatgttgc	tttgc	tttgc	tttgc	tttgc	tttgc	4140
ataatagata	ccacgctt	tcttattatc	tgtatatgt	ttgctttca	tgtttgat	4200
tttccatgc	caagatttgc	ttatata	tttca	aaattaaatt	gat	4260
actttcttcc	ccaagaaagt	atttcccc	ttaagtataa	atctgact	gttgggt	4309

<210> 15  
<211> 108  
<212> PRT  
<213> Homo sapiens  
<400> 15

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu  
1 5 10 15  
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu  
20 25 30  
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu  
35 40 45  
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro  
50 55 60  
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser  
65 70 75 80  
Asp Arg Ile Tyr Tyr Leu Gly Asn Lys Ser Leu Ile Asp His Asp Arg  
85 90 95  
Phe Ser Lys Ser Lys Met Pro Glu Ile Ala Ser Ser  
100 105

<210> 16  
<211> 620  
<212> DNA  
<213> Homo sapiens  
<400> 16

aagtgtaaa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cgttcgccgc	ctgggttgtc	accggcgccg	ccgcccagga	agccactgca	accaggacgg	120
gagtggaggc	ggcgcagcat	gaagcggcgc	aggcccgtc	catagcgcac	gtcgggacgg	180
tccggggggg	gccggggggg	aggaaaaatgc	aacatggcag	cagcaatgg	aacagaacag	240
ctgggtgtt	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agecctttta	tgttggcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tggtaacaag	480
tcattaattt	atcatgatcg	ttttcaaaa	tcgaagatgc	cagaaattgc	ttcttcctaa	540
agctagctt	aatgcctt	ctttagatgg	tctgattagg	aaaacaaaaca	ataaaaaccat	600
tagtttgttc	ccactcaaca					620

<210> 17  
<211> 194  
<212> PRT  
<213> Homo sapiens  
<400> 17

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu  
 1 5 10 15  
 Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu  
 20 25 30  
 Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu  
 35 40 45  
 Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro  
 50 55 60  
 His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser  
 65 70 75 80  
 Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr  
 85 90 95  
 Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu  
 100 105 110  
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp  
 115 120 125  
 Tyr Gly Met Tyr Ser Arg Glu Glu Leu Leu Arg Glu Arg Lys Arg  
 130 135 140  
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly  
 145 150 155 160  
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly  
 165 170 175  
 Gly Pro Gln Gly Phe Thr Gln Pro Leu Arg Pro Asn Leu Val Glu Thr  
 180 185 190  
 Cys Ala

<210> 18  
 <211> 832  
 <212> DNA  
 <213> Homo sapiens  
 <400> 18

aagtgtaaa	gcctccgagg	ccaaggccgc	tgctactgcc	gcccgtgctt	cttagtgccg	60
cgttcggccgc	ctgggttgtc	accggcgccg	ccgcccagga	agccactgca	accaggaccg	120
gagtggaggc	ggcgacat	gaagcggcgc	aggcccgtc	catagcgcac	gtcgggacgg	180
tccggggcggg	gccgggggga	agaaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaatttgg	agcctttta	tgtttagcgg	tattccttga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctcttta	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtggaa	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgttcaagc	cggtagtgga	720
atttatcacg	taaaagatgg	agggccacaa	ggatttacgc	wacaacctt	aaggccaaat	780
ctagtggaaa	ctasttgts	caracytgca	tgacccaaatc	agatcctgta	ga	832

<210> 19  
 <211> 658  
 <212> PRT  
 <213> Homo sapiens  
 <400> 19

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu  
 1 5 10 15  
 Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu  
 20 25 30  
 Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu  
 35 40 45  
 Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro

50	55	60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser		
65	70	75
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr		80
85	90	95
Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu		
100	105	110
Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp		
115	120	125
Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg		
130	135	140
Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly		
145	150	155
Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly		160
165	170	175
Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu		
180	185	190
Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp		
195	200	205
Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn		
210	215	220
Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu		
225	230	235
Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val		
245	250	255
Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys		
260	265	270
Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu		
275	280	285
Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met		
290	295	300
Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr		
305	310	315
Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala		
325	330	335
Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe		
340	345	350
Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr		
355	360	365
Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr		
370	375	380
Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu		
385	390	395
Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser		
405	410	415
Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn		
420	425	430
Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile		
435	440	445
Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr		
450	455	460
Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly		
465	470	475
Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile		
485	490	495
Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn		
500	505	510
Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys		
515	520	525
Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro		

530	535	540
Gly	Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys	
545	550	555
Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys		560
565	570	575
Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp		
580	585	590
Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala		
595	600	605
Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser		
610	615	620
Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu		
625	630	635
Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Arg		640
645	650	655
Val Lys		

<210> 20  
<211> 4676  
<212> DNA  
<213> Homo sapiens  
<400> 20

aagtgcataaa	gcctccgagg	ccaaggccgc	tgctactgcc	ggcgctgctt	cttagtgccg	60
cgttcgcgc	ctgggttgtc	accggcgcgc	ccgcccagga	agccactgca	accaggaccc	120
gagtggaggc	ggcgcagcat	gaagcggcgc	aggccccctc	catagcgcac	gtcgggacgg	180
tccggcggg	gccgggggga	agaaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agcctttta	tgttgcggg	tattcttgg	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tttattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctttg	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggttagtgg	720
atttacacg	taaaagatgg	agggccacaa	ggatttacgc	aacaaccttt	aaggccaaat	780
ctagtgaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattt	cttttataca	tagcaacatg	atttggatat	ctaacatcg	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtgg	gttaaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgagggtgg	aattattcat	gttacatccc	ctatgttgg	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaatac	ctaaagtcac	ttttaagatg	1200
tcagaaataa	tgattgatgc	tgaaggaagg	atcatagatg	tcatagataa	ggaactaatt	1260
caacctttt	agattctatt	tgaaggagtt	gaatatattt	ccagagctgg	atggactcct	1320
gaggaaaaat	atgcttggtc	catcctacta	gatcgcccc	agactcgcc	acagatagtg	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgcctgattc	tgtgacgcca	ctaaattatct	atgaagaaac	aacagacatc	1500
tggataaata	tccatgacat	ctttcatgtt	tttccccaaa	gtcacgaaga	ggaaattttag	1560
tttattttt	cctctgaatg	caaaacaggt	ttccgtcatt	tataaaaaat	tacatctatt	1620
ttaaaggaaa	gcaaataataa	acgatccagt	ggtgggctgc	ctgctccaag	tgatttcaag	1680
tgtcctatca	aagaggagat	agaatttacc	agtggtaat	ggaagttct	tggccggcat	1740
ggatctaata	tccaagggt	tgaagtca	aggctgtat	atttgaagg	caccaaagac	1800
tcccctttag	agcatcacct	gtacgtatc	agttacgtaa	atccctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattcttgc	tgcacatgc	agcaactgtg	cttcttata	1920
agtaagtata	gtaccagaa	gaatccacac	tgtgtgtccc	ttacaagct	atcaagtcc	1980
gaagatgacc	caacttgcaa	aacaaaggaa	ttttggcca	ccatgggaa	ttcagcaggt	2040
cctcttcctg	actatactcc	tccagaaatt	ttctcttttgc	aaagtactac	tggatttaca	2100
ttgtatggga	tgctctacaa	gcctcatgat	ctacagcctg	gaaagaaata	tcctactgtg	2160
ctgttcatat	atgggtgtcg	ggtcaaata	aaattgacga	tcaggtggaa	ggactccaat	2220

atcttagcttc tcgatatatgtat	ttcatttgact	tagatcggtgt	gggcattccac	ggctggcctt	2280
atggaggata cctctccctg	atggcattaa	tgcagaggtc	agatatcttc	agggttgcta	2340
ttgctgggc cccagtca	ctgtggatct	tctatgatac	aggatacacg	gaacgttata	2400
tgggtcacc	tgaccagaat	attacttagg	atctgtggcc	atgcaagcag	2460
aaaagtcccc ctctgaacca	aatcgttac	tgctcttaca	tgggttcctg	gatgagaatg	2520
tccatTTgc acataccagt	atattactga	gttttttagt	gagggctgga	aagccatatg	2580
atttacagat ctatcctcag	gagagacaca	gcataagagt	tcctgaatcg	ggagaacatt	2640
atgaactgca tctttgcac	taacctcaag	aaaaccttgg	atcacgttatt	gctgctctaa	2700
aagtgatata attttgac	gtgtagaact	ctctggtata	cactggctat	ttaaccaaata	2760
gaggaggttt aatcaacaga	aaacacagaa	ttgatcatca	cattttgata	cctgccatgt	2820
aacatctact cctgaaaata	aatgtggtgc	catgcagggg	tctacgggtt	gtggtagtaa	2880
tctaatacct taaccccaca	tgctcaaaat	caaatacgtatac	atattcctga	gagacccagc	2940
aataccataa gaattactaa	aaaaaaaaaa	aaaaaaaaaga	cattagcacc	atgtattcat	3000
actaccctat ttca	tttca	taaacttcat	gaacttaatt	atgttatttt	3060
tacagtatac ttttgagttt	gttaaaat	gatgatatta	gtgattgggtt	tggttcagtt	3120
ccagaatctt tgacttagta	cagatttgat	agcacttaaa	tgtattgaa	tagcttatgc	3180
ttcattgctt gggcatatcc	agcatgttat	gaactaataa	ctattaaact	tgacttaacc	3240
agtcattcat taataatttt	tcaaggataa	cttagtgccc	tcctaaagac	acttggtttgc	3300
gcactgacca gtttttagcc	aatttaatct	gtatcttagta	taaataattc	tcattttct	3360
ttgatgatataa	taacagatgt	tttgcat	ggcttagtaac	tgtatatgt	3420
gcatggatt aattagtcat	gatattgata	attacaggca	gaaaattttt	aatcaaatga	3480
tttagagctta aatattttgca	ggcaagttt	ttttttcc	ttaagaaaag	aaaaaagtac	3540
acattcacta gaattcttc	gaaaatttag	ttggccagt	ttccatttgg	tatccctta	3600
ttaaaatatt ctagaatttt	aaggagattg	aagggaatca	cagtgggtg	gggagacctg	3660
ggtttgggaa atgacagaga	gaagaggtgg	tgagggcctg	ataaaaact	aagcagaagt	3720
agtttaaca aaaatactca	tgaaaatgtt	tggaaactga	aatttaaaca	actgtaatat	3780
taaggaaacc agaatcaata	aatcaactgtc	ttgccagcac	agctacagag	taacatgatt	3840
caggggagga aaagttccct	agagttactt	ttataattct	ttttttttt	cctcttaggt	3900
tttagaaatct tacaaatttta	aactttatcc	ttttaaaatt	atttgaacat	aatttagata	3960
ttgttaagctt aaaaatac	aaaatac	taaccttctt	accataaaact	aatccctggc	4020
aagccatggc tctctttttt	tttttggtgt	ttaaagcctg	taaacagttt	ttctgaatga	4080
tcatgaactt ttcttggtt	agcacttagga	tttagctatg	aagagagctc	ataggcttc	4140
agggtgtaat ttagatctgc	cctgttagag	tcttgggtg	ctagattgg	cacattgaca	4200
ccagttggcag ggaaggcatc	tatgagttt	atgctttta	tcacacactt	cagtgtttag	4260
aaagtatttta ccaatacttt	taaacaacac	tccaagaaaa	tttgctat	ttctttctca	4320
tcactacaga gagagtagat	ttccccatag	agagcacagc	ctccatttagt	aaggtggtg	4380
actatggta agaggtggac	ttcattgaca	ccaagtggga	ggttagggaaa	gcccagaaat	4440
ggcaggatga tatggtggtt	ctgtcggtgg	gaaaggtatt	gggttttgct	gtttgtattt	4500
atactgtata atagatacca	cgcttttct	tattatctgt	atatgtattt	ctttctatgt	4560
ttgatatttt cccatgccaa	gatttgtta	tatataattt	caatgttaaa	ttaaattgtat	4620
ttgggttaact ttcttccccaa	agaaagtatt	ttccccctta	agtataaaatc	tgactg	4676

<210> 21  
<211> 613  
<212> PRT  
<213> Homo sapiens  
<400> 21

Met	Ala	Ala	Ala	Met	Glu	Thr	Glu	Gln	Leu	Gly	Val	Glu	Ile	Phe	Glu
1				5				10						15	
Thr	Ala	Asp	Cys	Glu	Glu	Asn	Ile	Glu	Ser	Gln	Asp	Arg	Pro	Lys	Leu
							20		25					30	
Glu	Pro	Phe	Tyr	Val	Glu	Arg	Tyr	Ser	Trp	Ser	Gln	Leu	Lys	Lys	Leu
							35		40				45		
Leu	Ala	Asp	Thr	Arg	Lys	Tyr	His	Gly	Tyr	Met	Met	Ala	Lys	Ala	Pro
							50		55				60		
His	Asp	Phe	Met	Phe	Val	Lys	Arg	Asn	Asp	Pro	Asp	Gly	Pro	His	Ser
							65		70		75			80	
Asp	Arg	Ile	Tyr	Tyr	Leu	Ala	Met	Ser	Gly	Glu	Asn	Arg	Glu	Asn	Thr
							85		90				95		

Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu  
     100                     105                     110  
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp  
     115                     120                     125  
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg  
     130                     135                     140  
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly  
     145                     150                     155                     160  
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly  
     165                     170                     175  
 Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu  
     180                     185                     190  
 Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp  
     195                     200                     205  
 Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn  
     210                     215                     220  
 Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu  
     225                     230                     235                     240  
 Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val  
     245                     250                     255  
 Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys  
     260                     265                     270  
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu  
     275                     280                     285  
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met  
     290                     295                     300  
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr  
     305                     310                     315                     320  
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala  
     325                     330                     335  
 Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe  
     340                     345                     350  
 Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr  
     355                     360                     365  
 Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr  
     370                     375                     380  
 Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu  
     385                     390                     395                     400  
 Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser  
     405                     410                     415  
 Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn  
     420                     425                     430  
 Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Ile  
     435                     440                     445  
 Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr  
     450                     455                     460  
 Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly  
     465                     470                     475                     480  
 Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile  
     485                     490                     495  
 Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn  
     500                     505                     510  
 Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys  
     515                     520                     525  
 Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro  
     530                     535                     540  
 Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys  
     545                     550                     555                     560  
 Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys  
     565                     570                     575

Asn	Pro	His	Cys	Val	Ser	Leu	Tyr	Lys	Leu	Ser	Ser	Pro	Glu	Asp	Asp
				580				585				590			
Pro	Thr	Cys	Lys	Thr	Lys	Glu	Phe	Trp	Ala	Thr	Ile	Leu	Asp	Ser	Val
				595			600				605				
Leu	Arg	Cys	Ser	Trp											
				610											

&lt;210&gt; 22

&lt;211&gt; 4685

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

aagtgcataaa	gcctccgagg	ccaaggccgc	tgctactgcc	gcccgtgctt	cttagtgccg	60
cgttcggccgc	ctgggttgtc	accggcgccg	ccgcccggagga	agccactgca	accaggaccc	120
gagttggaggc	ggcgcagcat	gaagcggcgc	aggcccgctc	catagcgcac	gtcgggacgg	180
tccggggcggg	gccccggggg	aggaaaatgc	aacatggcag	cagcaatgg	aacagaacag	240
ctgggtgttg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcg	300
cctaaattgg	agcctttta	tgttggcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgataccca	aaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctctt	gaagcctt	ttggatctt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtccg	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgttcaagc	cggttagtgg	720
atttatacgc	taaaagatgg	agggccacaa	ggatttacgc	aacaacctt	aaggccaaat	780
ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattt	cttttataca	tagcaacgtat	atttggatat	ctaacatgt	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtgc	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtgg	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattat	gttacatccc	ctatgttgg	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaattc	ctaaagtcac	ttttaagatg	1200
tcagaaataa	tgattgtatgc	tgaaggaagg	atcatagatg	tcatagataa	ggaactaatt	1260
caaccttttgc	agattctatt	tgaaggagtt	gaatatattg	ccagagctgg	atggactcct	1320
gagggaaaat	atgcttggc	catcctacta	gatgcctccc	agactgcct	acagatagt	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgcctgattt	tgtgacgcca	ctaattatct	atgaagaaaac	aacagacatc	1500
tggataataa	tccatgacat	ctttcatgtt	tttccccaaa	gtcacgaaga	ggaaatttgg	1560
tttatttttgc	cctctgaatg	caaaacaggt	ttccgttatt	tataaaaaat	tacatctatt	1620
ttaaaggaaa	gcaaataataa	acgatccagt	ggtgggctgc	ctgctccaag	tgatttcaag	1680
tgtcctatca	aagaggagat	agcaatttac	agtggtgaat	gggaagttt	tggccggcat	1740
ggatctaata	tccaaaggta	tgaagtcaga	aggctggat	attttgaagg	caccaaagac	1800
tcccctttag	agcatcacct	gtacgtatc	agttacgtaa	atccctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattcttgc	tgcatacgatc	agcaactgtg	cttcttata	1920
agtaagtata	gtaaccagaa	gaatccacac	tgtgttccc	tttacaagat	atcaagtct	1980
gaagatgacc	caacttgc	aacaaaggaa	ttttggcca	ccatttttgg	ttcagtccctc	2040
aggtgcagtt	ggtgaataat	cggtttaaag	gagtcaagta	tttccgtt	aataccctag	2100
cctctctagg	ttatgtgg	gtatgtatag	acaacagggg	atccgttca	cgaggccta	2160
aatttgaagg	cgccctttaaa	tataaaatgg	gtcaaata	aatttgcgt	cagggtgg	2220
gactccaata	tctagttct	cgatatgat	tcatttgc	agatcgtgt	ggcatccacg	2280
gctggtccta	tggaggatac	cttccctga	tggcattaa	gcagaggta	gatatttca	2340
gggttgcata	tgctggggcc	ccagtca	tgtggatctt	ctatgtatca	ggatacacgg	2400
aacgttatata	gggtcaccct	gaccagaatg	aacagggtca	ttacttagga	tctgtggcc	2460
tgcaagcaga	aaagtcccc	tctgaaccaa	atcgat	gcttcttacat	ggtttccctgg	2520
atgagaatgt	ccattttgc	cataccagta	tattactgag	ttttttatgt	agggtggaa	2580
agccatata	tttacagatc	tatcctcagg	agagacacag	cataagagg	cctgaatcgg	2640
gagaacatta	tgaactgc	cttttgcact	accttcaaga	aaaccttgg	tcacgtattt	2700
ctgctctaa	agtgtatataa	tttgacctg	tgtagaactc	tctgttatac	actggctt	2760
taaccaaata	aggagttt	atcaacagaa	aacacagaat	tgatcatcac	attttata	2820

ctgccatgt	acatctactc	ctgaaaataa	atgtgggcc	atgcagggtt	ctacggtt	2880
tggtagtaat	ctaataccctt	aaccccacat	gctcaaaatc	aatgataca	tattcctgag	2940
agacccagca	ataccataag	aattactaaa	aaaaaaaaaa	aaaaaaagac	attagcacca	3000
tgtattcata	ctaccctatt	ttcactttt	atagtattat	aaacttcatg	aacttaatta	3060
gtgtatTTT	acagtatact	tttgagTTT	ttaaaatATG	atgatattAG	tgattggTTT	3120
ggTCAGTTC	cagaatCTT	gactagttac	agatttgata	gcacttaaat	gtaattgaat	3180
agCTTATGCT	tcattgCTT	ggcatatcca	gcatgttatg	aactaataac	tattaaactt	3240
gacttaacca	gtcattcatt	aataattttt	caaggataac	ttagtggcct	cctaaagaca	3300
cttgTTTGG	cactgaccag	tttttagcca	atthaatctg	tatctagtat	aaataattct	3360
cattttctt	tgatgatatt	aacagagtgg	gctttcctt	ttgcataaaag	gctagtaact	3420
gtatATGTA	catggattta	attagtcatg	atattgataa	ttacagggcag	aaaattttt	3480
atcaaATGAT	tagagcttaa	atatttgcag	gcaagTTTT	tttttcctt	taagaaaagg	3540
aaaaaAGTACA	cattcactag	aattcttcag	aaaatttagt	ggtgcCAGTT	tccatttggt	3600
atTCCTTAT	taaaatattc	tagaattttt	aggagattga	aggaaatcac	agtggggTGG	3660
ggagacCTGG	gtttgggaa	tgacagagag	aagaggTGT	gaggggCCTGA	ttaaaaacta	3720
agcagaAGTA	gttttaacaa	aaatactcat	gaaaatgttt	ggaaactgaa	atTTAAACAA	3780
ctgtaatATT	aaggaAACCA	gaatcaataa	atcaCTGTCT	tgccagcaca	gctacagagt	3840
aacatgATT	aggggaggaa	aagttcCTTA	gagttacttt	tataatttCTT	ttttttttc	3900
cttttaggtt	tagaaatctt	acaaatttaa	actttatcct	tttaaaatTTA	tttgaacata	3960
atTTAGATAT	tgtaagCTTA	aaatacaaaat	gtttatAGAT	aaccttCTTA	ccataaaACTA	4020
atCCCTGGCA	agccatGGCT	ctctttttt	ttttggTGT	taaAGCCTGT	aaacagTTT	4080
tctgaatGAT	catgaacttt	tcttggTTA	gcaCTAGGAT	ttagCTATGA	agagagCTCA	4140
taggCTTCA	ggtgCtaatt	gagatCTGCC	ctgttagagt	cttgggGTGC	tagattggTC	4200
acattgacac	cagtggcagg	gaaggcatct	atgagTTGA	tgctttttat	cacacacttc	4260
agtGTTAGA	aagtattac	caatactttt	aaacaacact	ccaagaaaat	ttgctatatt	4320
tcttctCAT	cactacagag	agagtagatt	tccccataga	gagcacagcc	tccatttagta	4380
aggttGGTGA	ctattggtaa	gaggtggact	tcattgacac	caagtggag	gtaggaaag	4440
cccagAAAATG	gcaggatgtat	atggTGGTTC	tgcgttggg	aaaggatTTG	ggtttgCTG	4500
tttGTTATTA	tactgtataa	tagataccac	gcttttCTT	attatCTGTA	tatgtattGC	4560
tttcatGTT	tgatattttc	ccatGCCAAG	atttggTTT	atataatttC	aatgttaaat	4620
taaattGATT	tgggtaactt	tcttccccaa	gaaagtattt	tcccccttaa	gtataaaatct	4680
gactg						4685

<210> 23  
<211> 892  
<212> PRT  
<213> Homo sapiens  
<400> 23

Met	Arg	Lys	Val	Lys	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser
1				5				10			15				
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr
							20			25				30	
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp
							35			40				45	
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg
							50			55				60	
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys
							65			70				75	
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro
							85			90				95	
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu
							100			105				110	
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala
							115			120				125	
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr
							130			135				140	
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg
							145			150				155	
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu

	165	170	175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg			
180	185	190	
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu			
195	200	205	
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro			
210	215	220	
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val			
225	230	235	240
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln			
245	250	255	
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr			
260	265	270	
Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys			
275	280	285	
Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile			
290	295	300	
Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro			
305	310	315	320
Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg			
325	330	335	
Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln			
340	345	350	
Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val			
355	360	365	
Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala			
370	375	380	
Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg			
385	390	395	400
Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile			
405	410	415	
Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val			
420	425	430	
Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val			
435	440	445	
Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly			
450	455	460	
Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe			
465	470	475	480
Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp			
485	490	495	
Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile			
500	505	510	
Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg			
515	520	525	
His Gly Ser Lys Ile Trp Val Asn Glu Glu Thr Lys Leu Val Tyr Phe			
530	535	540	
Gln Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr Val Val Ser			
545	550	555	560
Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro Gly Phe Ser			
565	570	575	
His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val Ser His Tyr			
580	585	590	
Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys Leu Ser Gly			
595	600	605	
Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp Ala Ser Met			
610	615	620	
Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro Glu Ile Phe			
625	630	635	640
His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met Ile Tyr Lys			

	645	650	655
Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val Leu Phe Val			
660	665	670	
Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe Lys Gly Ile			
675	680	685	
Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr Ala Val Val			
690	695	700	
Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg Phe Glu Gly			
705	710	715	720
Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp Gln Val Glu			
725	730	735	
Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp Leu Ser Arg			
740	745	750	
Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser Leu Met Gly			
755	760	765	
Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala Gly Ala Pro			
770	775	780	
Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu Arg Tyr Met			
785	790	795	800
Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly Ser Val Ala			
805	810	815	
Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu Leu Ile Leu			
820	825	830	
His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr Asn Phe Leu			
835	840	845	
Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu Gln Ile Tyr			
850	855	860	
Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly Glu His Tyr			
865	870	875	880
Glu Val Thr Leu Leu His Phe Leu Gln Glu Tyr Leu			
885	890		

<210> 24  
 <211> 4302  
 <212> DNA  
 <213> Homo sapiens  
 <400> 24

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgtgtccgccc	gcccgtgtcg	tcccccgctc	ccgcccacttc	cggggtcgca	gtccccggca	120
tggagccgccc	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cgcccgccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctgaaatg	gaggctctct	ggacccttta	240
gaaggccaccc	ctgcccctct	gaggtcagct	gagcggtaa	tgcggaaggt	taagaaaactg	300
cgcctggaca	aggagaacac	cggaaagttgg	agaagttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccacccgg	gaccccaacg	gccgaccggag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgcttcca	ggtgcagaag	cactctgtgg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtcagaaga	cgatgagtc	tggcccccac	tcccaccgcc	tctactacct	ggaaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaaagag	660
gtctctgtgc	tcctgtctcg	gaagcagatg	ctggatcatt	tcaggccac	gccccaccat	720
ggggctact	ctcgggagga	ggagctgctg	agggagcggaa	aacgcctggg	gttcttcggc	780
atcacctcct	acgacttcca	cagcgagatg	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gcccgcacgg	cggcaagaac	ggcttcattgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	aggccccccgg	atggacccca	aatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggccggc	tgaccttctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gtttcaactgg	gtactggtgg	1140
tgccccacag	cctcctggga	agttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgc	agaagaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccctgaaa	1320

ctggctgagt	tccagactga	cagccagggo	aagatcgct	cgacccagga	gaaggagctg	1380
gtcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgcccaggc	cgggtggacc	1440
cgggatggca	aatacgccctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtccctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	aatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgcttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtacc	1740
gccgtttaa	aatcccagg	ctacgattgg	agtgagccct	tcagccccgg	ggaagatgaa	1800
ttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	gttttggcg	1860
aggcacggct	ccaagatctg	ggtcaatgag	gagaccaagc	tggtgtactt	ccagggcacc	1920
aaggacacgc	cgctggagca	ccacacctac	gtggtcagct	atgaggcggc	cgcgagatc	1980
gtacgcctca	ccacgccccg	cttctccat	agctgctcca	tgagccagaa	cttcgacatg	2040
ttcgtcagcc	actacagcag	cgtgagcacg	ccgcctcg	tgcacgtcta	caagctgagc	2100
ggcccccacg	acgacccct	gcacaaggcag	ccccgcttct	gggctagcat	gatggaggca	2160
gccagctgcc	ccccggatta	tgttcctcca	gagatcttcc	atttccacac	gctcggtat	2220
gtgcggctct	acggcatgtat	ctacaagccc	cacgccttgc	agccagggaa	gaagcacc	2280
accgtctct	ttgtatatgg	aggcccccag	gtgcagctgg	tgaataactc	cttcaaaggc	2340
atcaagtact	tgcggctcaa	cacactggcc	tccctggct	acgccgttgt	tgtgattgac	2400
ggcaggggct	cctgtcagcg	agggttcgg	ttcgaagggg	ccctgaaaaaa	ccaaatggc	2460
caggtggaga	tgcaggacca	ggtggagggc	ctgcagttcg	tggccgagaa	gtatggctc	2520
atcgacactga	gcccggattgc	catccatggc	tggtcctacg	ggggcttcct	ctcgctcatg	2580
gggctaattcc	acaagcccca	ggtgttcaag	gtggccatcg	cgggtgcccc	ggtcaccgtc	2640
tggatggcct	acgacacagg	gtacactgag	cgctacatgg	acgtccctga	gaacaaccag	2700
cacggctatg	aggcgggttc	ctggccctg	cacgtggaga	agctgccc	tgagccaa	2760
cgcttgccta	tcctccacgg	cttcctggac	gaaaacgtgc	acttttcca	cacaaacttc	2820
ctcgctccc	aactgatccg	acgaggaaa	ccttaccagc	tccagatcta	ccccaaacgag	2880
agacacagta	ttcgctgccc	cgagtccggc	gagcaactatg	aagtca	gctgacttt	2940
ctacaggaat	acctctgagc	ctgcccaccc	ggagccgca	catcacagca	caagtggctg	3000
cagctccgc	ggggaaaccag	gccccgggaa	ctgagtgcc	cgccggcccc	agtgaggc	3060
tttgcggcc	ccagcgttgt	ccagccccga	ggagccgctg	ccttcaccc	ccgacgcct	3120
tttatacttt	tttaaacgct	tttgggtttt	atgtccgctg	tttcttggtt	gccgagacag	3180
agagatggtg	gtctcggcc	agccctct	ctccccc	tctgggagga	ggaggtcaca	3240
cgcttgcgttgg	caactggagag	gcccagaagag	actcagagga	gcccgttgc	ttccgcctgg	3300
ggctccctgt	gacctctcag	tcccctggcc	cggccagcca	ccgtcccc	caccaagca	3360
tgcaattgcc	tgtccccccc	ggccagcctc	cccaacttga	tgtttgtgtt	ttgtttgggg	3420
ggatatttt	cataattatt	taaaagacag	gcccggcgc	gtggctca	tctgtatcc	3480
cagcactttg	ggaggctgag	gccccggat	cacctgaggt	tgggagttca	agaccagcct	3540
ggccaacatg	ggggaaacccc	gtctctacta	aaaataaaaa	aaatttagcc	ggtgtgg	3600
cgcgtgccta	taatccc	actcggag	gctgaggcag	gagaatcg	tgaacccgg	3660
aggtggaggt	tgcgtgagc	caagatcgca	ccattgcact	ccagcctgg	caacaagagc	3720
gaaactctgt	ctcaaaataa	ataaaaaata	aaagacagaa	agcaagggt	gcctaaatct	3780
agacttgggg	tccacaccgg	gcaaggggt	tgcaaccc	cacctggtag	gctccatttc	3840
ttcccaagcc	cgagcagagg	gtcatgcgg	ccccacagga	gaagcggcca	gggcccgcgg	3900
ggggcaccac	ctgtggacag	ccctctgtc	cccaagctt	caggcagga	ctgaaacgca	3960
ccgaacttcc	acgctctgt	ggtca	ggctgtcccc	tcccagccc	agccccc	4020
ccacatgtgt	ctgcctgacc	cgta	agggttcc	gggttgggag	ctgaaccatc	4080
cccacctcg	ggttatattt	ccctctccc	ttccctcccc	gccaagagct	ctgcccagg	4140
cgggcaaaaa	aaaaagtaaa	aagaaaagaa	aaaaaaaaaa	aagaaacaaa	ccacctctac	4200
atattatgg	aagaaaat	tttgcgtat	tcttatttctt	ttataattat	gctgttggaa	4260
agttagacaca	ttaaacgatt	ccagttggaa	acatgtcacc	tg		4302

<210> 25  
 <211> 518  
 <212> PRT  
 <213> Homo sapiens  
 <400> 25

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser  
 1 5 10 15  
 Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr

20	25	30
Thr Gly Thr Pro Thr Ala Asp Arg	Gly Asp Ala Ala Ala	Thr Asp Asp
35	40	45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg		
50	55	60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys		
65	70	75
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro		
85	90	95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu		
100	105	110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala		
115	120	125
Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr		
130	135	140
Pro His His Gly Val Tyr Ser Arg Glu Glu Leu Leu Arg Glu Arg		
145	150	155
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu		
165	170	175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg		
180	185	190
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu		
195	200	205
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro		
210	215	220
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val		
225	230	235
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln		
245	250	255
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr		
260	265	270
Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys		
275	280	285
Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile		
290	295	300
Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro		
305	310	315
Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg		
325	330	335
Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln		
340	345	350
Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val		
355	360	365
Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala		
370	375	380
Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg		
385	390	395
Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile		
405	410	415
Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val		
420	425	430
Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val		
435	440	445
Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly		
450	455	460
Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe		
465	470	475
Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp		
485	490	495
Trp Ser Glu Pro Phe Ser Pro Gly Glu Gly Glu Gln Ser Leu Thr Asn		

500  
Ala Val Asp Ser Ser Arg  
515

505

510

<210> 26  
<211> 2411  
<212> DNA  
<213> Homo sapiens  
<400> 26

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaagggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gccccgtcg	tcccccgctc	ccgcccaccc	cggggtcgca	gtcccccggca	120
tggagccgccc	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cgcccgccgc	180
cccacgcccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcaccc	ctgcccctct	gaggtcagct	gagcggtaa	tgcgaaagggt	taagaaaactg	300
cgcctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gaccccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gaccggccg	cccgcttcca	ggtcagaag	cactcggtgg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtcagaaga	cggtatgatc	tggcccccac	tcccacccgc	tctactacct	ggaaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagggt	ccggaaagag	660
gctctgtgc	tcctgtctcg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggctact	ctcgggagga	ggagctgtcg	agggagcgga	aacgcctggg	gttctcgcc	780
atcacctcct	acgacttcca	cagcagatg	ggccttcc	tctccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cgcaagaac	ggcttcatgg	tgtcccttat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggcccccgg	atggacccca	aatatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgcac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagccggcgc	tgaccttctg	ccaccaagggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gccccgtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gtactgggtgg	1140	
tgccccacag	cctcttgggaa	aggttcagag	ggcctaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgtatg	agtcccgaggt	ggaggtcatt	cacgtcccc	ctcctgcgt	agaagaaaagg	1260
aagaacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccttggaaa	1320
ctgggttgtgt	tccttcgt	catacaggaa	gatgtccatgg	gttccactgg	1380	
gtcagccct	tcagctcgct	gttcccgaa	gtggagtaca	tcgcccaggc	cggttggacc	1440
cgggatggca	aatacgcctg	ggccatgttc	ctggaccggc	cccagcagt	gtccagctc	1500
gtccttcctcc	ccccggccct	gttcatcccc	agcacagaga	atgaggagca	gcccgttagcc	1560
tctgccagag	ctgtccccag	aatgtccatgg	ccgtatgtgg	tgtacggaga	gttacccaac	1620
gtctggatca	atgttcatga	catcttctat	ccctttcccc	aatcagaggg	agaggacgag	1680
ctctgttttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgtt	caaagtccacc	1740
gccgttttaa	aatcccagg	ctacgattgg	agtggccct	tccggccccc	ggaaggtgag	1800
cagacgcctga	cgaaatgtgt	cgactcatcg	cgtagtcac	gtgtggttca	atatgtgtt	1860
tgttcattgg	tccggccccc	cactcagcca	gcacaccctg	cgggagaagg	aacagggatc	1920
ggcaggaagc	cagccttc	cagtactgc	atgatctggc	agggctttaga	gcacccaact	1980
gttggcttat	tcaggcagca	gatttactga	gcacccccc	tgtggccaggc	ccttagcaca	2040
accagggggtt	ggccacccat	ggcccacacgg	tcaaattccgg	cccaccaccc	gtgttcataa	2100
ataaaatgttt	attggcactg	agccacagcc	acttggttac	agagactgtc	tgtgtcgct	2160
tttgtgtgc	agcagcagaa	ctgggttagtc	ccagcagaaa	ctgttgtgc	aggccaagat	2220
ttactgtcta	gcccttgc	gaaacatgg	ccagctcctg	ctgttaggtg	ctgtgtatgg	2280
attgttca	gtaaataaaag	aaaaaggaaa	atccctgtc	ttgggaccc	ctagtggagg	2340
aggcagtatt	ccagaaacag	ttagaggtgc	tgcctctgg	gtgctgtgg	tggcagatgc	2400
agatcctagt	c					2411

<210> 27  
<211> 892  
<212> PRT  
<213> Homo sapiens  
<400> 27

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser  
1 5 10 15

Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr  
                  20                 25                 30  
 Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp  
                  35                 40                 45  
 Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg  
                  50                 55                 60  
 Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys  
                  65                 70                 75                 80  
 Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro  
                  85                 90                 95  
 His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu  
                  100                105                110  
 Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala  
                  115                120                125  
 Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr  
                  130                135                140  
 Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg  
                  145                150                155                160  
 Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu  
                  165                170                175  
 Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg  
                  180                185                190  
 Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu  
                  195                200                205  
 Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro  
                  210                215                220  
 Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val  
                  225                230                235                240  
 Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln  
                  245                250                255  
 Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr  
                  260                265                270  
 Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys  
                  275                280                285  
 Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile  
                  290                295                300  
 Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro  
                  305                310                315                320  
 Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg  
                  325                330                335  
 Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln  
                  340                345                350  
 Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val  
                  355                360                365  
 Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala  
                  370                375                380  
 Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg  
                  385                390                395                400  
 Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile  
                  405                410                415  
 Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val  
                  420                425                430  
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val  
                  435                440                445  
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly  
                  450                455                460  
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe  
                  465                470                475                480  
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp  
                  485                490                495

Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile  
               500                  505                  510  
 Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg  
               515                  520                  525  
 His Gly Ser Lys Ile Trp Val Asn Glu Glu Thr Lys Leu Val Tyr Phe  
               530                  535                  540  
 Gln Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr Val Val Ser  
               545                  550                  555                  560  
 Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro Gly Phe Ser  
               565                  570                  575  
 His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val Ser His Tyr  
               580                  585                  590  
 Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys Leu Ser Gly  
               595                  600                  605  
 Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp Ala Ser Met  
               610                  615                  620  
 Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro Glu Ile Phe  
               625                  630                  635                  640  
 His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met Ile Tyr Lys  
               645                  650                  655  
 Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val Leu Phe Val  
               660                  665                  670  
 Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe Lys Gly Ile  
               675                  680                  685  
 Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr Ala Val Val  
               690                  695                  700  
 Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg Phe Glu Gly  
               705                  710                  715                  720  
 Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp Gln Val Glu  
               725                  730                  735  
 Gly-Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp Leu Ser Arg  
               740                  745                  750  
 Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser Leu Met Gly  
               755                  760                  765  
 Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala Gly Ala Pro  
               770                  775                  780  
 Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu Arg Tyr Met  
               785                  790                  795                  800  
 Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly Ser Val Ala  
               805                  810                  815  
 Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu Leu Ile Leu  
               820                  825                  830  
 His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr Asn Phe Leu  
               835                  840                  845  
 Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu Gln Ile Tyr  
               850                  855                  860

Pro	Asn	Glu	Arg	His	Ser	Ile	Arg	Cys	Pro	Glu	Ser	Gly	Glu	His	Tyr
865							870			875					880
Glu	Val	Thr	Leu	Leu	His	Phe	Leu	Gln	Glu	Tyr	Leu				
					885				890						

<210> 28  
<211> 4219  
<212> DNA  
<213> Homo sapiens  
<400> 28

caggccgcg	cctgggtcgc	tcaacttccg	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgttccgcc	gcggctgtcg	tccccgcgc	ccgcccacttc	cggggtcgca	gtcccccggca	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cgcccgccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctgaaatg	gaggctcttct	ggacccttta	240
gaaggcaccc	ctgccccttct	gaggtcagct	gagcggtaa	tgcgaaaggta	taagaaaactg	300
cgccctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gaccccaacg	gccgaccggag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgcttcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttcagttt	540
gtcagaaga	cggatgagtc	tggcccccac	tcccacggcc	tctactacct	gggaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagg	ccggaaaagag	660
gctctgtgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
gggtctact	ctcgggagga	ggagctgctg	agggagcgg	aacgccttggg	ggtcttcggc	780
atcacctct	acgacttcca	cagcgagat	ggccttcttc	tcttccaggc	cagcaacagc	840
ctcttccact	gcccgcacgg	cgcaagaac	ggcttcatgg	tgtcccttat	gaaaccgctg	900
gaaatcaaga	cccagtctc	aggccccgg	atggacccca	aatctgccc	tgccgaccct	960
gccttcttct	cttcatcaa	taacagcgcac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgacctctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcccgtgtgg	ccacctcgt	catacaggaa	gagttcgacc	gttcacttgg	gtactggtgg	1140
tgccccacag	ctctcttggg	agttcagag	ggcctaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgt	agaagaaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagaaga	atcccaagat	tgccttgaaa	1320
ctgctgtgat	tccagactga	cagccagggg	aagatcgtt	cgacccagga	gaaggagctg	1380
gtcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cgggtggacc	1440
cggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccagcagt	gctccagctc	1500
gtcctcttcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcccgttagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	ccctttccccc	aatcagaggg	agaggacgag	1680
ctctgcttcc	tccgcgc当地	tgaatgc当地	accggcttct	gccatttgc当地	caaagtccacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtggccct	ttagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggg	ggtttggcg	1860
aggcacggct	ccaagatctg	ggtaatgag	gagaccaagc	ttgtgtactt	ccagggcacc	1920
aaggacacgc	cgctggagca	ccacctctac	gtggtcagct	atgaggcggc	cggcggagatc	1980
gtacgcctca	ccacgcccgg	cttctccat	agctgctcca	tgagccagaa	cttcgacatg	2040
ttcgtcagcc	actacagcag	cgtgagcagc	ccgcctcg	tgcacgtcta	caagctgagc	2100
ggccccgacg	acgccccct	gcacaaggcag	ccccgcttct	gggctagcat	gatggaggca	2160
gccagctgcc	ccccggatta	tgttccctcca	gagatcttcc	atttccacac	gcccgtggat	2220
gtcgggctct	acggcatgat	ctacaagccc	cacgccttgc	agccaggggaa	gaaggacccccc	2280
accgtctct	ttgtatatgg	aggccccccag	gtgcagctgg	tgaataactc	cttcaaaggc	2340
atcaagact	tgccgctcaa	cacactggcc	tccctgggt	acgcccgtgt	tgtgattgac	2400
ggcaggggct	cctgtcagcg	agggcttcgg	ttcgaagggg	ccctgaaaaaa	ccaaatgggc	2460
caggtggaga	tcgaggacca	ggtggagggg	ctgcagttcg	tggcegagaa	gtatggcttc	2520
atcgacctga	gccgagttgc	catccatggc	tggcttacg	ggggcttcct	ctcgctcatg	2580
ggctaatcc	acaagcccc	ggtgttcaag	gtggccatcg	cggggtcccc	ggtcacccgtc	2640
tggatggcct	acgacacagg	gtacactgag	cgctacatgg	acgtccctga	gaacaaccag	2700
cacggctatg	aggcggttc	cgtggccctg	cacgtggaga	agctgccccaa	tgagcccaac	2760
cgcttgc当地	tcctccacgg	cttcctggac	gaaaacgtgc	acttttccca	cacaaacttc	2820
ctcgtctccc	aactgatccg	agcaggggaaa	ccttaccage	tccagatcta	ccccaaacgag	2880
agacacagta	ttcgctgccc	cgagtcgggg	gagcaactatg	aagtcaacgtt	gctgcacttt	2940

ctacaggaat	acctctgagc	ctgcccacccg	ggagccgcac	catcacagca	caagtggctg	3000
cagcctccgc	ggggAACCCAG	gccccggggga	ctgagtgcc	cgccggcccc	agtgaggcac	3060
tttgcctccgc	ccagcgctgg	ccagccccga	ggagccgctg	ccttcaccgc	cccgacgcct	3120
tttatccttt	tttaaacgct	cttgggtttt	atgtccgctg	cttcttggtt	gccgagacag	3180
agagatggtg	gtctcgggcc	agccccctct	ctccccgcct	tctgggagga	ggaggtcaca	3240
cgctgtggg	cactggagag	gccagaagag	actcagagga	gcgggctgcc	ttccgcctgg	3300
ggctccctgt	gacctctcag	tcccctggcc	cggccagcca	ccgtccccag	cacccaagca	3360
tgcaattgcc	tgtccccccc	ggccagcctc	cccaacttga	tgtttgtgtt	ttgtttgggg	3420
ggatatttt	cataattatt	taaaaagacag	gccgggcgcg	gtggctcacg	tctgtatcc	3480
cagcacttg	ggaggctgag	gccccggat	cacctgaggt	tggagttca	agaccagcct	3540
ggccaacatg	ggaaaccccc	gtctctacta	aaaataaaaa	aaattagccg	ggtgtggtgg	3600
cgcgtgccta	taatcccagc	tactcgggag	gctgaggcag	gagaatcgct	tgaacccggg	3660
aggtggaggt	tgcggtgagc	caagatcgca	ccattgcact	ccagcctggg	caacaagagc	3720
gaaactctgt	ctcaaaaataa	ataaaaaata	aaagacagaa	agcaaggggt	gcctaaatct	3780
agacttgggg	tccacaccgg	gcagcggggt	tgcaacccag	cacctggtag	gctccatttc	3840
tteccaagcc	cgactttcag	gcaggcactg	aaacgcacccg	aacttccacg	ctctgctgg	3900
cagtggcgcc	tgtccccctcc	ccagccccgc	cggccagcca	catgtgtctg	cctgaccctgt	3960
acacaccagg	ggttccgggg	ttgggagctg	aaccatcccc	acctcagggt	tatatttccc	4020
tctcccttc	cctcccccc	aagagctctg	ccagggcggg	gcaaaaaaaaaa	aagtaaaaaag	4080
aaaagaaaaa	aaaaaaaaag	aaacaaacca	cctctacata	ttatggaaag	aaaatatttt	4140
tgtcgattct	tattcttta	taattatgct	tggaagaagt	agacacatta	aacgattcca	4200
gttggaaaca	tgtcacctg					4219

<210> 29  
 <211> 832  
 <212> PRT  
 <213> Homo sapiens  
 <400> 29

Met	Arg	Lys	Val	Lys	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser
1				5				10					15		
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr
					20			25					30		
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp
					35			40				45			
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg
					50			55			60				
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys
					65			70			75			80	
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro
					85			90			95				
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu
					100			105			110				
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala
					115			120			125				
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr
					130			135			140				
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Leu	Leu	Arg	Glu	Arg	
					145			150			155			160	
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu
					165			170			175				
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg
					180			185			190				
Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu
					195			200			205				
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro
					210			215			220				
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val
					225			230			235			240	
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Glu	Arg	Arg	Ile	Thr	Phe	Cys	His	Gln

	245	250	255												
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr
				260				265					270		
Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr	Trp	Trp	Cys
				275				280					285		
Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr	Leu	Arg	Ile
				290			295			300					
Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile	His	Val	Pro
				305			310			315			320		
Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg	Tyr	Pro	Arg
				325			330						335		
Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala	Glu	Phe	Gln
				340			345						350		
Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys	Glu	Leu	Val
				355			360						365		
Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile	Ala	Arg	Ala
				370			375						380		
Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe	Leu	Asp	Arg
				385			390			395			400		
Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala	Leu	Phe	Ile
				405			410			410			415		
Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala	Arg	Ala	Val
				420			425						430		
Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val	Thr	Asn	Val
				435			440						445		
Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln	Ser	Glu	Gly
				450			455						460		
Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys	Thr	Gly	Phe
				465			470			475			480		
Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln	Gly	Tyr	Asp
				485			490						495		
Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys	Cys	Pro	Ile
				500			505						510		
Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val	Leu	Ala	Arg
				515			520						525		
His	Gly	Ser	Lys	Ile	Trp	Val	Asn	Glu	Glu	Thr	Lys	Leu	Val	Tyr	Phe
				530			535						540		
Gln	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr	Val	Val	Ser
				545			550			555			560		
Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro	Gly	Phe	Ser
				565			570						575		
His	Ser	Cys	Ser	Met	Ser	Gln	Asn	Phe	Asp	Met	Phe	Val	Ser	His	Tyr
				580			585						590		
Ser	Ser	Val	Ser	Thr	Pro	Pro	Cys	Val	His	Val	Tyr	Lys	Leu	Ser	Gly
				595			600						605		
Pro	Asp	Asp	Asp	Pro	Leu	His	Lys	Gln	Pro	Arg	Phe	Trp	Ala	Ser	Met
				610			615						620		
Met	Glu	Ala	Ala	Ser	Cys	Pro	Pro	Asp	Tyr	Val	Pro	Pro	Glu	Ile	Phe
				625			630			635			640		
His	Phe	His	Thr	Arg	Ser	Asp	Val	Arg	Leu	Tyr	Gly	Met	Ile	Tyr	Lys
				645			650						655		
Pro	His	Ala	Leu	Gln	Pro	Gly	Lys	Lys	His	Pro	Thr	Val	Leu	Phe	Val
				660			665						670		
Tyr	Gly	Gly	Pro	Gln	Val	Gln	Leu	Val	Asn	Asn	Ser	Phe	Lys	Gly	Ile
				675			680						685		
Lys	Tyr	Leu	Arg	Leu	Asn	Thr	Leu	Ala	Ser	Leu	Gly	Tyr	Ala	Val	Val
				690			695						700		
Val	Ile	Asp	Gly	Arg	Gly	Ser	Cys	Gln	Arg	Gly	Leu	Arg	Phe	Glu	Gly
				705			710			715			720		
Ala	Leu	Lys	Asn	Gln	Met	Gly	Gln	Val	Glu	Ile	Glu	Asp	Gln	Val	Glu

	725	730	735
Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp Leu Ser Arg			
740	745	750	
Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser Leu Met Gly			
755	760	765	
Leu Ile His Lys Pro Gln Val Phe Lys Ala Gln Pro Leu Ala Tyr Pro			
770	775	780	
Pro Arg Leu Pro Gly Arg Lys Arg Ala Leu Phe Pro His Lys Leu Pro			
785	790	795	800
Arg Leu Pro Thr Asp Pro Ser Arg Glu Thr Leu Pro Ala Pro Asp Leu			
805	810	815	
Pro Gln Arg Glu Thr Gln Tyr Ser Leu Pro Arg Val Gly Arg Ala Leu			
820	825	830	

<210> 30  
<211> 4159  
<212> DNA  
<213> Homo sapiens  
<400> 30

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaagg	gcctgagccg	gcgggtcccc	60
tgtgtccgccc	gccccgtgtcg	tcccccgctc	ccgccacttc	cggggtcgc	gtcccccggca	120
tggagccgccc	accgtgaggc	gccccgtggac	ccgggacgcac	ctgcccagtc	cgcccgccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctgaaatg	gaggctctct	ggacccttta	240
gaaggcacc	ctgcccctcct	gagggtcagct	gagcggtaa	tgcgaaagg	taagaaaactg	300
cgcctggaca	aggagaacac	cggaagttgg	agaagottct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccegg	gaccccaacg	gccgaccegg	gcgacgcagc	cgccacagat	420
gaccggcccg	cccgcttcca	ggtgcagaag	cactcggtgg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgeagaaga	cggtatgatc	tgggccccac	tcccacccgc	tctactaccc	gggaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagg	ccggaaagag	660
gctctgtgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gcccaccat	720
gggggtetact	ctegggaggg	ggagctgctg	agggagcgg	aacgcctggg	ggtttcggc	780
atcacctcct	acgacttcca	cagcagagat	ggccttcc	tctccaggc	cagcaacagc	840
ctcttccact	gcccgcacgg	cgccaagaac	ggcttcatgg	tgtcccttat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggccccgg	atggacccca	aatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgc	ctgtgggtgg	ccaacatcga	gacaggcag	1020
gagccggccgc	tgaccttctg	ccaccaagg	ttatccaatg	tcctggatga	ccccaagtct	1080
gccccgtgtgg	ccaccttcgt	catacaggaa	gattcgacc	gcttactgg	gtactgggtgg	1140
tgcaccacag	cctctggga	agttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtccct	ctcctgcgc	agaagaaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccttggaa	1320
ctggctgagt	tccagactga	cagccaggc	aagatcgtct	cgacccagg	gaaggagctg	1380
gtcagccct	tcagctcgct	gttcccgaag	gtggagtc	tgcaggggc	cggttggacc	1440
cgggatggca	aatacgcctg	ggccatgttc	ctggaccggc	cccaggcgt	gctccagctc	1500
gtccctctcc	ccccggccct	gttcatccc	agcacagaga	atgaggagca	gcccgttagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catttctat	ccttcccccc	aatcagaggg	agaggacgag	1680
ctctgcttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgc	caaagtacc	1740
gccgtttaa	aatcccaagg	ctacgattgg	agtggccct	tccggccccc	ggaagatgaa	1800
ttaagtgc	ccattaagga	agagattgt	ctgaccagg	gtaaatggg	ggttttggcg	1860
aggcacggct	ccaagatctg	ggtaatgag	gagaccaagc	tggtgtactt	ccagggcacc	1920
aaggacacgc	cgctggagca	ccacctctac	gtggtcagct	atgaggcggc	cgccgagatc	1980
gtacgcctca	ccacgccccgg	cttctccat	agctgc	tgcacgttca	caagctgagc	2040
ttcgtcagcc	actacagcag	cgtgagcag	ccgcctgc	tgcacgttca	caagctgagc	2100
ggccccgacg	acgacccct	gcacaagg	ccccgttct	gggctagcat	gatggaggca	2160
gccagctgcc	ccccggatta	tgttcccca	gagatcttcc	atttccacac	gcccgtggat	2220
gtgcggctct	acggcatgtat	ctacaagccc	cacgccttgc	agccaggaa	gaagcacccc	2280
accgtcttc	ttgttatatgg	aggccccag	gtgcagctgg	tgaataactc	cttcaaaggc	2340
atcaagtact	tgccgctcaa	cacactggc	tccctgggct	acggcgttgt	tgtgattgac	2400

ggcaggggct	cctgtcagcg	agggcttcgg	ttcgaagggg	ccctgaaaaa	ccaaatgggc	2460
caggtggaga	tcgaggacca	ggtggagggc	ctgcagttcg	tggccgagaa	gtatggcttc	2520
atcgacactga	gccgagttgc	catccatggc	tggcttacg	ggggcttcct	ctcgctcatg	2580
gggctaattcc	acaagccccca	ggtgttcaag	gcccaaccgc	ttgcttatcc	tccacggctt	2640
cctggacgaa	aacgtgoact	tttccacac	aaacttcctc	gtctcccaac	tgatccgagc	2700
aggaaaacct	taccagctcc	agatctaccc	caacgagaga	cacagtattc	gctgccccga	2760
gtcgggcccgg	cactatgaag	tcacgttgct	gcactttcta	caggaatacc	tctgagccctg	2820
cccacccggg	gcccgcacat	cacagcacaa	gtggctgcag	cctccgcggg	gaaccaggcg	2880
ggagggactg	agtggcccg	gggccccagt	gaggcactt	gtcccgcaca	gctggccca	2940
gccccgagga	gcccgtgcct	tcaccgcccc	gacgcctttt	atcccttttt	aaacgctttt	3000
gggtttatg	tccgctgttt	cttgggttgc	gagacagaga	gatgggtggtc	tcgggcccagc	3060
ccctcccttc	cccgcccttc	gggaggagga	ggtcacacgc	tgatgggcac	tggagaggcc	3120
agaagagact	cagaggagcg	ggctgccttc	cgccctgggc	tccctgtgac	ctctcagtcc	3180
cctggcccccgg	ccagccacccg	tccccagcac	ccaagcatgc	aattgcctgt	cccccccgcc	3240
cagcctcccc	aacttgcgt	tttgttttgc	tttgggggga	tattttcat	aattatttaa	3300
aagacaggcc	gggcgcgggt	gctcacgtct	gtaatcccag	cactttggga	ggctgaggcg	3360
ggcggatcac	ctgaggttgg	gagttcaaga	ccagcctggc	caacatgggg	aaaccccgtc	3420
tctactaaaa	atacaaaaaa	ttagccgggt	gtgggtggcg	gtgcctataa	tcccagctac	3480
tcgggaggct	gaggcaggag	aatcgcttgc	acccgggagg	tggaggttgc	ggtgagccaa	3540
gatcgaccca	ttgcactcca	gcctggcaa	caagagcga	actctgtctc	aaaataaaata	3600
aaaaataaaa	gacagaaagc	aagggtgcc	taaatctaga	cttgggttcc	acaccggca	3660
gcgggggttgc	aaccaggcac	ctggtaggct	ccatttcttc	ccaagcccg	gcagagggtc	3720
atcgggggcc	cacaggagaa	ggggccaggg	cccgccgggg	gcaccacctg	tggacagccc	3780
tcctgtcccc	aagctttcag	gcaggcactg	aaacgcaccg	aacttccacg	ctctgctggt	3840
cagtggccgc	tgtccctcc	ccagcccagc	cgcccgagca	catgtgtctg	cctgaccctgt	3900
acacaccagg	ggttccgggg	ttgggagctg	aaccatcccc	acctcagggt	tatatttccc	3960
tctcccttc	cctcccccgc	aagagctctg	ccagggcg	gcaaaaaaaaaa	aagtaaaaaaag	4020
aaaagaaaaa	aaaaaaaaag	aaacaaacca	cctctacata	ttatggaaag	aaaatatttt	4080
tgtcgattct	tatttttta	taattatgcg	tggaagaagt	agacacatta	aacgattcca	4140
gttggaaaca	tgtcacctg					4159

<210> 31  
 <211> 832  
 <212> PRT  
 <213> Homo sapiens  
 <400> 31

Met	Arg	Lys	Val	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser	
1				5				10				15			
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr
					20				25				30		
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp
					35			40				45			
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg
					50			55			60				
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys
					65			70			75			80	
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro
					85			90			95				
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu
					100			105			110				
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala
					115			120			125				
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr
					130			135			140				
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg
					145			150			155			160	
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu
					165			170			175				
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg

180	185	190
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu		
195	200	205
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro		
210	215	220
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val		
225	230	235
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln		
245	250	255
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr		
260	265	270
Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys		
275	280	285
Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile		
290	295	300
Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro		
305	310	315
Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg		
325	330	335
Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln		
340	345	350
Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val		
355	360	365
Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala		
370	375	380
Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg		
385	390	395
Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile		
405	410	415
Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val		
420	425	430
Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val		
435	440	445
Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly		
450	455	460
Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe		
465	470	475
Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp		
485	490	495
Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile		
500	505	510
Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg		
515	520	525
His Gly Ser Lys Ile Trp Val Asn Glu Glu Thr Lys Leu Val Tyr Phe		
530	535	540
Gln Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr Val Val Ser		
545	550	555
Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro Gly Phe Ser		
565	570	575
His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val Ser His Tyr		
580	585	590
Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys Leu Ser Gly		
595	600	605
Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp Ala Ser Met		
610	615	620
Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro Glu Ile Phe		
625	630	635
His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met Ile Tyr Lys		
645	650	655
Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val Leu Phe Val		

660	665	670													
Tyr	Gly	Pro	Gln	Val	Gln	Leu	Val	Asn	Asn	Ser	Phe	Lys	Gly	Ile	
675						680					685				
Lys	Tyr	Leu	Arg	Leu	Asn	Thr	Leu	Ala	Ser	Leu	Gly	Tyr	Ala	Val	Val
690						695				700					
Val	Ile	Asp	Gly	Arg	Gly	Ser	Cys	Gln	Arg	Gly	Leu	Arg	Phe	Glu	Gly
705						710				715			720		
Ala	Leu	Lys	Asn	Gln	Met	Gly	Gln	Val	Glu	Ile	Glu	Asp	Gln	Val	Glu
						725			730			735			
Gly	Leu	Gln	Phe	Val	Ala	Glu	Lys	Tyr	Gly	Phe	Ile	Asp	Leu	Ser	Arg
						740			745			750			
Val	Ala	Ile	His	Gly	Trp	Ser	Tyr	Gly	Gly	Phe	Leu	Ser	Leu	Met	Gly
						755			760			765			
Leu	Ile	His	Lys	Pro	Gln	Val	Phe	Lys	Ala	Gln	Pro	Leu	Ala	Tyr	Pro
770						775			780						
Pro	Arg	Leu	Pro	Gly	Arg	Lys	Arg	Ala	Leu	Phe	Pro	His	Lys	Leu	Pro
785						790			795			800			
Arg	Leu	Pro	Thr	Asp	Pro	Ser	Arg	Glu	Thr	Leu	Pro	Ala	Pro	Asp	Leu
						805			810			815			
Pro	Gln	Arg	Glu	Thr	Gln	Tyr	Ser	Leu	Pro	Arg	Val	Gly	Arg	Ala	Leu
						820			825			830			

<210> 32  
 <211> 4076  
 <212> DNA  
 <213> Homo sapiens  
 <400> 32

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tcccccgctc	ccgcccacttc	cggggctcgc	gtcccccggca	120
tggagccg	accgtgaggc	gccgctggac	ccgggacgcac	ctgcccagtc	cggccggccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcaccc	ctgcccctcct	gaggtcagct	gagcggtaa	tgcgaaaggt	taagaaaactg	300
cgcctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gacccaacg	gccgaccgag	gcgacgcagc	cgcacagat	420
gaccggccg	cccgcttcca	ggtgcagaag	cactcggtgg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tgggccccac	tcccaccgcc	tctactacct	ggaaatgc当地	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaaaagag	660
gctctgctgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgctg	agggagcgg	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gcccgcacgg	cggcaagaac	ggttcatgg	tgtcccttat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggccccgg	atggacccca	aatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttctgt	catacaggaa	gattcgacc	gttcaactgg	gtactgggtgg	1140
tgccccacag	cctcctggga	agttcagag	ggcctaaga	cgctgcgaat	cctgtatgag	1200
gaagtgcgt	agtccgaggt	ggaggtcatt	cacgtcccct	ctctcgccgt	agaagaaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccttgaaa	1320
ctggctgagt	tccagactga	cagccaggcc	aagatcgtct	cgacccaggaa	gaaggagctg	1380
gtcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tgcaggggc	cgggtggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccaggcgt	gtccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	cgggctagcc	1560
tctgcccag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgcttcc	tccgcgccaa	tgaatgcaag	accggcttct	gccatitgta	caaagtccacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtgagccct	ttagccccgg	ggaagatgaa	1800
ttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggg	ggtttggcg	1860
aggcacggct	ccaagatctg	ggtaatgag	gagaccaagc	tggtgtactt	ccagggcacc	1920

aaggacacgc	cgctggagca	ccacctctac	gtggtcagct	atgaggcggc	cggcgagatc	1980
gtacgcctca	ccacgccccg	cttctccat	agctgctcca	ttagccagaa	cttcgacatg	2040
ttcgtcagcc	actacagcag	cgtgagcacg	ccgccccgtcg	tgcacgtcta	caagctgagc	2100
ggccccgacg	acgacccccct	gcacaaggcag	ccccgcttct	gggctagcat	gatggaggca	2160
gccagctgcc	ccccggatta	tgttcctcca	gagatctcc	atttccacac	gcgctcgat	2220
gtgcggctct	acggcatgat	ctacaagccc	cacgccttgc	agccaggaa	gaagcacc	2280
accgtcctct	ttgttatatgg	aggccccag	gtgcagctgg	tgaataactc	cttcaaaggc	2340
atcaagtact	tgccgctcaa	cacactggcc	tccctgggct	acgcccgttgt	tgtgattgac	2400
ggcagggct	cctgtcagcg	agggttcgg	ttcgaagggg	ccctgaaaaaa	ccaaatggc	2460
caggtggaga	tcgaggacca	ggtggaggc	ctgcagttcg	tggccgagaa	gtatggctc	2520
atcgacctga	gccgagttgc	catccatggc	tggccttacg	ggggcttct	ctcgctcatg	2580
gggctaattcc	acaagcccc	ggtgttcaag	gcccaaccgc	ttgcttatcc	tccacggctt	2640
cctggacgaa	aacgtgcact	tttccacac	aaacttcctc	gtctcccaac	tgatccgagc	2700
agggaaacct	taccagctcc	agatctaccc	caacgagaga	cacagtattc	gctggcccga	2760
gtcgggcccag	cactatgaag	tcacgttgct	gcactttcta	caggaataacc	tctgagcctg	2820
cccaccggga	gccgcacat	cacagcacaa	gtggctgcag	cctccggg	gaaccaggcg	2880
ggagggactg	agtggcccgc	gggccccagt	gaggcactt	gtcccgccca	gcgctggcca	2940
gccccgagga	gccgctgcct	tcaccggccc	gacgcctttt	atcctttttt	aaacgcttt	3000
gggttttatg	tccgctgctt	cttgggttgc	gagacagaga	gatgggtgtc	tcggccagc	3060
ccctcctctc	ccgccttct	gggaggagga	ggtcacacgc	tgatggcact	tggagaggcc	3120
agaagagact	cagaggagcg	ggctgccttc	cgcctggggc	tccctgtgac	ctctcagtcc	3180
cctggcccg	ccagccaccg	tccccagcac	ccaagcatgc	aattgcctgt	cccccccgcc	3240
cagectcccc	aacttgcgt	ttgtgtttt	tttgggggaa	tattttcat	aattattnaa	3300
aagacaggcc	gggcgcggtg	gctcacgtct	gtaatcccag	cactttggga	ggctgaggcg	3360
ggcggatcac	ctgagggttg	gagttcaaga	ccagcctggc	caacatgggg	aaaccccgcc	3420
tctactaaaa	atacaaaaaaa	ttagccgggt	gtgggtggcgc	gtgcctataaa	tcccagctac	3480
tcgggaggct	gaggcaggag	aatcgcttga	accgggagg	tggaggttgc	ggtgagccaa	3540
gatcgcacca	ttgcactcca	gcctggca	caagagcga	actctgtctc	aaaataaaata	3600
aaaaataaaa	gacagaaagc	aagggtgccc	taaatctaga	cttgggttcc	acaccggca	3660
ggggggttgc	aaccacgcac	ctgttagget	ccatttcttc	ccaagcccc	ctttcaggca	3720
ggcactgaaa	cgccacccgaa	ttccacgcctc	tgctggtcag	tggcggctgt	ccccccccca	3780
gccccggcc	ccagccacat	gtgtctgcct	gaccgtaca	caccagggtt	tccggggttg	3840
gggagctgaa	cacateccccacc	tcagggttat	atttccctct	ccccttcct	cccccccaag	3900
agctctgcca	ggggcgggca	aaaaaaaaaa	taaaaagaaa	agaaaaaaaaa	aaaaaagaaa	3960
caaaccacct	ctacatatta	tgaaagaaa	atattttgt	cgattcttat	tctttataaa	4020
ttatgcgtgg	aagaagtata	cacattaaac	gattccagtt	ggaaacatgt	cacctg	4076

<210> 33  
 <211> 879  
 <212> PRT  
 <213> Homo sapiens  
 <400> 33

Met	Arg	Lys	Val	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser	
1				5			10					15			
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr
					20			25				30			
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp
					35			40				45			
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg
					50			55			60				
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys
						65		70			75		80		
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro
						85		90			95				
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu
						100		105			110				
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala
						115		120			125				
Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr	

130	135	140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu		Leu Leu Arg Glu Arg
145	150	155
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu		160
165	170	175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg		
180	185	190
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu		
195	200	205
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro		
210	215	220
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val		
225	230	235
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln		
245	250	255
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr		
260	265	270
Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys		
275	280	285
Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile		
290	295	300
Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro		
305	310	315
Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg		
325	330	335
Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln		
340	345	350
Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val		
355	360	365
Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala		
370	375	380
Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg		
385	390	395
Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile		
405	410	415
Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val		
420	425	430
Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val		
435	440	445
Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly		
450	455	460
Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe		
465	470	475
Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp		
485	490	495
Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile		
500	505	510
Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg		
515	520	525
His Gly Ser Lys Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr		
530	535	540
Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro		
545	550	555
		560

Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val  
               565                     570                     575  
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys  
               580                     585                     590  
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp  
               595                     600                     605  
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro  
               610                     615                     620  
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met  
               625                     630                     635                     640  
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val  
               645                     650                     655  
 Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe  
               660                     665                     670  
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr  
               675                     680                     685  
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg  
               690                     695                     700  
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp  
               705                     710                     715                     720  
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp  
               725                     730                     735  
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser  
               740                     745                     750  
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala  
               755                     760                     765  
 Gly Ala Pro Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu  
               770                     775                     780  
 Arg Tyr Met Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly  
               785                     790                     795                     800  
 Ser Val Ala Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu  
               805                     810                     815  
 Leu Ile Leu His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr  
               820                     825                     830  
 Asn Phe Leu Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu  
               835                     840                     845  
 Gln Ile Tyr Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly  
               850                     855                     860  
 Glu His Tyr Glu Val Thr Leu Leu His Phe Leu Gln Glu Tyr Leu  
               865                     870                     875

&lt;210&gt; 34

&lt;211&gt; 4263

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 34

caggccgccc	cctgggtcgc	tcaacttccg	ggtaaaaggt	gcctgagccg	gcgggtcccc	60
tgttccgcc	gcggctgtcg	tccccgctc	ccgcccattc	cggggtcgca	gtcccgccga	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cggccgcccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctgaaatg	gaggctctct	ggacccttta	240
gaaggcaccc	ctgcccctcct	gaggtcagct	gagcggtaa	tgcgaaaggt	taagaaaactg	300
cgcctggaca	aggagaacac	cggaagtgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccacccg	gacccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgcttcca	ggtgcagaag	cactcgtgg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tggcccccac	tcccaccgccc	tctactacct	ggaaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaaaagag	660
gctctgctgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgctg	agggagcgg	aacgcctggg	ggtcttcggc	780

atcacccct	acgacttcca	cagcgagagt	ggcctttcc	tcttcaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cgccaagaac	ggcttcatgg	tgtccccat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggccccgg	atggacccc	aaatctgcc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcg	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttctgt	catacaggaa	gagttcgacc	gottcaactgg	gtactgggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctaaga	cgctgcgaat	cctgttatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccc	ctcctgcgc	agaagaaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagaaga	atcccaagat	tgccttgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgct	cgacccagg	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgcccagg	cgggtggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggacggc	cccaggagt	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatccc	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	aatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgttttc	tccgcgcca	tgaatgcaag	accggcttct	gccatttgt	caaagtcc	1740
gccgttttaa	aatcccagg	ctacgattgg	agtgagccct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggg	gttttggcg	1860
aggcacggct	ccaaggggcac	caaggacacg	ccgctggagc	accacctcta	cgtggtcagc	1920
tatgagggcg	ccggcgagat	cgtacgcctc	accacgccc	gctctccca	tagtgcctc	1980
atgagccaga	acttcgacat	gttcgtcagc	cactacagca	gcgtgagcac	gcccccctgc	2040
gtgcacgtct	acaagctgag	cggccccgac	gacgacccccc	tgcacaagca	gcccccttc	2100
tgggcttagca	tgtggaggc	agccagctgc	ccccggatt	atgttctcc	agagatctc	2160
catttccaca	cgcgctcgga	tgtcggtc	tacggcatga	tctacaagcc	ccacgcctt	2220
cagccaggga	agaagcaccc	caccgtcctc	tttgtatatg	gaggccccca	ggtgcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	ttcggtctca	acacactggc	ctccctggc	2340
tacccgtgg	ttgtgattga	cgccaggggc	tcctgtcagc	gagggttctg	gttcgaaggg	2400
gccctaaaaa	accaaattgg	ccaggtggag	atcgaggacc	aggtggaggg	cctgcagttc	2460
gtggccgaga	agtatggctt	catcgacctg	agccgagttg	ccatccatgg	ctggctctac	2520
gggggcttcc	tctcgctcat	ggggctaatac	cacaagcccc	aggtgttcaa	ggtggccatc	2580
gcgggtgccc	cggtcaccgt	ctggatggcc	tacgacacag	ggtacactga	gchgctacatg	2640
gacgtccctg	agaacaacca	gcacggctat	gaggcggtt	ccgtggccct	gcacgtggag	2700
aagctgccc	atgagccaa	ccgcttgc	atcctccacg	gcttcctgg	cgaaaacgt	2760
cacttttcc	acacaactt	cctcgctc	caactgatcc	gagcagg	acattaccag	2820
ctccagatct	accccaacga	gagacacagt	attcgctgc	ccgagtcgg	cgagcactat	2880
gaagtcacgt	tgctgcactt	tctacaggaa	tacctctgag	cctgcccacc	gggagccg	2940
acatcacagc	acaagttgct	gcagcctcc	cggggaa	ggcgggaggg	actgagtggc	3000
ccgcgggccc	cagtgggca	cttgcctcc	cccagcg	gccagcccc	aggagccg	3060
gccttccac	ccccgacg	ttttatc	ttttaaacgc	tcttggg	tatgtcc	3120
gcttcttgg	tgccgagaca	gagagatgg	ggtctcgg	cagcccc	tctcccc	3180
ttctgggagg	aggaggtcac	acgctgatgg	gcactgg	ggccaga	gactcagagg	3240
agccggctgc	cttgcctc	gggctcc	tgacctc	gtccc	ccggccag	3300
accgtcccc	gcacccaa	atgcaattgc	ctgtcccc	cgcc	ccccaa	3360
atgtttgtt	tttgggg	ggatatttt	tcataattat	ttaaa	ggcggg	3420
ggggctcac	gtctgtatc	ccagcactt	gggagg	ggcggg	tcac	3480
ttgggagttc	aagaccagcc	tgccaacat	ggggaa	cgtct	tact	3540
aaaattagcc	gggtgtgg	gcccgtgc	ataatccc	ctact	cggg	3600
ggagaatcgc	ttgaacccgg	gagg	ttgcgtg	ccaagat	accatt	3660
tccagcctgg	gcaacaagag	cggaaact	tctcaaaata	aataaaa	aaaagacaga	3720
aagcaagggg	tgcctaaatc	tagacttgg	gtccacacc	ggcag	gggg	3780
gcacctggta	ggctccattt	cttccca	ccgag	ggtcat	gccc	3840
agaagcggcc	agggcccg	ggggc	cctgtgg	gccct	ccccaa	3900
tcagggcaggc	actgaaacgc	accgaa	cacgt	ttgtc	cggtgt	3960
ctccccagcc	cagccccc	gccacat	tctgc	ccgt	acac	4020
gggggtggg	gctgaaccat	ccccac	gggtt	tccct	cttccc	4080
cgc当地	tctgcagg	ggggcaaaa	aaaaaa	aaagaaa	aaaaaaa	4140
aaagaaacaa	accac	ctta	catattatgg	aaagaaaata	ttttgtc	4200
tttataattt	tgcgtgaa	aagtagac	attaaacgat	tccagttg	aacatgtc	4260
ctg						4263

<210> 35  
<211> 879  
<212> PRT  
<213> Homo sapiens  
<400> 35

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser  
1               5               10               15  
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr  
20              25              30  
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Thr Asp Asp  
35              40              45  
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg  
50              55              60  
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys  
65              70              75              80  
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro  
85              90              95  
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu  
100             105             110  
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala  
115             120             125  
Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr  
130             135             140  
Pro His His Gly Val Tyr Ser Arg Glu Glu Leu Leu Arg Glu Arg  
145             150             155             160  
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu  
165             170             175  
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg  
180             185             190  
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu  
195             200             205  
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro  
210             215             220  
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val  
225             230             235             240  
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln  
245             250             255  
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr  
260             265             270  
Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys  
275             280             285  
Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile  
290             295             300  
Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro  
305             310             315             320  
Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg  
325             330             335  
Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln  
340             345             350  
Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val  
355             360             365  
Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala  
370             375             380  
Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg  
385             390             395             400  
Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile  
405             410             415

Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val  
 420 425 430  
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val  
 435 440 445  
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly  
 450 455 460  
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe  
 465 470 475 480  
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp  
 485 490 495  
 Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile  
 500 505 510  
 Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg  
 515 520 525  
 His Gly Ser Lys Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr  
 530 535 540  
 Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro  
 545 550 555 560  
 Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val  
 565 570 575  
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys  
 580 585 590  
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp  
 595 600 605  
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro  
 610 615 620  
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met  
 625 630 635 640  
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val  
 645 650 655  
 Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe  
 660 665 670  
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr  
 675 680 685  
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg  
 690 695 700  
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp  
 705 710 715 720  
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp  
 725 730 735  
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser  
 740 745 750  
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala  
 755 760 765  
 Gly Ala Pro Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu  
 770 775 780 785  
 Arg Tyr Met Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly  
 790 795 800  
 Ser Val Ala Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu  
 805 810 815  
 Leu Ile Leu His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr  
 820 825 830  
 Asn Phe Leu Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu  
 835 840 845  
 Gln Ile Tyr Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly  
 850 855 860  
 Glu His Tyr Glu Val Thr Leu Leu His Phe Leu Gin Glu Tyr Leu  
 865 870 875

<210> 36  
<211> 4180  
<212> DNA  
<213> Homo sapiens  
<400> 36

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaagg	gtctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tcccccgctc	ccgccacttc	cggggtcgca	gtcccccggca	120
tggagccgca	accgtgaggc	gcgcgctggac	ccgggacgcac	ctgcccagtc	cggccgcgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctgaaatg	gaggctctct	ggaccctta	240
gaaggcaccc	ctgcccctct	gaggtcagct	gagcggtaa	tgcgaaagg	taagaaaactg	300
cgcctggaca	aggagaacac	cggaaagtgg	agaagcttct	cgtgtattc	cgagggggct	360
gagaggatgg	ccaccacccg	gaccccaacg	gccgaccgag	gcgcgcage	cgccacagat	420
gacccggccg	cccgcttcca	ggtgcagaag	caactgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggccttatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tggggccac	tcccacccgc	tctactacct	ggaaatgcca	600
tatggcagcc	gagagaactc	cctcccttac	tctgagattc	ccaagaagg	ccggaaagag	660
gctctgctgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
gggtctact	ctcgggagga	ggagctgtg	agggagcgg	aacgcctggg	ggtcttcggc	780
atcacctct	acgacttcca	cagcgagagt	ggccttctcc	tcttccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcgaagaac	ggcttcatgg	tgtcccttat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggcccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	cettcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgg	1020
gagcggcggc	tgaccttctg	ccaccaagg	ttatccaatg	tcctggatga	ccccaaagtct	1080
gccccgtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttcaactgg	gtactgggtgg	1140
tgccccacag	ccttcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggttatt	cacgtcccct	ctcctgcgc	agaagaaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccttggaa	1320
ctggctgagt	tccagactga	cagccaggc	aagatcgtct	cgaccagg	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tgcaggggc	cgggtggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccagcagt	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gccccgttagcc	1560
tctgccagag	ctgtccccag	aatgtccag	ccgtatgtgg	tgtacgagg	ggtcaccac	1620
gtctggatca	atgttcatga	catcttctat	ccctttcccc	aatcagagg	agaggacgag	1680
ctctgcttcc	tccgcuccaa	tgaatgcag	accggcttct	gccatttgt	caaagtacc	1740
gccgttttaa	aatcccagg	ctacgattgg	agtgagccct	tcaaaaaaaaa	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggg	ggtttggcg	1860
aggcacggct	ccaaggggcac	caaggacacg	ccgctggagc	accacactcta	cgtggtcage	1920
tatgaggccg	ccggcggagat	cgtacgcctc	accacgccc	gcttctccca	tagctgctc	1980
atgagccaga	acttcgacat	gttcgtcagc	cactacagca	gcgtgagcac	gccccctgc	2040
gtgcacgtct	acaagctgag	cggccccgac	gacgaccccc	tgcacaagca	gccccgttcc	2100
tggctagca	tgatggaggc	accagctgc	ccccggatt	atgttctcc	agagatctc	2160
catttccaca	cgcgctcgga	tgtcggtc	tacggcatga	tctacaagg	ccacgcctt	2220
cagccaggga	agaagcacc	caccgtctc	tttgtatatg	gaggccccca	ggtgcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	ttgcggctca	acacactggc	ctccctggc	2340
taGCCGTTGG	ttgtgattga	cggcaggggc	tcctgtcagc	gagggtttcg	gttgcggagg	2400
gcctgaaaaa	accaaattgg	ccaggtggag	atcgaggacc	aggtggaggg	cctgcagttc	2460
gtggccgaga	agtatggctt	catcgacctg	agccgagtt	ccatccatgg	ctggcttac	2520
gggggcttcc	tctcgctcat	ggggctaattc	cacaagcccc	aggtgttcaa	ggtggccatc	2580
gcgggtgccc	cggtcaccgt	ctggatggcc	tacgacacag	ggtacactga	gctacatc	2640
gacgtccctg	agaacaacca	gcacggctat	gaggegggtt	ccgtggccct	gcacgtggag	2700
aagctgcccc	atgagccaa	ccgcttgctt	atcctccacg	gcttccctgg	cgaaaacgt	2760
cacttttcc	acacaaactt	cctcgctcc	caactgatcc	gagcaggaa	accttaccag	2820
ctccagatct	accccaacga	gagacacagt	attcgtgc	ccgagtcgg	cgagactat	2880
gaagtacgt	tgctgcactt	tctacaggaa	tacctcttag	cctgcccacc	gggagccg	2940
acatcacagc	acaagtggct	gcagcctccg	cggggaaacca	gcccggaggg	actgagtggc	3000
ccggggcccc	cagtgaggca	cttgcctccg	cccagcgct	gccagcccc	aggagccgct	3060
gccttcaccg	ccccgacgccc	ttttatcctt	ttttaaacgc	tcttgggttt	tatgtccgct	3120
gttcttgggt	tgccgagaca	gagagatgtt	ggtctcgcc	cagccccctcc	tctccccggcc	3180

ttctgggagg	aggaggtcac	acgctgatgg	gcactggaga	ggccagaaga	gactcagagg	3240
agcgggctgc	tttccgcctg	ggctccctg	tgacctctca	gtcccctggc	cgcccgacc	3300
accgtccccca	gcacccaagc	atcaattgc	ctgtcccccc	cggccagct	ccccaaacttg	3360
atgtttgtgt	tttgggggg	ggatatttt	tcataattat	ttaaaagaca	ggccgggcgc	3420
ggggctcac	gtctgtaatc	ccagcacttt	gggaggctga	ggcggggcgg	tcacctgagg	3480
ttgggagttc	aagaccagcc	tggccaacat	ggggaaaccc	cgtctctact	aaaaatacaa	3540
aaaattagcc	gggtgtggtg	gcgcgtgcct	ataatcccag	ctactcggga	ggctgaggca	3600
ggagaatcgc	ttgaacccgg	gagggtggagg	ttgcggtag	ccaagatcgc	accattgcac	3660
tccagcctgg	gcaacaagag	cgaaactctg	tctcaaaata	aataaaaaat	aaaagacaga	3720
aagcaagggg	tgcctaaatc	tagacttggg	gtccacaccg	ggcagcgggg	ttgcaaccca	3780
gcacctggta	ggctccattt	cttcccaagc	ccgacttca	ggcaggcact	gaaacgcacc	3840
gaacttccac	gctctgtgg	tcagtggcgg	ctgtccctc	cccagccca	ccgcccagcc	3900
acatgtgtct	gcctgaccgg	tacacaccag	gggtccggg	gttgggagct	gaaccatccc	3960
cacccatggg	ttatatttcc	ctctccctt	ccctccccgc	caagagctct	gccagggcg	4020
ggcaaaaaaaaa	aaagtaaaaa	gaaaagaaaa	aaaaaaaaa	gaaacaaacc	acctctacat	4080
attatggaaa	gaaaatattt	ttgtcgattc	ttatttttt	ataattatgc	gtggaagaag	4140
tagacacatt	aaacgattcc	agttggaaac	atgtcacctg			4180

<210> 37  
<211> 819  
<212> PRT  
<213> Homo sapiens  
<400> 37

Met	Arg	Lys	Val	Lys	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser
1						5				10			15		
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr
								20			25			30	
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp
								35			40			45	
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg
								50			55			60	
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys
								65			70			75	
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro
								85			90			95	
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu
								100			105			110	
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala
								115			120			125	
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr
								130			135			140	
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg
								145			150			155	
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu
								165			170			175	
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg
								180			185			190	
Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu
								195			200			205	
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro
								210			215			220	
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val
								225			230			235	
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Arg	Arg	Leu	Thr	Phe	Cys	His	Gln	
								245			250			255	
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr
								260			265			270	

Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys  
 275 280 285  
 Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile  
 290 295 300  
 Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro  
 305 310 315 320  
 Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg  
 325 330 335  
 Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln  
 340 345 350  
 Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val  
 355 360 365  
 Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala  
 370 375 380  
 Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg  
 385 390 395 400  
 Pro Gln Gln Trp Leu Gln Leu Val Leu Pro Pro Ala Leu Phe Ile  
 405 410 415  
 Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val  
 420 425 430  
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val  
 435 440 445  
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly  
 450 455 460  
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe  
 465 470 475 480  
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp  
 485 490 495  
 Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile  
 500 505 510  
 Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg  
 515 520 525  
 His Gly Ser Lys Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr  
 530 535 540  
 Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro  
 545 550 555 560  
 Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val  
 565 570 575  
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys  
 580 585 590  
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp  
 595 600 605  
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro  
 610 615 620  
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met  
 625 630 635 640  
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val  
 645 650 655  
 Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe  
 660 665 670  
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr  
 675 680 685  
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg  
 690 695 700  
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp  
 705 710 715 720  
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp  
 725 730 735

Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser  
 740 745 750  
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Ala Gln Pro Leu  
 755 760 765  
 Ala Tyr Pro Pro Arg Leu Pro Gly Arg Lys Arg Ala Leu Phe Pro His  
 770 775 780  
 Lys Leu Pro Arg Leu Pro Thr Asp Pro Ser Arg Glu Thr Leu Pro Ala  
 785 790 795 800  
 Pro Asp Leu Pro Gln Arg Glu Thr Gln Tyr Ser Leu Pro Arg Val Gly  
 805 810 815  
 Arg Ala Leu

<210> 38  
 <211> 4120  
 <212> DNA  
 <213> Homo sapiens  
 <400> 38

caggccgccc	cctgggtcgc	tcaacttccg	ggtaaaagg	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tccccgcgc	ccgccaacttc	cggggtcgca	gtcccgggca	120
tggagccgccc	accgtgaggc	gcgcgtggac	ccgggacgcac	ctgcccagtc	cggccgccc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctgaaatg	gaggctctct	ggacccttta	240
gaaggcacc	ctgcccctct	gaggtcagct	gagcggtaa	tgcggaagg	taagaaactg	300
cgcctggaca	aggagaacac	cggaagtgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gacccaaacg	gccgaccgag	gcgcacgc	cgccacacat	420
gacccggccg	cccgcttcca	ggtgcagaag	cactcggtgg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tggcccccac	tcccacccgc	tctactacct	ggaaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagg	ccggaaagag	660
gctctgtgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgtcg	agggagcgg	aacgcctggg	gttctccggc	780
atcacctct	acgacttcca	cagcgagat	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cgcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggcccccgg	atggacccca	aatctgc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgg	1020
gagcggcggc	tgaccttctg	ccaccaagg	ttatccaatg	tcttggatga	ccccaaagtct	1080
gccccgtgtgg	ccaccttcgt	catacaggaa	gattcgacc	gcttcaactgg	gtactgggtgg	1140
tgccccacag	cctcctggga	agttcagag	ggcctaaga	cgctgcgaat	cctgttatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctcgct	agaagaaagg	1260
aagacggact	cgtatecgta	ccccaggaca	ggcagcaaga	atcccaagat	tgccttgaaa	1320
ctggctgagt	tccagactga	cagccagg	aagatcgtct	cgacccagg	gaaggagctg	1380
gtgcagccct	tcaagtcgt	gttcccgaag	gtggagtaca	tgc	cggggtggacc	1440
cggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccacgcgt	gtcccgctc	1500
gtcctctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcccgttagcc	1560
tctgcccag	ctgtccccag	aatgtccag	cgatgtgtgg	tgtacgagg	ggtcacaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagagg	agaggacgag	1680
ctctgttttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgt	caaagtacc	1740
gccgttttaa	aatcccagg	ctacgattgg	agtggccct	tca	ggaaatgaa	1800
ttaagtgtcc	ccattaagga	agagattgt	ctgaccagcg	gtgaatggg	ggtttggcg	1860
aggcacggct	ccaaggc	caaggacacg	ccgctggagc	accacctcta	cgtggcagc	1920
tatgaggcgg	ccggc	cgatcgctc	accacccc	gcttctccca	tagctgtcc	1980
atgagccaga	acttcgacat	gttcgtc	cactacagca	gcgtgagc	gccccc	2040
gtgcacgtct	acaagctgag	cggccccc	gacgaccc	tgcacaag	gcccccttc	2100
tgggctagca	tgtggaggc	agccagctgc	ccccggatt	atgttctcc	agagatctc	2160
catttccaca	cgcgctcg	tgtcggtct	tacggcatg	tctacaag	ccacgc	2220
cagccagg	agaagcacc	caccgtctc	tttgtatatg	gaggcccc	ggtcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	ttgcgtct	acacactgc	ctccctggc	2340
tacggcgtgg	ttgtgattga	cggcagg	tcctgtc	gagggttcg	gttcaaggg	2400
gccctgaaaa	accaaatggg	ccaggtggag	atcgagg	agg	ttggaggg	2460

gtggccgaga	agtatggctt	catcgacctg	agccgagttg	ccatccatgg	ctggctcac	2520
gggggcttc	tctcgctcat	ggggctaatac	cacaagecccc	agggtttcaa	ggcccaaccg	2580
cttgcttatac	ctccacggct	tcctggacga	aaacgtgcac	tttttccaca	caaacttcct	2640
cgtctcccaa	ctgatccgag	caggaaacc	ttaccagctc	cagatctacc	ccaacgagag	2700
acacagtatt	cgctgccccg	agtccggcga	gcactatgaa	gtcacgttgc	tgcactttct	2760
acagaatac	ctctgagcc	gcccacccgg	agccgcac	tcacagcaca	agtggctgca	2820
gcctccgggg	ggaaccaggc	gggaggggact	gagtggcc	cgggccccag	tgaggcactt	2880
tgtcccgccc	agcgctggcc	agccccgagg	agccgctgcc	ttcaccgccc	cgacgcctt	2940
tatcctttt	taaacgctct	tgggttttat	gtccgctgct	tcttggttgc	cgagacagag	3000
agatggtgtt	ctcggccag	ccccctct	ccccgccttc	tgggaggagg	aggtcacacg	3060
ctgatggca	ctggagaggc	cagaagagac	tcagaggagc	gggctgcctt	ccgcctgggg	3120
ctccctgtga	cctctcagtc	ccctggcccg	gccagccacc	gtccccagca	cccaagcatg	3180
caattgcctg	tcccccccg	ccagcctccc	caacttgatg	tttgtttt	gtttgggggg	3240
atattttca	taattat	aaagacaggc	cgggcgcgg	ggctcacgtc	tgtatccca	3300
gcactttggg	aggctgaggc	gggcggatca	cctgaggtt	ggagttcaag	accagcctgg	3360
ccaaacatggg	gaaaacccgt	ctctactaaa	aataaaaaa	attagccggg	tgtggtggcg	3420
cgtgcctata	atcccagcta	ctcgggaggc	tgaggcagga	aatcgctt	aacccgggag	3480
gtggaggtt	cggtgagcca	agatcgcacc	attgcactcc	agcctggca	acaagagcga	3540
aactctgtct	caaaaataat	aaaaaataaa	agacagaaag	caaggggtgc	ctaaatctag	3600
acttgggtc	cacaccgggc	agcggggtt	caacccagca	cctggtaggc	tccatttctt	3660
cccaagcccg	agcagagggt	catgcggg	ccacaggaga	agcggccagg	gcccgcgggg	3720
ggcaccac	gtggacagcc	ctccctgtccc	caagcttca	ggcaggcact	gaaacgcacc	3780
gaacttccac	gctctgtgg	tcagtgccgg	ctgtccc	cccagccag	ccgcccagcc	3840
acatgtgtct	gcctgacccg	tacacaccag	gggttccggg	gttggagct	gaaccatccc	3900
cacccatggg	ttatatttcc	ctctccccc	ccctccccgc	caagagctct	gccagggcg	3960
ggcaaaaaaa	aaagtaaaaaa	gaaaagaaaaa	aaaaaaaaaa	gaaacaaacc	acctctacat	4020
attatggaaa	gaaaatattt	ttgtcgattc	ttattttt	ataattatgc	gtggaagaag	4080
tagacacatt	aaacgattcc	agttggaaac	atgtcacctg			4120

<210> 39  
 <211> 819  
 <212> PRT  
 <213> Homo sapiens  
 <400> 39

Met	Arg	Lys	Val	Lys	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser
1					5					10				15	
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr
								20			25			30	
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp
								35			40			45	
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg
								50			55			60	
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys
								65			70			75	
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro
								85			90			95	
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu
								100			105			110	
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala
								115			120			125	
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr
								130			135			140	
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg
								145			150			155	
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu
								165			170			175	
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg
								180			185			190	

Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu  
                  195                 200                 205  
 Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro  
                  210                 215                 220  
 Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val  
                  225                 230                 235                 240  
 Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln  
                  245                 250                 255  
 Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr  
                  260                 265                 270  
 Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys  
                  275                 280                 285  
 Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile  
                  290                 295                 300  
 Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro  
                  305                 310                 315                 320  
 Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg  
                  325                 330                 335  
 Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln  
                  340                 345                 350  
 Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val  
                  355                 360                 365  
 Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala  
                  370                 375                 380  
 Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg  
                  385                 390                 395                 400  
 Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile  
                  405                 410                 415  
 Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val  
                  420                 425                 430  
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val  
                  435                 440                 445  
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly  
                  450                 455                 460  
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe  
                  465                 470                 475                 480  
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp  
                  485                 490                 495  
 Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile  
                  500                 505                 510  
 Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg  
                  515                 520                 525  
 His Gly Ser Lys Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr  
                  530                 535                 540  
 Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro  
                  545                 550                 555                 560  
 Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val  
                  565                 570                 575  
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys  
                  580                 585                 590  
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp  
                  595                 600                 605  
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro  
                  610                 615                 620  
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met  
                  625                 630                 635                 640  
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val  
                  645                 650                 655

Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe  
 660 665 670  
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr  
 675 680 685  
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg  
 690 695 700  
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp  
 705 710 715 720  
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp  
 725 730 735  
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser  
 740 745 750  
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Ala Gln Pro Leu  
 755 760 765  
 Ala Tyr Pro Pro Arg Leu Pro Gly Arg Lys Arg Ala Leu Phe Pro His  
 770 775 780  
 Lys Leu Pro Arg Leu Pro Thr Asp Pro Ser Arg Glu Thr Leu Pro Ala  
 785 790 795 800  
 Pro Asp Leu Pro Gln Arg Glu Thr Gln Tyr Ser Leu Pro Arg Val Gly  
 805 810 815  
 Arg Ala Leu

<210> 40  
 <211> 4037  
 <212> DNA  
 <213> Homo sapiens  
 <400> 40

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tccccgctc	ccgcccattc	cggggtcgc	gtcccccggca	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgc	ctgcccagtc	cgccgcgcgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctgaaatg	gaggctctct	ggacccttta	240
gaaggcaccc	ctgcccctct	gaggtcagct	gagcggtaa	tgcggaaggt	taagaaaactg	300
cgcctggaca	aggagaacac	cgaaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gaccccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgcttcca	ggtgcaaaag	cactcggtgg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttcagttt	540
gtgcagaaga	cggatgagtc	tggcccccac	tcccaccgcc	tctactacct	ggaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaaagag	660
gctctgctgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctaact	ctcgggagga	ggagctgctg	agggagcgg	aacgcctggg	ggtttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tctccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtcccttat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggcccccgg	atggacccca	aatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggccggc	tgaccttctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttcaactgg	gtactgggtgg	1140
tgccccacag	cctcctggga	agttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	tccctgcgt	agaagaaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccttggaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgacccagg	gaaggagctg	1380
gtgcagccct	ttagctcgct	gttcccgaag	gtggagtaca	tgcgcagg	cggtggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccaggcgt	gtccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	cggttagcc	1560
tctgcccag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagagg	agaggacgag	1680
ctctgcttcc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtccacc	1740
gcccgtttaa	aatcccagg	ctacgattgg	agtgagccct	ttagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggg	ggtttggcg	1860

aggcacggct	ccaagggcac	caaggacacg	ccgctggagc	accacctcta	cgtggtcags	1920
tatgaggcg	ccggcgagat	cgtacgcctc	accacgccc	gcttctccca	tagctgtcc	1980
atgagccaga	acttcgacat	gttcgtcagc	cactacagca	gcgtgagcac	gccgcctgc	2040
gtgcacgtct	acaagctgag	cgccccgac	gacgaccccc	tgcacaagca	gccccgcctc	2100
tgggctagca	tgtggaggc	agccagctgc	ccccccgatt	atgttcctcc	agagatctc	2160
catttccaca	cgcgctcgga	tgtcggtc	tacggcatga	tctacaagcc	ccacgccttg	2220
cagccaggga	agaagcaccc	caccgtcctc	tttgtatatg	gaggccccca	ggtgcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	ttgcggctca	acacactggc	ctccctgggc	2340
tacgcccgtgg	ttgtgattga	cggcaggggc	tcctgtcagc	gagggttctg	ttcgaagagg	2400
gccctgaaaa	accaaattggg	ccaggtggag	atcgaggacc	aggtggaggg	cctgcagttc	2460
gtggccgaga	agtatggctt	catcgacctg	agccgagttg	ccatccatgg	ctggctctac	2520
gggggcttcc	tctcgctcat	ggggctaattc	cacaagcccc	aggtgttcaa	ggcccaaccg	2580
cttgcttata	ctccacggct	tcctggacga	aaacgtgcac	tttttccaca	caaacttcct	2640
cgtctcccaa	ctgatccgag	cagggaaacc	ttaccagctc	cagatctacc	ccaacgagag	2700
acacagtatt	cgctgccccg	agtcgggcga	gcactatgaa	gtcacgttgc	tgcactttct	2760
acaggaatac	ctctgagcct	gcccaccggg	agccgcacaca	tcacagcaca	agtggctgca	2820
gcctccgcgg	ggaaccaggc	gggaggact	gagtggcccg	cgggccccag	tgaggcactt	2880
tgtcccgccc	agcgctggcc	agccccgagg	agccgctgcc	ttcaccgccc	cgacgcctt	2940
tatcctttt	taaacgtct	tgggtttat	gtccgtct	tettggttgc	cgagacagag	3000
agatgggtt	ctcgggccag	ccctctct	ccccgcctc	tgggaggagg	aggtcacacg	3060
ctgatggca	ctggagaggc	cagaagagac	tcagaggagc	gggctgcctt	ccgcctgggg	3120
ctccctgtga	cctctcagtc	ccctggcccg	gccagccacc	gtccccagca	ccaaagcatg	3180
caattgcctg	cccccccccgg	ccagcctccc	caactttagt	tttgggtttt	gtttgggggg	3240
atattttca	taattattta	aaagacaggc	cgggcgcggt	ggctcacgtc	tgtaatccca	3300
gcactttggg	aggctgaggc	gggctgatca	cctgaggttg	ggagttcaag	accagcctgg	3360
ccaaacatggg	gaaacccgt	ctctactaaa	aataaaaaaa	attagccggg	tgtggggcg	3420
cgtgcctata	atcccagcta	ctcgggaggc	tgaggcagga	gaatcgctt	aacccgggag	3480
gtggaggtt	cggtgagcca	agatcgacc	attgcactcc	agcctggcga	acaagagcga	3540
aactctgtct	caaaaataat	aaaaaataaa	agacagaaag	caaggggtgc	ctaaatctag	3600
acttggggtc	cacaccgggc	agcggggtt	caacccagca	cctggtaggc	tccatttctt	3660
cccaagcccg	actttcaggc	aggcactgaa	acgcacccgaa	cttccacgc	ctgctggtca	3720
gtggcgctg	tccctccccc	agcccagccg	cccagccaca	tgtgtctgcc	tgaccctgtac	3780
acaccagggg	ttccggggtt	gggagctgaa	ccatccccac	ctcagggtta	tatcccttc	3840
tcccttccc	tcccgccaa	gagctctgcc	agggggggc	aaaaaaaaaa	gtaaaaagaa	3900
aagaaaaaaaaa	aaaaaaaaaa	acaaaccacc	tctacatatt	atggaaagaa	aatatttttg	3960
tcgattctt	ttctttata	attatgcgtg	gaagaagtag	acacattaaa	cgattccagt	4020
tggaaacatg	tcacactg					4037

<210> 41  
 <211> 706  
 <212> PRT  
 <213> Homo sapiens  
 <400> 41

Asp	Thr	Asp	Val	Val	Tyr	Lys	Ser	Glu	Asn	Gly	His	Val	Ile	Lys	Leu
1						5			10				15		
Asn	Ile	Glu	Thr	Asn	Ala	Thr	Thr	Leu	Leu	Leu	Glu	Asn	Thr	Thr	Phe
								20				25			30
Val	Thr	Phe	Lys	Ala	Ser	Arg	His	Ser	Val	Ser	Pro	Asp	Leu	Lys	Tyr
								35				40			45
Val	Leu	Leu	Ala	Tyr	Asp	Val	Lys	Gln	Ile	Phe	His	Tyr	Ser	Tyr	Thr
								50			55			60	
Ala	Ser	Tyr	Val	Ile	Tyr	Asn	Ile	His	Thr	Arg	Glu	Val	Trp	Glu	Leu
								65			70			75	
Asn	Pro	Pro	Glu	Val	Glu	Asp	Ser	Val	Leu	Gln	Tyr	Ala	Ala	Trp	Gly
								85			90			95	
Val	Gln	Gly	Gln	Gln	Leu	Ile	Tyr	Ile	Phe	Glu	Asn	Asn	Ile	Tyr	Tyr
								100			105			110	

Gln Pro Asp Ile Lys Ser Ser Ser Leu Arg Leu Thr Ser Ser Gly Lys  
     115                 120                 125  
 Glu Glu Ile Ile Phe Asn Gly Ile Ala Asp Trp Leu Tyr Glu Glu Glu  
     130                 135                 140  
 Leu Leu His Ser His Ile Ala His Trp Trp Ser Pro Asp Gly Glu Arg  
     145                 150                 155                 160  
 Leu Ala Phe Leu Met Ile Asn Asp Ser Leu Val Pro Thr Met Val Ile  
     165                 170                 175  
 Pro Arg Phe Thr Gly Ala Leu Tyr Pro Lys Gly Lys Gln Tyr Pro Tyr  
     180                 185                 190  
 Pro Lys Ala Gly Gln Val Asn Pro Thr Ile Lys Leu Tyr Val Val Asn  
     195                 200                 205  
 Leu Tyr Gly Pro Thr His Thr Leu Glu Leu Met Pro Pro Asp Ser Phe  
     210                 215                 220  
 Lys Ser Arg Glu Tyr Tyr Ile Thr Met Val Lys Trp Val Ser Asn Thr  
     225                 230                 235                 240  
 Lys Thr Val Val Arg Trp Leu Asn Arg Pro Gln Asn Ile Ser Ile Leu  
     245                 250                 255  
 Thr Val Cys Glu Thr Thr Gly Ala Cys Ser Lys Lys Tyr Glu Met  
     260                 265                 270  
 Thr Ser Asp Thr Trp Leu Ser Gln Gln Asn Glu Glu Pro Val Phe Ser  
     275                 280                 285  
 Arg Asp Gly Ser Lys Phe Phe Met Thr Val Pro Val Lys Gln Gly Gly  
     290                 295                 300  
 Arg Gly Glu Phe His His Ile Ala Met Phe Leu Ile Gln Ser Lys Ser  
     305                 310                 315                 320  
 Glu Gln Ile Thr Val Arg His Leu Thr Ser Gly Asn Trp Glu Val Ile  
     325                 330                 335  
 Lys Ile Leu Ala Tyr Asp Glu Thr Thr Gln Lys Ile Tyr Phe Leu Ser  
     340                 345                 350  
 Thr Glu Ser Ser Pro Arg Gly Arg Gln Leu Tyr Ser Ala Ser Thr Glu  
     355                 360                 365  
 Gly Leu Leu Asn Arg Gln Cys Ile Ser Cys Asn Phe Met Lys Glu Gln  
     370                 375                 380  
 Cys Thr Tyr Phe Asp Ala Ser Phe Ser Pro Met Asn Gln His Phe Leu  
     385                 390                 395                 400  
 Leu Phe Cys Glu Gly Pro Arg Val Pro Val Val Ser Leu His Ser Thr  
     405                 410                 415  
 Asp Asn Pro Ala Lys Tyr Phe Ile Leu Glu Ser Asn Ser Met Leu Lys  
     420                 425                 430  
 Glu Ala Ile Leu Lys Lys Ile Gly Lys Pro Glu Ile Lys Ile Leu  
     435                 440                 445  
 His Ile Asp Asp Tyr Glu Leu Pro Leu Gln Leu Ser Leu Pro Lys Asp  
     450                 455                 460  
 Phe Met Asp Arg Asn Gln Tyr Ala Leu Leu Ile Met Asp Glu Glu  
     465                 470                 475                 480  
 Pro Gly Gly Gln Leu Val Thr Asp Lys Phe His Ile Asp Trp Asp Ser  
     485                 490                 495  
 Val Leu Ile Asp Met Asp Asn Val Ile Val Ala Arg Phe Asp Gly Arg  
     500                 505                 510  
 Gly Ser Gly Phe Gln Gly Leu Lys Ile Leu Gln Glu Ile His Arg Arg  
     515                 520                 525  
 Leu Gly Ser Val Glu Val Lys Asp Gln Ile Thr Ala Val Lys Phe Leu  
     530                 535                 540  
 Leu Lys Leu Pro Tyr Ile Asp Ser Lys Arg Leu Ser Ile Phe Gly Lys  
     545                 550                 555                 560  
 Gly Tyr Gly Gly Tyr Ile Ala Ser Met Ile Leu Lys Ser Asp Glu Lys  
     565                 570                 575

Leu Phe Lys Cys Gly Ser Val Val Ala Pro Ile Thr Asp Leu Lys Leu  
 580 585 590  
 Tyr Ala Ser Ala Phe Ser Glu Arg Tyr Leu Gly Met Pro Ser Lys Glu  
 595 600 605  
 Glu Ser Thr Tyr Gln Ala Ala Ser Val Leu His Asn Val His Gly Leu,  
 610 615 620  
 Lys Glu Glu Asn Ile Leu Ile Ile His Gly Thr Ala Asp Thr Lys Val  
 625 630 635 640  
 His Phe Gln His Ser Ala Glu Leu Ile Lys His Leu Ile Lys Ala Gly  
 645 650 655  
 Val Asn Tyr Thr Met Gln Val Tyr Pro Asp Glu Gly His Asn Val Ser  
 660 665 670  
 Glu Lys Ser Lys Tyr His Leu Tyr Ser Thr Ile Leu Lys Phe Phe Ser  
 675 680 685  
 Asp Cys Leu Lys Glu Glu Ile Ser Val Leu Pro Gln Glu Pro Glu Glu  
 690 695 700  
 Asp Glu  
 705

<210> 42  
 <211> 4541  
 <212> DNA  
 <213> Homo sapiens  
 <400> 42

gkctykgtkg	wtsmagatac	agatgtggtg	tataaaagcg	agaatggaca	tgtcattaaa	60
ctgaatata	aaacaaatgc	taccacatta	ttattggaaa	acacaactt	tgtaaccttc	120
aaagcatcaa	gacattcagt	ttcaccagat	ttaaaatatg	tccttctggc	atatgatgtc	180
aaacagatt	ttcattattc	gtatactgct	tcatatgtga	tttacaacat	acacactagg	240
gaagtttggg	agttaaatcc	tccagaagta	gaggactccg	tcttgcagta	cgcgcctgg	300
ggtgtccaag	ggcagcagct	gatttatatt	tttggaaaata	atatctacta	tcaacctgat	360
ataaaagagca	gttcattgcg	actgacatct	tctggaaaag	aagaataat	ttttaatggg	420
attgctgact	ggttatatga	agaggaactc	ctgcattctc	acatcgccc	ctgggtgtca	480
ccagatggag	aaagacttgc	cttcctgatg	ataaaatgact	ctttggtacc	caccatggtt	540
atccctcggt	ttactggagc	gttgtatccc	aaaggaaagc	agtatccgta	tcctaaggca	600
ggtcaagtga	acccaacaat	aaaattat	gttgtaaacc	tgtatggacc	aactcacact	660
ttggagctca	tgccacactga	cagcttaaa	tcaagagaat	actatatcac	tatggttaaa	720
tggtaagca	ataccaagac	tgtgtaaga	tggttaaacc	gacctcagaa	catctccatc	780
ctcacagtct	gtgagaccac	tacaggtgct	tgttagaaaa	aatatgagat	gacatcagat	840
acgtggctct	ctcagcagaa	tgaggagccc	gtgtttcta	gagacggcag	caaattctt	900
atgacagtgc	ctgttaagca	agggggacgt	ggagaatttc	accacatagc	tatttcctc	960
atccagagta	aaagtgagca	aattaccgtg	cggcatctga	catcaggaaa	ctgggaagtg	1020
ataaaagatct	tggcatacga	tgaaactact	caaaaaattt	actttctgag	cactgaatct	1080
tctcccgag	gaaggcagct	gtacagtgct	tctactgaag	gattattgaa	tcgccaatgc	1140
attcatgta	atttcatgaa	agaacaatgt	acatattttg	atgccagtt	tagccccatg	1200
aatcaacatt	tcttattatt	ctgtgaaggt	ccaaagggtcc	cagtggtcag	cctacatagt	1260
acggacaacc	cagcaaaata	tttataattt	gaaagaattt	ctatgctgaa	ggaagctatc	1320
ctgaagaaga	agatagaaaa	gccagaaatt	aaaatcttc	atattgacga	ctatgaactt	1380
ccttacagt	tgtcccttcc	caaagattt	atggaccgaa	accagtatgc	tcttcgttta	1440
ataatggatg	aagaaccagg	aggccagctg	gttacagata	agttccat	tgactggat	1500
tccgtactca	ttgacatgga	taatgtcatt	gtacatggat	tttatggcag	aggaagtgg	1560
ttccagggtc	tgaaaatttt	gcaggagatt	catcgaaat	tagttcagt	agaagtaaag	1620
gaccaaataa	cagctgtgaa	attttgtctg	aaactgcctt	acattgactc	caaaagatta	1680
agcatttttg	gaaagggtt	tgtggctat	attgcataa	tgatcttaaa	atcagatgaa	1740
aagctttta	aatgtggatc	cgtgggtgca	cctatcacag	acttggaaatt	gtatgcctca	1800
gcttctctg	aaagataacct	tggatgcca	tctaaggaag	aaagcactt	ccagcagcc	1860
agtgtgtac	ataatgtca	tggcttgaaa	gaagaaaata	tattaataat	tcatgaaact	1920
gctgacacaa	aagtccattt	ccaacactca	gcagaattaa	tcaagcacct	aataaaagct	1980
ggagtgaatt	atactatgca	ggtctaccca	gatgaaggc	ataacgtatc	tgagaagagc	2040

aagtatcatc	tctacagcac	aatcctcaaa	ttcttcagtg	attgtttgaa	ggaagaaaata	2100
tctgtctac	cacaggaacc	agaagaagat	gaataatgga	ccgtatttat	acagaactga	2160
agggaatatt	gaggctcaat	gaaacacctgc	aaagagactg	taatattgt	gttgctccag	2220
aatgtcaagg	ggagcttacg	gagatgtcac	tggagcagca	cgctcagaga	cagtgaacta	2280
gcatttgaat	acacaagtcc	aagtctactg	tgttgcctagg	ggtgcagaac	ccgtttcttt	2340
gtatgagaga	ggtcaaaggg	ttgggttctt	gggagaaatt	agttttgcat	taaagttagga	2400
gtagtcatg	ttttcttctg	ttatccccct	gtttgttctg	taactagttg	ctctcatttt	2460
aatttcactg	gccaccatca	tctttgcata	taatgcacaa	tctatcatct	gtcctacagt	2520
ccctgatctt	tcatggctga	gctgcaatct	aacactttac	tgtaccttta	taataagtgc	2580
aattcttca	ttgtctatta	ttatgcttaa	gaaaatattc	agttataaaa	aaacagagta	2640
tttatgtaa	tttctgtttt	taaaaaagaca	ttattaaatg	ggtcaaagga	catatagaaa	2700
tgtggatttc	agcaccttcc	aaagttcagc	cagttatcag	tagatacaat	atctttaat	2760
gaacacacga	gtgtatgtct	cacaatataat	atacacaagt	gtgcatatac	agttaatgaa	2820
actatctta	aatgttatttc	atgctataaa	gagtaaacgt	ttgatgaatt	agaagagatg	2880
ctctttcca	agctataatg	gatgctttgt	ttaatgagcc	aaatatgatg	aaacattttt	2940
tccaaattcaa	attctagcta	ttgctttctt	ataaaatgttt	gggttgtgtt	tggtattgtt	3000
tttagtgggt	aatagtttc	cagttgcatt	taattttttg	aatatgatac	cttgtcacat	3060
gtaaattaga	tacttaaata	ttaaattata	gtttctgata	aagaaatttt	gttaacaatg	3120
caatgccact	gagtgcattt	ttgctctttt	ggtggagaag	gctttttca	aaactcttgg	3180
tcctttact	tctttctctc	agtcagaat	caattctcat	tttcatcgta	aaagcaaata	3240
gctggattat	ttcatttgcc	agtttctatt	tagattcca	tgccgtccca	attcatctgt	3300
tactgtttaa	tttcaattct	tctggtgaga	attagaaatg	aaatattttt	tattcattgg	3360
ccaaaaagtt	cacagacacg	agtgtttgt	atttactttg	aattgaaggc	acaaaatgc	3420
tcaattcctg	tgctgtgtt	acttgcagta	gtaagtaact	gagagcataa	aataaacctg	3480
actgtatgaa	gtcaattttaa	gtgatgagaa	catttaactt	tggtgactaa	agtcagaata	3540
tcttcact	tcacttaagg	gatcttccag	aagatatcta	aaagtctgt	ataagcttag	3600
aagttcagat	aaatcttaggc	aggatactgc	atttttgtgg	ttttaaaaaa	gtccttagga	3660
cagactgaat	tatcataact	tatggcatca	ggagggaaact	ttaaaatatc	aaggaatcac	3720
tcagtcaccc	tcctgtttt	ttgaaggatc	aaccccaaat	tctgggtatt	tgagtacatg	3780
tgaatcatgg	atttggtatt	caacttttc	cctggatgct	ttggaatcgt	gtctccatg	3840
ctccactggg	ttcaattttaa	aataggagag	gctttctctt	ctgaaagatc	catttttaggt	3900
cttttcaag	aatagtgaac	acattttttta	acaaaataag	ttgtaatttt	aaaaggaaag	3960
ttttgcctat	tttatttaaga	tggaaaatttc	tttttaggct	aatttgaaaat	ccaaactgaag	4020
ctttttaacc	aatatttttaa	atttgaacca	ctagagttt	ttatgatgca	aatgattatg	4080
ttgtctgaaa	ggtgtgggtt	tattgaatgt	ctatttgagt	atcatttaaa	aagtatttgc	4140
cttttactgt	catcattttct	cttgcctttat	tattattatc	aatgtttatc	tattttcaa	4200
tttaatttaat	acagtttcta	atgtgaaaga	cattttctg	gaacccgttt	tccccttaaa	4260
cactaaagag	acctcaagt	aaagcatatt	gcttagtagg	aaggttagaaa	atgttaatcc	4320
ctgcgattct	ttgagtttta	atgacagggt	cattttcagt	aaaggaaatg	ctcaccaaca	4380
catagtcacc	aactattaaa	ggaatcatgt	gattggattt	tcccctgtat	acatgtaccc	4440
ttggtcataa	tcccactatt	tcatacatat	ttatgcattg	ctagattttc	ctaggactcc	4500
aataqcatqc	tttccaagt	ttattattcc	cttaatgtta	a		4541

<210> 43  
<211> 691  
<212> PRT  
<213> *Homo sapiens*  
<400> 43

Asp	Thr	Asp	Val	Val	Tyr	Lys	Ser	Glu	Asn	Gly	His	Val	Ile	Lys	Leu
1					5				10						15
Asn	Ile	Glu	Thr	Asn	Ala	Thr	Thr	Leu	Leu	Leu	Glu	Asn	Thr	Thr	Phe
							20				25				30
Val	Thr	Phe	Lys	Ala	Ser	Arg	His	Ser	Val	Ser	Pro	Asp	Leu	Lys	Tyr
							35			40					45
Val	Leu	Leu	Ala	Tyr	Asp	Val	Lys	Gln	Ile	Phe	His	Tyr	Ser	Tyr	Thr
							50			55					60
Ala	Ser	Tyr	Val	Ile	Tyr	Asn	Ile	His	Thr	Arg	Glu	Val	Trp	Glu	Leu
65							70			75					80

Asn Pro Pro Glu Val Glu Asp Ser Val Leu Gln Tyr Ala Ala Trp Gly  
                   85                     90                     95  
 Val Gln Gly Gln Gln Leu Ile Tyr Ile Phe Glu Asn Asn Ile Tyr Tyr  
                   100                    105                  110  
 Gln Pro Asp Ile Lys Ser Ser Ser Leu Arg Leu Thr Ser Ser Gly Lys  
                   115                    120                  125  
 Glu Glu Ile Ile Phe Asn Gly Ile Ala Asp Trp Leu Tyr Glu Glu Glu  
                   130                    135                  140  
 Leu Leu His Ser His Ile Ala His Trp Trp Ser Pro Asp Gly Glu Arg  
                   145                    150                  155                  160  
 Leu Ala Phe Leu Met Ile Asn Asp Ser Leu Val Pro Thr Met Val Ile  
                   165                    170                  175  
 Pro Arg Phe Thr Gly Ala Leu Tyr Pro Lys Gly Lys Gln Tyr Pro Tyr  
                   180                    185                  190  
 Pro Lys Ala Gly Gln Val Asn Pro Thr Ile Lys Leu Tyr Val Val Asn  
                   195                    200                  205  
 Leu Tyr Gly Pro Thr His Thr Leu Glu Leu Met Pro Pro Asp Ser Phe  
                   210                    215                  220  
 Lys Ser Arg Glu Tyr Tyr Ile Thr Met Val Lys Trp Val Ser Asn Thr  
                   225                    230                  235                  240  
 Lys Thr Val Val Arg Trp Leu Asn Arg Pro Gln Asn Ile Ser Ile Leu  
                   245                    250                  255  
 Thr Val Cys Glu Thr Thr Gly Ala Cys Ser Lys Lys Tyr Glu Met  
                   260                    265                  270  
 Thr Ser Asp Thr Trp Leu Ser Gln Gln Asn Glu Glu Pro Val Phe Ser  
                   275                    280                  285  
 Arg Asp Gly Ser Lys Phe Phe Met Thr Val Pro Val Lys Gln Gly Gly  
                   290                    295                  300  
 Arg Gly Glu Phe His His Ile Ala Met Phe Leu Ile Gln Ser Lys Ser  
                   305                    310                  315                  320  
 Glu Gln Ile Thr Val Arg His Leu Thr Ser Gly Asn Trp Glu Val Ile  
                   325                    330                  335  
 Lys Ile Leu Ala Tyr Asp Glu Thr Thr Gln Lys Ile Ser Ala Ser Thr  
                   340                    345                  350  
 Glu Gly Leu Leu Asn Arg Gln Cys Ile Ser Cys Asn Phe Met Lys Glu  
                   355                    360                  365  
 Gln Cys Thr Tyr Phe Asp Ala Ser Phe Ser Pro Met Asn Gln His Phe  
                   370                    375                  380  
 Leu Leu Phe Cys Glu Gly Pro Arg Val Pro Val Val Ser Leu His Ser  
                   385                    390                  395                  400  
 Thr Asp Asn Pro Ala Lys Tyr Phe Ile Leu Glu Ser Asn Ser Met Leu  
                   405                    410                  415  
 Lys Glu Ala Ile Leu Lys Lys Ile Gly Lys Pro Glu Ile Lys Ile  
                   420                    425                  430  
 Leu His Ile Asp Asp Tyr Glu Leu Pro Leu Gln Leu Ser Leu Pro Lys  
                   435                    440                  445  
 Asp Phe Met Asp Arg Asn Gln Tyr Ala Leu Leu Leu Ile Met Asp Glu  
                   450                    455                  460  
 Glu Pro Gly Gly Gln Leu Val Thr Asp Lys Phe His Ile Asp Trp Asp  
                   465                    470                  475                  480  
 Ser Val Leu Ile Asp Met Asp Asn Val Ile Val Ala Arg Phe Asp Gly  
                   485                    490                  495  
 Arg Gly Ser Gly Phe Gln Gly Leu Lys Ile Leu Gln Glu Ile His Arg  
                   500                    505                  510  
 Arg Leu Gly Ser Val Glu Val Lys Asp Gln Ile Thr Ala Val Lys Phe  
                   515                    520                  525  
 Leu Leu Lys Leu Pro Tyr Ile Asp Ser Lys Arg Leu Ser Ile Phe Gly  
                   530                    535                  540

Lys	Gly	Tyr	Gly	Gly	Tyr	Ile	Ala	Ser	Met	Ile	Leu	Lys	Ser	Asp	Glu
545					550					555					560
Lys	Leu	Phe	Lys	Cys	Gly	Ser	Val	Val	Ala	Pro	Ile	Thr	Asp	Leu	Lys
					565					570					575
Leu	Tyr	Ala	Ser	Ala	Phe	Ser	Glu	Arg	Tyr	Leu	Gly	Met	Pro	Ser	Lys
					580					585					590
Glu	Glu	Ser	Thr	Tyr	Gln	Ala	Ala	Ser	Val	Leu	His	Asn	Val	His	Gly
					595					600					605
Leu	Lys	Glu	Glu	Asn	Ile	Leu	Ile	Ile	His	Gly	Thr	Ala	Asp	Thr	Lys
					610					615					620
Val	His	Phe	Gln	His	Ser	Ala	Glu	Leu	Ile	Lys	His	Leu	Ile	Lys	Ala
					625					630					640
Gly	Val	Asn	Tyr	Thr	Met	Gln	Val	Tyr	Pro	Asp	Glu	Gly	His	Asn	Val
					645					650					655
Ser	Glu	Lys	Ser	Lys	Tyr	His	Leu	Tyr	Ser	Thr	Ile	Leu	Lys	Phe	Phe
					660					665					670
Ser	Asp	Cys	Leu	Lys	Glu	Glu	Ile	Ser	Val	Leu	Pro	Gln	Glu	Pro	Glu
					675					680					685
Glu	Asp	Glu			690										

<210> 44  
 <211> 4496  
 <212> DNA  
 <213> Homo sapiens  
 <400> 44

gkctykgtkg	wtsmagatac	agatgtggtg	tataaaagcg	agaatggaca	tgtcattaaa		60
ctgaatatag	aaacaaatgc	taccacatta	ttattggaaa	acacaactt	tgtaaccttc		120
aaagcatcaa	gacattcagt	ttcaccagat	ttaaaatatg	tccttctggc	atatgatgtc		180
aaacagattt	ttcattattc	gtatactgct	tcatatgtga	tttacaacat	acacactagg		240
gaagtttggg	agttaaatcc	tccagaagta	gaggactccg	tcttgcagta	cgcggcctgg		300
ggtgtccaag	ggcagcagct	gatttatatt	tttggaaaata	atatctacta	tcaacctgtat		360
ataaagagca	gttcattgct	actgacatct	tctggaaaag	aagaataat	ttttaatggg		420
attgctgact	ggttatatga	agaggaactc	ctgcattctc	acatcgccc	ctgggttca		480
ccagatggag	aaagacttgc	cttcctgatg	ataaatgact	cttggtacc	caccatgggt		540
atccctcggt	ttactggagc	gttgtatccc	aaaggaaagc	agtatccgt	tcctaaggca		600
ggtcaagtga	acccaacaat	aaaattatat	gttgtaaacc	tgtatggacc	aactcacact		660
ttggagctca	tgccacctga	cagctttaaa	tcaagagaat	actatatcac	tatgtttaaa		720
tgggtaagca	ataccaagac	tgtgtaaga	tggttaaacc	gacctcgaaa	catctccatc		780
ctcacagtct	gtgagaccac	tacaggtct	tgttagaaaa	aatatgagat	gacatcagat		840
acgtggctct	ctcagcagaa	tgaggagccc	gtgtttcta	gagacggcag	caaattctt		900
atgacagtgc	ctgttaagca	agggggacgt	ggagaatttc	accacatagc	tatttcctc		960
atccagagta	aaagtggagca	aattaccgtg	cggcatctga	catcaggaaa	ctgggaagtg		1020
ataaaagatct	tggcatacga	tgaaaactact	caaaaaatca	gtgttctac	tgaaggatta		1080
ttgaatcgcc	aatgcatttc	atgtatattc	atgaaagaac	aatgtacata	ttttatgcc		1140
agttttagtc	ccatgaatca	acatttctta	ttattctgt	aaaggccaag	ggtcccagt		1200
gtcagcctac	atagtacgga	caacccagca	aaatatttt	tattggaaaag	caattctatg		1260
ctgaagggaa	ctatcctgaa	gaagaagata	ggaaagccag	aaatttttt	ccttcatttt		1320
gacgactatg	aacttccctt	acagttgtcc	cttcccaaag	attttatgg	ccgaaaccag		1380
tatgtcttc	tgttaataat	ggatgaagaa	ccaggaggcc	agctggttac	agataagtgc		1440
catattgact	gggattccgt	actcattgac	atggataatg	tcattgtac	aagatttgat		1500
ggcagagggaa	gtggattcca	gggtctgaaa	atttgcagg	agattcatcg	aagatttagt		1560
tcagtagaa	taaaggacca	aataacagct	gtgaaatttt	tgctgaaact	gccttacatt		1620
gactccaaaa	gattaagcat	ttttggaaaag	ggttatggtg	gctatattgc	atcaatgatc		1680
ttaaaaatcg	atgaaaagct	ttttaatgt	ggatccgtgg	ttgcacctat	cacagacttg		1740
aaattgtatg	cctcagcttt	ctctgaaaaga	taccttggg	tgccatctaa	ggaagaaaagc		1800
acttaccagg	cagccagtg	gctacataat	gttcatggct	tgaaaagaagaa	aaatatatta		1860
ataattcatg	gaactgctga	cacaaaagtt	catttccaac	actcagcaga	attaatcaag		1920

cacctaataa	aagctggagt	gaattatact	atgcaggct	accagatga	aggcataac	1980
gtatctgaga	agagcaagta	tcatctctac	agcacaatcc	tcaaattctt	cagtattgt	2040
ttgaaggaag	aaatatctgt	gctaccacag	gaaccagaag	aagatgaata	atggaccgt	2100
tttatacaga	actgaaggga	atattgagge	tcaatgaaac	ctgacaaaga	gactgtata	2160
ttgttagttgc	tccagaatgt	caagggcago	ttacggagat	gtcactggag	cagcacgctc	2220
agagacagt	aactagcatt	tgaatacaca	agtccaagtc	tactgttttg	ctaggggtgc	2280
agaacccgtt	tctttgtatg	agagaggta	aagggttgtt	ttcctgggag	aaatttagtt	2340
tgcattaaag	taggagtagt	gcatgtttt	ttctgttac	cccctgtttt	ttctgttaact	2400
agttgctctc	attttaattt	cactggccac	catcatctt	gcatataatg	cacaatctat	2460
catctgtcct	acagtcctg	atcttcatg	gctgagctgc	aatctaacac	tttactgtac	2520
ctttataata	agtcaattc	tttcattgtc	tattattatg	cttaagaaaa	tattcagtt	2580
ataaaaaaaca	gagtatttt	tgtatattct	gtttttaaaa	agacattatt	aatgggtca	2640
aaggacat	agaaatgtgg	atttcagcac	cttccaaagt	tcagccagtt	atcagtagat	2700
acaatatctt	taaatgaaca	cacgagtgt	tgtctcacaa	tatataataca	caagtgtgc	2760
tatacagtta	atgaaactat	ctttaatgt	tattcatgct	ataaaagagta	aacgtttgat	2820
gaattagaag	agatgcttt	ttccaagcta	taatggatgc	tttgcatttt	gagccaaata	2880
tgtgaaaaca	tttttccaa	ttcaattct	agctattgt	ttcctataaa	ttttgggtt	2940
gtgtttggta	ttgtttttag	ttgttaatag	tttccagtt	gcatttaatt	tttgaatat	3000
gataccttgt	cacatgtaaa	ttagatactt	aaatattaaa	ttatagttt	tgataaagaa	3060
attttgttaa	caatgcaatg	ccactgagtg	ctattttgc	ctttgggtgg	agaaggctt	3120
tttcaaaact	tttggcctt	ttacttctt	ctctcaigtgc	agaatcaatt	ctcattttca	3180
tcgtaaaagc	aaatagctgg	attatttcat	ttgccagtt	ctattttagta	ttccatgcct	3240
gcccaattca	tctgttactg	tttaatttca	attcttctgg	tgagaattag	aaatgaaata	3300
ttttttattc	attggccaaa	aagttcacag	acagcagtgt	ttgtctattt	ctttgaattt	3360
aaggcacaaa	atgcataat	tctgtgtcg	ttgtgacttg	cagtagtaag	taactgagag	3420
cataaaaataa	acctgactgt	atgaagtcaa	tttaagtgtat	gagaacattt	aactttgggt	3480
actaaagtca	gaatatcttc	tcacttcact	taaggatct	tccagaagat	atctaaaagt	3540
ctgtataaag	cttagaagtt	cagataatc	taggcaggat	actgcatttt	tgtggtttta	3600
aaaaagtcct	taggacagac	tgaattatca	taacttatgg	catcaggagg	aaactttaaa	3660
atatcaagga	atcactcagt	caccctcctg	tttgcgtt	ggatcaacccc	caaattctgg	3720
gtatttgagt	acatgtgaat	catggatttgc	gtattcaact	tttccctgg	atgctttgg	3780
atcggtctt	ccatgtccca	ctgggttcaa	tttaaaatag	gagaggctt	ctcttctgaa	3840
agatccattt	tagtctttt	tcaagaatag	tgaacacattt	tttaacaaa	ataagttgt	3900
atttaaaag	gaaagttttgc	ccatattttat	taagatggaa	atttctttt	aggcttattt	3960
gaaatccaaac	tgaagcttttgc	taaccaatat	tttaaatttg	aaccactaga	gtttttatgt	4020
atgcaaatga	ttatgttgc	tggaaagggtgt	gtttttatttgc	aatgtcttatt	tgagtatcat	4080
ttaaaaagta	tttgccttttgc	actgtcatca	tttctcttgc	tttatttattt	ttatcaatgt	4140
ttatctattt	ttcaattaat	ttaatacagt	ttctaatgttgc	aaagacattt	ttctggacc	4200
cgtttcccc	ttaaacacta	aagagacctc	aagtggaaagc	atattgctta	gtaggaagggt	4260
agaaaatgtt	aatccctgcgc	attcttttgag	tttaatgtac	agggtcattt	tcaagaaagg	4320
aaatgctcac	caacacatag	tcaccaacta	ttaaaggaat	catgtgatttgc	gattttcccc	4380
tgtatacatg	taccctgggt	cataatccca	ctatttcata	catattttagt	cattgctaga	4440
tttccttagg	actccaatag	catgctttcc	aagtgttattt	attcccttaa	tgttaa	4496

<210> 45  
<211> 29  
<212> DNA  
<213> Homo sapiens  
<400> 45

cggtaccatg gcagcagcaa tggaaacag

29

<210> 46  
<211> 39  
<212> DNA  
<213> Homo sapiens  
<400> 46

ggagctcgcg gcccgtcata tcacttttag agcagcaat

39

<210> 47  
<211> 27  
<212> DNA  
<213> Homo sapiens  
<400> 47

caagctttat cacttttaga gcagcaa

27

<210> 48  
<211> 22  
<212> DNA  
<213> Homo sapiens  
<400> 48

cacattcttg ctgcatacgta ca

22

<210> 49  
<211> 22  
<212> DNA  
<213> Homo sapiens  
<400> 49

ttgggtcatc ttcaggactt ga

22

<210> 50  
<211> 27  
<212> DNA  
<213> Homo sapiens  
<400> 50

caagcttacc atggccacca ccgggac

27

<210> 51  
<211> 37  
<212> DNA  
<213> Homo sapiens  
<400> 51

cgatatccgcg gccgctcaga ggtattcctg tagaaag

37

<210> 52  
<211> 27  
<212> DNA  
<213> Homo sapiens  
<400> 52

cgatatccagg tattcctgtt gaaaatgt

27

<210> 53  
<211> 20  
<212> DNA  
<213> Homo sapiens  
<400> 53

tacgccgtgg ttgtgattga

20

<210> 54  
<211> 20  
<212> DNA

<213> Homo sapiens  
<400> 54

ccatacttct cggccacgaa

20

<210> 55  
<211> 19  
<212> DNA  
<213> Homo sapiens  
<400> 55

gcctgggatt gtgcactgt

19

<210> 56  
<211> 29  
<212> DNA  
<213> Homo sapiens  
<400> 56

gtgtattcaa atgctagttc actgtctct

29

<210> 57  
<211> 22  
<212> DNA  
<213> Homo sapiens  
<400> 57

agcttagcact gtccagggtc ct

22

<210> 58  
<211> 25  
<212> DNA  
<213> Homo sapiens  
<400> 58

agggcccttc atcttcttct ggttc

25

<210> 59  
<211> 19  
<212> PRT  
<213> Homo sapiens  
<400> 59

Val Glu Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro  
1 5 10 15  
Asp Ser Val

<210> 60  
<211> 19  
<212> PRT  
<213> Homo sapiens  
<400> 60

Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val Pro  
1 5 10 15  
Arg Asn Val

<210> 61  
<211> 15

<212> PRT  
<213> Homo sapiens  
<400> 61

Lys Glu Ala Ile Leu Lys Lys Lys Ile Gly Lys Pro Glu Ile Lys  
1 5 10 15

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**